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1. Hematopoiesis
Hematopoiesis is the process that generates blood cells of all lineages. It is a 
continuously and closely regulated process that proceeds from the bone marrow. 
Every type of blood cell has its origin in common pluripotent stem cells. These 
hematopoietic stem cells (HSCs), have the ability to self-renew and, upon stimulation 
by different hematopoietic growth factors and cytokines, these HSCs will become 
progenitor cells committed to a particular lineage. Further progression of a progenitor 
cell towards a specific mature and functional blood cell takes place via several 
differentiation stages, which can be distinguished by morphological characteristics 
and cell-surface markers (Figure 1). During maturation, immature blood cells lose 
their proliferative capacity and gain their functional characteristics, whereupon 
they leave the bone marrow and enter the peripheral blood. Once matured, most 
blood cells have a limited life span and will soon leave the blood circulation system 
via the apoptotic pathway. During normal hematopoiesis HSC homeostasis reflects 
the balance between self-renewal and proliferation, differentiation and apoptosis. 
Each day, an adult produces hundreds of billions new blood cells, which is largely 
controlled by feedback mechanisms. When the demand for blood cells of a particular 
lineage increases or when the levels of certain cells fall in blood, the HSCs will be 
stimulated to generate sufficient numbers of mature blood cells. A complex network 
of growth factors and their receptors, signal transduction pathways and transcription 
factors that regulate the expression of lineage specific genes is involved in the 
regulation of blood cell differentiation. HSCs can undergo either self-renewal or 
differentiation into one of the two multipotent progenitor cells: a common myeloid 
progenitor (CMP) or a common lymphoid progenitor (CLP). These cells then give 
rise to more differentiated progenitors and ultimately, they will mature towards 
unilineage committed progenitors for natural killer cells, B-cells, T-cells, dendritic 
cells, monocytes, granulocytes, erythrocytes and megakaryocytes.1-3 
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Figure 1. Schematic representation of hematopoiesis. All mature blood cells originate from 
a pluripotent hematopoietic stem cell (HSC), which can differentiate into either a common 
lymphoid progenitor (CLP) or a common myeloid progenitor (CMP). These multipotent progenitor 
cells give rise to more committed progenitors, including the granulocyte-monocyte progenitor 
(GMP) and megakaryocyte-erythroid progenitor (MEP). The lymphoid progenitor cells ultimately 
generate the natural killer (NK) cells, B- and T-cells and lymphoid dendritic cells (DC), and the 
myeloid progenitor cells differentiate into myeloid DCs, monocytes, granulocytes, erythrocytes 
and megakaryocytes/platelets. 
2. Leukemia
Disturbance of the normal process of hematopoiesis leads to the development of 
blood disorders and diseases. Leukemia affects the immature stem cell population 
that resides in the bone marrow. It is characterised by abnormal proliferation of 
immature bone marrow cells that fail to differentiate and remain in the bone marrow. 
Eventually the bone marrow starts to release the malignant, immature cells into the 
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blood. The displacement of normal bone marrow cells by malignant cells, results in a 
shortage of normal blood cells and a concomitant range of symptoms, such as anemia, 
malaise, abnormal bleeding, excessive bruising, infection and fever.
There are several types of leukemia, which can be grouped according to how 
quickly the disease develops and becomes worse. When the disease develops quickly, 
it is classified as acute, whereas a more slowly progressing disease is classified as 
chronic. Early during chronic leukemia, the presence of abnormal blood cells, which 
have the ability to partially differentiate, may not cause any symptoms. Slowly, 
patients with chronic leukemia will get symptoms as the number of malignant cells 
rise. In the case of acute leukemia, a complete block in differentiation of malignant 
cells causes a rapid developing disease. According to the type of white blood cell 
that is affected, leukemia can be classified as myelogenous or lymphocytic. The four 
most common types of leukemia are: acute myeloid leukemia (AML), chronic myeloid 
leukemia (CML), acute lymphocytic leukemia (ALL) and chronic lymphocytic leukemia 
(CLL). AML is the most frequent form of leukemia that accounts for about 25% of all 
leukemias in adults in the Western world.4
Leukemogenesis is a process in which immature blood cells evade the tight 
coordination of proliferation, differentiation and apoptosis. The aberrant progenitor 
cells not only lose their differentiation potential but also gain uncontrolled 
proliferation ability and in addition apoptosis is reduced in these abnormal cells 
(Figure 2). The disturbed balance between proliferation, differentiation and 
apotosis is caused by a variety of mutations in pathways that are required for normal 
hematopoiesis. Specific growth factors and their receptors, signal transduction 
molecules, regulators of the cell cycle and apoptosis machinery and transcription 
factors that regulate lineage-specific genes, these may all be mutated in leukemia. 
Transformation of a normal progenitor cell towards an abnormal leukemic blast is a 
multistep process involving the accumulation of genetic mutations over time. Not a 
single, but several mutations are required to obtain a full-blown malignancy.5 Studies 
on the molecular events that occur during normal and malignant hematopoiesis 
increase our knowledge of the complex network of protein interactions and signaling 
pathways, providing multiple targets for therapeutic intervention. At the same time, 
molecular markers may be used to predict prognosis.
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Figure 2. Schematic representation of leukemogenesis. Due to an accumulation of multiple 
genetic alterations together with epigenetic changes, normal cells may undergo leukemic 
transformation. A common characteristic of leukemic cells is their loss of maturation ability, 
their uncontrolled proliferation and increased survival. Hematopoietic stem cell (HSC); 
common myeloid progenitor (CMP); common lymphoid progenitor (CLP).
3. Acute promyelocytic leukemia
Acute promyelocytic leukemia (APL) accounts for 5-10% of all AML cases, and is 
classified as AML-M3 according to the French-American-British (FAB) classification 
system that is predominantly based on morphological criteria.6-12 Recently, the World 
Health Organization (WHO) published a new classification system that includes many 
of the criteria of the FAB classification but also incorporates genetic, biologic and 
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clinical features to allow more appropriate categorization and therapy.13 In APL the 
leukemic blasts are blocked at the promyelocytic stage of development and they fail 
to differentiate towards mature granulocytes. Mutations that affect the retinoic acid 
receptor α gene (RARA) are characteristic for APL and in 98% of the APL cases, a 
chromosomal translocation occurs involving chromosome 15 and 17, fusing the RARA 
and the promyelocytic leukemia (PML) genes.14-17 The resulting chimeric fusion 
protein, PML-RARα, has oncogenic potential and may interfere with the normal 
function of PML and RARα (18 and references therein). Besides this unique genetic 
lesion, mutations in the FLT3 gene have been detected in approximately 45% of the 
APL cases.19;20 
RARα is a nuclear hormone receptor that acts as a ligand-dependent transcription 
factor. In order to regulate gene expression, RARα dimerizes with the retinoic X 
receptor (RXR).21 RARα/RXR heterodimers bind to specific DNA sequences or retinoic 
acid response elements (RAREs),22;23 which are present in retinoic acid responsive 
genes. Retinoic acid, such as all-trans retinoic acid (ATRA), and their receptors are 
important in the development and homeostasis of a wide variety of vertebrate tissues 
through their regulatory roles in cell proliferation, differentiation and apoptosis.24 In 
addition, ATRA exerts profound effects on the growth and maturation of hematopoietic 
cells. For example, ATRA is capable of suppressing the formation of erythroid and 
macrophage colonies, while inducing an increase in the number of neutrophil 
colonies from primary human progenitors.25-28 In the absence of ATRA, RARα/RXR 
heterodimers inhibit transcription through the recruitment of corepressor complexes 
containing histone deacetylase (HDAC) activity, resulting in chromatin compaction 
and a transcriptional inactive state. Upon ligand binding, the corepressor complexes 
are replaced by coactivator complexes with histone acetylase (HAT) activity, creating 
an accessible chromatin configuration that facilitates transcriptional activation29 
(Figure 3A). 
PML is a ubiquitously expressed protein, which is a component of nuclear 
substructures termed nuclear bodies (NBs). Over 50 protein partners, with a wide 
variety of functions, have been described for PML, including transcription factors, 
chromatin remodelling factors and DNA replication factors.30 PML has multiple tumour 
suppressor functions and is involved in growth control, replicative senescence and 
apoptosis.31 In APL cells the NBs are disrupted and PML is dispersed into numerous 
small microspeckles. Treatment of APL cells with ATRA, as discussed below, induces 
re-localization of PML into normal-appearing NBs.32;33
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Figure 3. Transcriptional activation by RARα/RXR and PML-RARα. (A) In the absence of ATRA, 
wild type RARα/RXR heterodimers repress transcription through the recruitment of corepressor 
complexes. Upon binding of ATRA, conformational changes in the receptor occur resulting in 
the dissociation of the corepressor complexes and binding of coactivator complexes allowing 
transcriptional activation. (B) Comparable to wild-type receptors, PML-RARα fusion proteins 
are able to transcriptionally repress their target genes by the recruitment of corepressor 
complexes. In contrast to wild-type receptors, physiological doses of ATRA do not induce the 
release of corepressor proteins. Only in the presence of high doses of ATRA the corepressor 
complexes are replaced by coactivator complexes resulting in transcriptional activation. 
PML-RARα fusion proteins have DNA binding capability by forming homodimers and 
ATRA is able to bind to PML-RARα 34;35. Compared to RARα, PML-RARα shows enhanced 
binding with corepressor proteins. Physiological concentrations of ATRA (10-9 M) are not 
able to release the corepressor complex and PML-RARα target genes remain silenced. 
However, at pharmacological doses of ATRA (10-6 M), the corepressors are replaced by 
coactivators allowing transcriptional activation of PML-RARα target genes36-42 (Figure 
3B). Several important RARα target genes have been identified that are deregulated 
by PML-RARα in APL cells, including p21waf1/Cip1 43-45 and the transcription factors 
CAAT/enhancer-binding-protein-β and -ε (C/EBPβ and C/EBPε).46;47 p21waf1/Cip1 is a 
cyclin-dependent kinase inhibitor that is involved in the regulation of the activity of 
several cyclin-dependent kinases. The C/EBP transcription factors are involved in the 
regulation of granulocytic differentiation.
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Unlike other types of AML, APL is uniquely sensitive to treatment with ATRA. APL 
patients benefit from the addition of pharmacological doses of ATRA to standard 
chemotherapy, leading to cure rates from 40% with chemotherapy alone to up to 90% 
when combined with ATRA. ATRA causes natural cell death of the malignant cells by 
inducing granulocytic differentiation.48-57
4. Transcriptional regulation of hematopoiesis
Hematopoiesis is controlled by specific combinations of transcription factors, 
which define lineage commitment and stage differentiation. Improved technologies 
to identify and isolate highly purified populations of HSCs and lineage restricted 
progenitor cells allow us to map specific transcription factor expression patterns 
that correlate with specific stages of differentiation. Further understanding of 
the function of these transcription factors during hematopoietic differentiation is 
determined by two general approaches: overexpression and inhibition of specific 
transcription factors. Some transcription factors are expressed in HSCs, such as Runt-
related transcription factor 1 (RUNX1), whereas others have a more lineage-specific 
expression pattern. GATA1, PU.1, the transcription factors CCAAT/enhancer-binding-
protein-α and -ε (C/EBPα and C/EBPε) and the transcriptional repressor Gfi1 are 
lineage-specific transcription factors that are implicated in myeloid development. 
The results of both knockout and overexpression studies have shown that GATA1 
participates in the differentiation of common myeloid progenitors to megakaryocytic/
erythroid progenitors, PU.1 is involved in the development of monocytes/macrophages 
and C/EBPα, C/EBPε and Gfi1 have a role in granulopoiesis.58;59 Transcription factors 
may specify cell lineage and promote differentiation actively by auto-stimulation of 
their own expression. In addition, they may inhibit the expression of transcription 
factors that are involved in other differentiation routes, as has been described for 
PU.1 and GATA1.60 Thus, both transcriptional activation and transcriptional repression 
are important for lineage decisions. 
In general, transcription factors are involved in many protein-protein interactions 
and different combinations of interactions may reflect different functions of the same 
protein. One example is the RARα protein, which can function as a transcriptional 
repressor in the absence of ligand by binding to corepressor proteins, but when ligand-
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bound turns into a transcriptional activator through interaction with coactivator 
proteins. In addition, changes in composition of a complex may direct the complex to 
distinct enhancers or may inhibit DNA binding. The presence of a mutated gene within 
these complex networks may change the expression of many genes contributing 
to malignant transformation. In addition to these genetic changes that have been 
demonstrated to be implicated in tumorigenic processes, there are many other 
genes contributing to tumorigenesis that do not show any mutation. Deregulated 
expression of genes is not only determined by genetic alterations in transcription 
factors or their interacting proteins, also epigenetic changes play an important role 
in the level of gene expression. Several epigenetic modifications exist that change 
the gene expression capacity without DNA sequence alterations. DNA methylation, 
which occurs at cytosine residues in CpG dinucleotides, is the major epigenetic 
modification of mammalian genomes that is required for processes such as genomic 
imprinting and X chromosome inactivation and is indispensable for normal embryonic 
development. Methylation of DNA, mediated by specific DNA methyltransferases 
and methyl-CpG-binding domain proteins, is associated with an inactive chromatin 
state and transcriptional repression.61 Altered methylation patterns have been 
associated with cancer cells. CpG islands located in promoter regions of many tumour 
suppressor genes show hypermethylation and, as a consequence, these genes are 
transcriptionally inactive in cancer cells. In addition, loss of methylation at sites that 
are normally methylated may be associated with genomic instability and increased 
chromosomal rearrangements or with the potential activation of oncogenes (62-65 and 
references therein). 
Recently, the discovery of microRNA (miRNA) molecules has led to new insights 
into the regulation of gene expression. MiRNAs are small, non-coding, single 
stranded RNAs that are able to bind specific mRNA sequences and due to inhibition of 
translation or mRNA degradation miRNAs induce repression of protein expression 66 
(Figure 4). MiRNAs have been linked to several important biological processes such as 
early stage development, cell growth, cell differentiation and apoptosis and strong 
evidence exists for a role of miRNAs during hematopoiesis. In addition, impaired 
miRNA expression has been implicated in tumorigenesis.67-69
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Box 1. Epigentics, cancer and therapeutic interventions
The epigenetic control of gene expression involves the formation of chromatin that 
is either transcriptionally inactive or transcriptionally active. The two most studied 
modifications of chromatin include DNA methylation, which is associated with 
transcriptionally inactive chromatin, and histone acetylation, which is associated 
with transcriptionally active chromatin. Nowadays, strong evidence exists for a 
correlation between DNA hypermethylation, hypoacetylation of histones, tightly packed 
chromatin, and transcriptional repression. On the other hand, unmethylated DNA and 
hyperacetylation of the histones are associated with an open chromatin structure and 
transcriptional activation. The process of DNA methylation and histone acetylation 
involves several proteins. DNA methyltransferases (DNMTs) and methyl-CpG-binding 
proteins (MBDs) are involved in the process of DNA methylation, mediating silencing of 
gene expression. Histones are acetylated by histone acetyltransferases (HATs), which 
create an accessible chromatin configuration that facilitates transcriptional activity. 
Histones are deacetylated by histone deacetylases (HDACs), which facilitate chromatin 
compaction and transcriptional inactivation. In cancer, aberrant epigenetic silencing 
of tumour suppressor genes frequently occurs by DNA hypermethylation and/or by 
decreased histone acetylation. The reversible characteristic of epigenetic modifications 
is being explored to revert the tumour phenotype using hypomethylating agents in 
combination with agents that inhibit the deacetylation. For instance, the combination 
of either 5-azacytidine or 5-aza-2’-deoxycytidine, which are potent hypomethylating 
agents when used in a low dose, with an HDAC inhibitor has significant activity in 
myelodysplastic syndrome and acute myelogenous leukemia167-169 (Figure box 1).
DNA methylation
HDAC inhibitors
Transcriptionally inactive 
chromatin state
Transcriptionally active 
chromatin state
Hypomethylating agents 
Histone acetylation
Figure box 1. Schematic representation of two important ways to epigenetically modify 
the DNA. DNA methylation is associated with a transcriptionally inactive chromatin state, 
while histone acetylation is associated with a transcriptionally active chromatin state. 
With HDAC inhibitors acetylation of histones can be increased resulting in transcriptional 
activation. With hypomethylating agents methylation of DNA can be decreased also resulting 
in transcriptional activation. 
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Figure 4. Schematic overview of miRNA processing. The majority of miRNA genes are 
transcribed by RNA polymerase II. First, a primary miRNA transcript (pri-miRNA) is transcribed 
from the genome and this pri-miRNA forms stem-loop structures of about 70-100 nucleotides in 
length. The precursor miRNA (pre-miRNA) is subsequently processed from the pri-miRNA by the 
enzyme Drosha, which cleaves both strands of the stem-loop. The pre-miRNA is then transported 
from the nucleus to the cytoplasm by the export receptor Exportin-5. In the cytoplasm, an 
enzyme called Dicer further processes the pre-miRNA. Dicer cuts the loop from the pre-miRNA 
to generate the mature miRNA (indicated by an asterisk) as part of a short RNA duplex and 
subsequently, this double stranded RNA is unwound by helicase activity. The mature miRNA 
is incorporated into a complex that is similar to the RNA-induced silencing complex (RISC) 
that participates in RNA interference. After incorporation of the miRNA strand into the RISC 
complex, the other strand of the duplex is degraded. When the mature miRNA is incorporated 
into the RISC complex it is ready to perform its function. 
The identification of tissue- and cell-specific gene and miRNA expression profiles 
and the comparison of these expression profiles between normal and malignant cells 
is a step towards the unravelling of the involvement of certain genes and miRNAs 
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in specific biological processes. Advances in the understanding of the molecular 
mechanisms of normal and malignant biological processes will offer the possibility 
of identifying new and more rational therapeutic strategies. Rather than a common 
therapy for all leukemic patients, ongoing research focuses on drugs that target 
unique alterations in protein networks, or deregulated cellular pathways that are 
specific for certain subgroups of patients, to obtain more disease pathogenesis-based 
and individualized therapy with a better over-all survival.
5. Basic helix-loop-helix transcription factors
One major class (>240 members) of regulatory factors that have been implicated in 
cell growth, cell differentiation, and cell fate decisions in many different tissues, 
including myogenesis,70 neurogenesis71 and hematopoiesis,72 is the helix-loop-helix 
(HLH) family of proteins.73 Developmental processes may be positively or negatively 
controlled by basic helix-loop-helix (bHLH) transcription factors and their inhibitors. 
As a common theme, tissue-specific bHLH factors form heterodimers with members 
of the more widely expressed E-protein bHLH family members E12/47, HEB and 
E2-2. For example, E-protein bHLH family members are heterodimerization partners 
for the tissue-specific bHLH factors such as the MyoD family of muscle regulatory 
bHLH proteins, the NeuroD family involved in nervous system development and the 
hematopoietic bHLH factor SCL/TAL1. In addition, E-proteins also have the capacity 
to homodimerize.74 Dimerization of these positively acting bHLH factors is essential 
for binding to DNA sequences that contain the (G/A)CANNTG(G/A) E-box consensus 
sequence present in the promoter region of responsive genes75 (Figure 5A). 
HLH factors play important roles in hematopoiesis. For example, the bHLH 
transcription factor SCL/TAL1 is essential for primitive hematopoiesis and is 
therefore a critical factor in the development of HSCs towards all hematopoietic cell 
lineages.72;76 Disruption of the SCL/tal1 gene in mice leads to a complete absence 
of blood and early embryonic lethality. The E2A gene is required for lymphocyte 
development, as revealed by E2A-/- mice, which show both severe defects in early 
B-cell development77;78 as well as abnormalities during the early stages of thymocyte 
differentiation. In addition, a high incidence of T-cell tumours was observed in 
these mice.79-81 Several mutations affecting bHLH proteins have been implicated in 
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lymphoid leukemia. Three bHLH family members (SCL/TAL1, LYL1 and E2A) are located 
at the sites of recurrent chromosomal translocations breakpoints in leukemia.82-84
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Figure 5. Transcriptional regulation by HLH proteins. (A) bHLH transcription factors contain 
a HLH motif, through which hetero- and homodimeric interactions are mediated. Furthermore, 
the bHLH proteins contain a conserved basic region that interacts with DNA. By forming dimers 
bHLH transcription factors can bind to specific DNA sequences, known as E-boxes, resulting in 
transcriptional activation of their target genes. (B) ID proteins constitute a separate class of HLH 
proteins lacking the DNA-binding domain and acting as dominant-negative regulators of bHLH 
transcription factors by trapping them in heterodimeric complexes that are unable to bind DNA. 
(C) Comparable to ID proteins, HES1 proteins function as dominant-negative regulators of bHLH 
transcription factors, but in contrast to ID proteins, HES1 proteins do contain a DNA-binding 
domain. This mechanism of transcriptional repression by HES1 is called passive repression. (D) 
By forming homodimers HES1 can bind to specific DNA sequences, known as N-boxes. Upon DNA 
binding corepressor complexes are recruited to mediate active transcriptional repression. 
6. ID proteins
The inhibitor of DNA binding (ID) proteins constitute a HLH subfamily and act as 
dominant-negative regulators of bHLH transcription factors.85 While capable of 
forming dimers with other HLH proteins, the four mammalian ID members (ID1-4)85-90 
lack a basic DNA-binding domain, thereby trapping bHLH factors in heterodimeric 
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complexes which are unable to bind DNA. Therefore, ID proteins prevent the bHLH 
protein complex from activating or inactivating downstream events. ID proteins 
contain a highly conserved HLH domain and are capable of binding to various common 
partner proteins91 (Figure 5B). In line with this, they were shown to exert similar 
or redundant biological functions in various experimental models. However, the 
differential expression patterns of different ID proteins in various tissues indicate 
different biological functions for each of the ID proteins under normal physiological 
conditions.90;92-95 Their intracellular expression level and their cytoplasmic or 
nuclear localization determine the specificity and functional activity of the 
individual ID proteins.96-98 In addition, posttranslational modifications may alter 
the activity of the ID proteins.99;100 Although E-proteins have been established as 
bona fide ID-interacting proteins in vivo, a range of other partners have been 
identified, including transcription factors that do not contain a HLH domain, such 
as retinoblastoma (Rb) proteins,101;102 Ets-family proteins,103 Pax,104 MIDA1,105-107 
SREBP-1c108 and PC2.109 The relevance of these various interactions in mediating 
biological functions of ID proteins in a truly physiological context in vivo has yet to be 
established.
Traditionally, ID proteins have been considered to function as negative regulators 
of cell differentiation. Nowadays this family of regulatory proteins has been ascribed 
much wider biological roles. Recent work has revealed that ID proteins act as 
negative as well as positive regulators dependent on the specific cell lineages and 
developmental stages analysed. They have been implicated in developmental biology, 
cell cycle regulation, tumorigenesis and angiogenesis.110;111
Besides the ID proteins, Hairy-Enhancer of Split (HES) proteins (HES1-7)112-119 
also act as transcriptional repressors of bHLH-regulated genes. Just like ID proteins, 
HES1 acts by sequestration of positive bHLH transcription factors into non-functional 
heterodimeric complexes113;116 (Figure 5C). In addition to this passive repression 
mechanism, HES1 proteins function as active repressors by binding to DNA. HES1 
proteins contain a DNA binding domain that preferentially recognizes the consensus 
sequence CACNAG (or N-box).113 HES1 homodimers bind to the N-box sequence and 
the corepressor TLE/Groucho is subsequently recruited to mediate repression by 
interaction with HDACs (Figure 5D). A third repression mechanism is mediated by the 
orange domain/helix3-helix4 in combination with the DNA-binding domain.120
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Box 2. ID2 as a functional target of the retinoblastoma protein
The retinoblastoma (Rb) protein is involved in the molecular machinery controlling the 
cell cycle by acting as a negative regulator of cell cycle progression. The G1/S transition 
is a key step for cell cycle progression and the Rb protein is able to repress this transition 
by inhibiting gene transcription that is required for S-phase entry. An important target 
of Rb proteins is the E2F family of transcription factors, which plays a pivotal role during 
entry into the S-phase. Rb family members are posttranslationally regulated and their 
phosphorylation leads to functional inactivation and the release of E2F factors. The Rb 
gene has an important role in suppressing tumorigenesis and is functionally inactivated 
in many human tumour types.170 Another Rb-interacting protein is Id2. By binding to Rb, 
Id2 is able to abolish its growth-suppressing activity. In addition, it has been suggested 
that Id2 is a downstream target of Rb, since rescue of embryonic lethality of Rb-/- mice 
by loss of Id2 was observed.101;102;150;152 By keeping control of Id2, Rb might prevent 
Id2-mediated inhibition of transcription factors that control normal development. 
The relationship between the Rb-E2F interaction and the Rb-Id2 interaction is poorly 
understood and remains to be further clarified. Rb might simultaneously bind E2F and 
Id2, but alternatively E2F and Id2 might compete for binding to Rb (Figure box 2). 
Rb-/- mice show profound abnormalities of fetal liver macrophages and loss of Id2 rescues 
this defect. A molecular cross-talk between Rb, Id2 and PU.1 in the transcriptional 
activation of a gene that controls macrophage development (CSF-1R) has been proposed 
as a model for the rescue of the Rb-deficient phenotype by loss of Id2. It has been 
suggested that by restraining Id2-mediated inhibition of the transcription factor PU.1, 
Rb promotes differentiation of macrophages.152
Figure box 2. Targets of the retinoblastoma protein.  By inhibiting E2F family members, 
Rb negatively regulates cell cycle progression, and by preventing Id2-mediated inhibition of 
transcription f actors, such as bHLH transcription factors, Rb stimulates growth suppression 
and differentiation. Furthermore, by binding to Rb, Id2 abolishes its growth-suppressing 
activity.
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6.1 ID proteins and lineage commitment
Knockout studies revealed a role for ID proteins during hematopoiesis (Table 1). 
Recently, it has been found that HSCs of Id1-/- mice showed a loss of self-renewal 
capacity and an increased tendency to myeloid differentiation.121 Id3-/- mice 
displayed defects in B-cell proliferation and a block in thymocyte maturation122;123 
and Id2-/- mice have the most severe phenotype of all single Id knockouts showing 
retarded growth and high neonatal morbidity. The surviving Id2-/- mice demonstrated 
an essential role for Id2 in the generation of peripheral lymph nodes and Peyer’s 
patches. These mice display disturbed differentiation of natural killer cells, they 
lack Langerhans cells and splenic CD8α+ dendritic cells were severly reduced. It was 
observed that spleens from Id2 -/- mice have lost their immature B-cell population 
while more mature B-cells were accumulated. Furthermore, the development of 
nasopharyngeal-associated lymphoid tissue was defective. T-cell development was 
not affected in these mice.124-129 No hematopoietic abnormalities were found in 
Id4-/- mice. All combinations of Id double knockout mice are embryonic lethal, which 
indicates that, at least in mammals, ID functions are required for survival.130;131 
Overexpression studies also demonstrate the involvement of ID proteins in the 
regulation of cell fate choices in the hematopoietic system (Figure 6). Upregulation 
of ID1 in CD34+ primary cells correlates with inhibition of erythrocyte differentiation 
while granulocyte differentiation was induced.132 In line with this, overexpression of 
ID1 in the erythroleukemia cell line K562 blocks erythrocyte differentiation.133;134 
In contrast, ID3 overexpression promotes differentiation in K562 cells, which might 
be explained by different preferences for partner proteins of the two ID proteins.135 
Recently, it has been shown that ectopic expression of ID1 in CD34+ cord blood 
cells enhances neutrophil differentiation whereas eosinophil development was 
inhibited. In contrast, ID2 overexpression enhances both neutrophil and eosinophil 
differentiation.136 These data indicate a differential role of ID proteins during 
lineage commitment. Overexpression of ID3 in human CD34+ fetal liver and thymic 
progenitor cells resulted in an inhibition of T-cell differentiation while natural killer 
cell development was promoted.137;138 Furthermore, transgenic mice in which Id1 or 
Id2 are specifically overexpressed in T-cells also show a block in T-cell development. 
Similar to the E2A-deficient mice and as would be expected given the opposing 
functions of ID and E2A gene products, Id1 and Id2 transgenic mice develop T-cell 
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lymphomas.139;140 Overexpression of Id1 in early B-cells, strongly impaired mouse 
B-cell development141 and when ID3 was introduced into uncommitted fetal liver cells, 
their capacity to develop into B-cells and lymphoid dendritic cells was inhibited while 
myeloid dendritic cell development was not affected.142;143 The latter has also been 
shown for ID2. Finally, constitutive expression of Id1 in a murine myeloid precursor 
cell line inhibited the ability to differentiate upon growth factor stimulation, which 
is in line with the observed increase in myeloid commitment of HSCs from Id1-
deficient mice.144 Evidence for a role of ID proteins in cell fate decisions also comes 
from expression profiling studies. Analysis of ID expression in human hematopoietic 
cell lines revealed that, in general, ID levels decline with increasing maturity. One 
exception is ID2, which shows upregulation during differentiation along monocyte-
macrophage, granulocytic and erythroid lineages.92;145-147 Together, these data 
suggest a role for ID proteins in regulating specific hematopoietic lineage choices.
Phenotype Reference
Id1 -/- – loss of HSC self-renewal capacity
– HSCs show increased tendency towards myeloid differentiation
121
Id2 -/- General
– high neonatal morbidity and retarded growth
Hematopoietic
– disturbed development of peripheral lymph nodes and Peyer’s patches
– defective NK cell differentiation
– lack of Langerhans cells
– reduction in the number of splenic CD8α+ DCs
– loss of immature B-cell population in the spleen
– accumulation of mature B-cells in the spleen
– defective NALT tissue
128,126,125,
129,127,124
Id3 -/- – defective B-cell proliferation
– block in thymocyte maturation
122,133
Id4 -/- – no hematopoietic abnormalities
Table 1. Hematopoietic abnormalities in Id knockout mice. Hematopoietic stem cell (HSC); 
natural killer (NK) cell; dendritic cell (DC); nasopharyngeal-associated lymphoid tissue (NALT). 
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Figure 6. Schematic overview of ID proteins and their effect on lineage specific 
differentiation. (A) Effect of overexpression of ID1 (+ ID1) on differentiation towards a specific 
lineage. (B) Effect of overexpression of ID2 (+  ID2) on differentiation towards a specific lineage. 
(C) Effect of overexpression of ID3 (+  ID3) on differentiation towards a specific lineage. 
The black bars represent defective or blocked differentiation; the black arrows represent 
enhancement of differentiation. 
6.2 ID proteins and cell cycle regulation
Since ID proteins have been shown to affect the balance between cell growth and 
differentiation and since, in many cases, cellular differentiation is accompanied by 
cell cycle arrest, it was postulated that ID proteins might also be involved in cell cycle 
regulation. Indeed, several lines of evidence suggest a role for ID proteins in cell 
cycle control. Since both positive and negative actions on cell cycle progression have 
been reported for the different ID genes, their role appears to be context-dependent. 
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For example, following serum stimulation of quiescent fibroblasts, the expression of 
Id1, Id2 and Id3 is induced and inhibition of Id protein synthesis inhibits cell cycle 
re-entry of G0-arrested fibroblasts.89;148;149 In contrast, ID2 is highly expressed in 
human CD34+ progenitor cells following growth arrest by cytokine starvation and 
the expression is decreased in the first hours after re-stimulation with cytokines. 
Therefore, ID2 expression seems to correlate with a state of quiescence rather than 
cell growth.145 Comparable, loss of Id1 in murine bone marrow HSCs induces an 
increase in HSC turnover.121 ID levels fluctuate throughout the cell cycle but whether 
this reflects an important role as modulator of cell cycle transitions remains to be 
clarified. 
The molecular mechanisms by which ID proteins are able to modulate the cell 
cycle are not well understood. Two distinct pathways have been described coupling 
ID function directly to promotion of cell cycle progression. One pathway involves the 
interaction between the Rb proteins and ID2 and ID4 that leads to the expression 
of genes required for S-phase transition.101;102;150 The second pathway, which 
is described for ID1, involves the inhibition of the E2A-mediated activation of the 
cyclin-dependent kinase inhibitor p21waf1/Cip1.151 
6.3 ID proteins and tumorigenesis
The ability of ID proteins to affect lineage commitment and to control cell cycling 
suggests that these proteins could have a role in tumorigenesis. Perhaps the best 
example that links ID overexpression to transformation of hematopoietic cells is the 
fact that Id1 and Id2 transgenic mice develop T-cell lymphomas.139;140 Since E2A-
deficient mice show a high incidence of T-cell tumours it might be possible that the 
inhibition of E2A by Id proteins is involved during tumorigenesis. Although the precise 
molecular mechanism remains unclear, these observations suggest an important role 
for ID and bHLH proteins in tumorigenesis within the hematopoietic system in vivo. 
Besides E-proteins, other ID interacting proteins such as Rb and Ets-family proteins 
are implicated in tumorigenesis. Rb proteins act as tumour suppressors and are 
functionally inactivated in the majority of human tumours. The lethality observed 
in Rb-/- mice at E14.5 is accompanied by widespread proliferation, defective 
differentiation and apoptosis in the nervous system and hematopoietic lineages. Loss 
of Id2 partially rescues the Rb-/- phenotype, suggesting that Rb is restraining the 
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activity of Id2.101;102;150;152 The data indicate that an increase in the available pool of 
Id2, which may also be achieved by hyperphosphorylated or inactive Rb protein, leads 
to cell cycle progression and defective differentiation. Concerning the Ets-family 
proteins, binding of ID1 targets Ets-mediated activation of the tumour suppressor 
p16Ink4a. It has been demonstrated that p16 Ink4a expression levels are controlled by a 
balance between Ets and ID1.153 It may well be possible that deregulated ID protein 
expression levels are involved in the inhibition of p16 Ink4a expression, which occurs 
frequently in a wide range of human cancers, including leukemia. 
One case has been described in which two ID4 short splice variants were found to 
be overexpressed due to a t(6;14)(p22;q32) chromosomal translocation in a B-cell 
lineage ALL.154 No other ID gene mutations were found in various tumour types, 
indicating that ID genes are not common oncogenes. However, since the ID genes 
have not been examined for genetic alterations in many studies, more studies are 
required to investigate this in more detail. In contrast to the observed overexpression 
of ID4 splice variants, ID4 was also found to be silenced by methylation in murine and 
human leukemias, indicating a possible role in tumour suppression.155 Further studies 
should clarify the possible roles of ID4 and its aberrant splice variants in distinct 
types of leukemia. 
Although ID genes may not be common oncogenes, elevated levels of ID mRNA 
and protein expression has been reported in diverse human tumour types, including 
leukemia, and it has been demonstrated that upregulation may be mediated by 
well-established oncoproteins as RAS,156;157 MYC 150;158;159 and the chimera Ewing’s 
sarcoma (EWS)-ETS.160;161
A feature of some oncoproteins, such as MYC and E2F1, is the ability to drive 
apoptosis when ectopically overexpressed. Depending on the cell context, these 
proteins can either function as anti-apoptotic or as pro-apoptotic molecules. Several 
groups have demonstrated that ID proteins also have pro-apoptotic properties in cell 
line and primary cell models.162-166 In addition, enforced expression of Id genes in vivo 
also induces apoptosis. For example, the T-cell block and the development of T-cell 
lymphomas in transgenic mice in which Id1 and Id2 are specifically overexpressed 
in T lymphocytes, is accompanied by widespread apoptosis.140 Together, these data 
indicate that, although ID family members are not common oncoproteins, at least 
they share some features of oncoproteins.
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Box 3. ID proteins and tumour angiogenesis
In addition to the involvement of ID proteins in lineage commitment and cell 
cycle regulation, an essential role of these proteins have been demonstrated in 
neovascularization of tumours, which allows rapid growth.171 This property of ID 
proteins was first discovered when studying the growth of tumours in Id1-/-/Id3+/- mice. 
In subcutaneous tumour models, the mice with reduced Id levels showed a marked 
decrease in primary tumour growth and/or metastasis due to poor vascularization with 
concomitant necrosis of the tumour cells.130 Bone marrow transplantation of these 
Id1-/-/Id3+/- mice with cells from a wild-type donor restores tumour angiogenesis and, 
conversely, introduction of Id1+/-/Id3-/- bone marrow cells into a wild-type host results 
in a profound delay in the appearance of subcutaneous tumours. It has been found that 
bone marrow-derived endothelial precursor cells and hematopoietic precursor cells 
play an important role in the formation of new vessels and that disruption of Id1 and Id3 
results in the failure to mobilize these bone marrow precursor cells from the marrow to 
the sites of tumour vasculature.172 Thus, by targeting ID proteins it might be possible to 
inhibit tumour angiogenesis.
7. Concluding remarks
As illustrated by the above overview of ID proteins and their roles during normal 
and malignant hematopoiesis, ID protein functions have been implicated in a wide 
range of biological processes. Since the expression pattern of the four mammalian ID 
proteins is cell lineage and developmental stage-specific, the different ID proteins 
have different binding specificities and their activity is regulated in several distinct 
ways, it is likely that their mode of action is cell type specific. Therefore, it is 
doubtful whether their biological functions and molecular mechanisms as found in 
a particular cell lineage can be extrapolated to other mammalian cell lineages. It 
has been proposed that ID proteins are good candidates for developing targeted 
therapies, since ID proteins have been demonstrated to mediate the activity of 
several important genes that are involved in carcinogenic processes. To target the 
functional activities of these intracellular proteins in myeloid malignancies, it will 
be important to further establish the role of ID proteins in normal and malignant 
myeloid development. The significance of the interactions between ID proteins 
and its various bHLH and non-bHLH binding partners, the identification of target 
genes whose expression is regulated by ID proteins, the transcriptional control of ID 
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protein expression and the posttranslational regulation of ID protein activity during 
myelopoiesis remains to be clarified in order to be able to use the ID proteins to 
target myeloid malignancies. In this thesis we investigated myeloid hematopoiesis by 
using APL as a model.
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Chapter 2
ID1 and ID2 are retinoic acid responsive genes 
and induce a G0/G1 accumulation in 
Acute Promyelocytic Leukemia cells
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Abstract
Acute promyelocytic leukemia (APL) is uniquely sensitive to treatment with all-
trans retinoic acid (ATRA), which results in the expression of genes that induce the 
terminal granulocytic differentiation of the leukemic blasts. Here we report the 
identification of two ATRA responsive genes in APL cells, ID1 and ID2. These proteins 
act as antagonists of basic helix-loop-helix (bHLH) transcription factors. ATRA induced 
a rapid increase in ID1 and ID2, both in the APL cell line NB4 as well as in primary 
patient cells. In addition, a strong downregulation of E2A was observed. E2A acts as 
a general heterodimerization partner for many bHLH proteins that are involved in 
differentiation control in various tissues. The simultaneous upregulation of ID1 and 
ID2, and the downregulation of E2A suggest a role for bHLH proteins in the induction 
of differentiation of APL cells following ATRA treatment. To test the relevance of this 
upregulation, ID1 and ID2 were overexpressed in NB4 cells. Overexpression inhibited 
proliferation and induced a G0/G1 accumulation. These results indicate that ID1 
and ID2 are important retinoic acid responsive genes in APL, and suggest that the 
inhibition of specific bHLH transcription factor complexes may play a role in the 
therapeutic effect of ATRA in APL.
ID1 and ID2 inhibit APL cell proliferation
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Introduction
In 98% of the cases of acute promyelocytic leukemia (APL), the promyelocytic (PML) 
gene on chromosome 15 is fused to the retinoic acid receptor α (RARA) gene on 
chromosome 17 resulting in a PML-RARα fusion protein. PML-RARα may interfere 
with the normal function of the retinoic acid receptor, a nuclear hormone receptor 
that acts as a ligand-dependent transcription factor.1 Several important RARα target 
genes have been identified that are deregulated by PML-RARα in APL cells including 
p21waf1/Cip1 2-4 and the transcription factors CCAAT/enhancer-binding-protein-β and 
-ε (C/EBPβ and C/EBPε).5;6 p21waf1/Cip1 is a cyclin-dependent kinase inhibitor that 
is involved in the regulation of the activity of several cyclin-dependent kinases and 
in the cell cycle. The C/EBP transcription factors are involved in the regulation of 
granulocytic differentiation. 
Hematopoietic differentiation is controlled by specific combinations of 
transcription factors. Some of these are expressed in stem cells, such as AML1, 
whereas others have a more lineage-specific expression pattern. GATA1, PU.1, C/
EBPα and C/EBPε are lineage-specific transcription factors that are important in 
myeloid development. The results of both knockout and expression studies have 
shown that GATA1 participates in the differentiation of common myeloid progenitors 
to megakaryocyte/erythroid progenitors, PU.1 is involved in the development of 
monocytes/macrophages and C/EBPα and C/EBPε have a role in granulopoiesis. 
These transcription factors may lock lineage commitment decisions irreversibly by 
autostimulation of their own expression. In addition, they may inhibit the expression 
of transcription factors that are involved in alternate differentiation routes, as has 
been described for PU.1 and GATA1.7 
Members of the bHLH family of transcription factors have been implicated in 
cell fate decisions in many different tissues. For example, the bHLH transcription 
factors MyoD and myogenin are involved in the development of muscle tissue and 
during neurogenesis the bHLH protein MASH-1 plays an essential role.8 As a common 
theme, tissue-specific bHLH factors form heterodimers with members of the more 
ubiquitously expressed E-protein bHLH family members E12/47, HEB and E2-2, which 
are generally considered as promiscuous heterodimerization partners. 
ID proteins constitute a separate class of helix-loop-helix (HLH) proteins lacking 
the basic DNA-binding domain and acting as dominant-negative regulators of bHLH 
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transcription factors by trapping them in heterodimeric complexes which are unable 
to bind DNA.8 In addition, ID proteins have been implicated in cell cycle control 
through direct interaction with the retinoblastoma protein,9 and by interaction 
with the centrosome.10 Recent data indicate the involvement of ID proteins in 
angiogenesis, metastasis and tumorigenesis.11-14 In hematopoiesis, bHLH transcription 
factors and their dominant-negative regulators, the ID proteins, have been implicated 
in lymphopoiesis. Constitutive expression of Id1 targeted to pro-B cells in transgenic 
mice revealed impairment of B lymphocyte development.15 In addition, several 
mutations affecting bHLH proteins have been implicated in lymphoid leukemia. 
Three bHLH family members (SCL/TAL-1, LYL-1 and E2A) are located at the sites of 
recurrent chromosomal translocation breakpoints in leukemia. The t(1;14) in patients 
with T-cell acute lymphoblastic leukemia (T-ALL) transposes the SCL gene to the TCR 
α/δ locus on chromosome 14.16 The t(7;19) in T-ALL involves the LYL-1 gene that 
is translocated to the TCR β locus.17 E2A is involved in the t(1;19) that occurs in 
approximately 25% of the cases of childhood pre-B-ALL and results in the generation 
of an E2A-PBX fusion protein.18 In this paper, we describe the involvement of ID1 and 
ID2 in the response of APL cells to retinoic acid treatment.
Materials and methods
Cell culture
Bone marrow mononuclear cells of APL patients were isolated at diagnosis by lysis of erythrocytes 
in 0.14 M NH4Cl buffer for 30 min on ice. Indirect immunostaining with a monoclonal anti-
PML antibody (PG-M3, Santa Cruz Biotechnology, Santa Cruz, CA, USA) showed a microspeckled 
pattern characteristic for the PML-RARα fusion protein.19-21 Cytogenetic analysis showed that 
all patients were positive for the t(15;17)(q22;q21) chromosome translocation. Patients and 
NB4 cells22 were cultured in RPMI 1640 medium (Life Technologies, Gaithersburg, MD, USA) 
supplemented with 10% fetal calf serum (FCS) and 2 mM glutamine (Life Technologies). The 
amphotrophic Phoenix cell line (Φ-NX-A) (kindly provided by Dr. G.P. Nolan, Stanford University 
Medical Center, Stanford, CA) was cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Life 
Technologies) supplemented with 10% FCS and 2mM glutamine. Cultures were incubated at 37°C 
in a 5% CO2 completely humidified atmosphere.
ID1 and ID2 inhibit APL cell proliferation
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Northern blotting
NB4 cells were induced with all-trans retinoic acid (ATRA) (dissolved in ethanol to a stock 
solution of 10-3 M, Sigma, St Louis, MO, USA) at a final concentration of 10-6 M. Total cellular RNA 
was isolated by guanidinium-isothiocyanate lysis and centrifugation on a 5.7 M CsCl cushion. 
PolyA+ RNA was isolated from total RNA by using a mRNA purification kit (Pharmacia Biotech, 
Uppsala, Sweden). In total, 10 μg of total RNA or 1 μg of PolyA+ RNA was size-fractionated by 
1% agarose-formaldehyde gel electrophoresis and transferred onto Hybond N+ nylon membranes 
(Amersham, Buckinghamshire, UK). The filters were pre-hybridized and hybridized at 65°C 
overnight in phosphate buffer (2N NaH2PO4, 2N Na2HPO4), 7% sodium dodecyl sulphate (SDS), 
1 mM ethylenediaminetetraacetic acid (EDTA) pH=8.0 and 1% bovine serum albumine (BSA). 
DNA probes were labeled with [32P]α-dATP by random primed labeling (Boehringer, Mannheim, 
Germany). After hybridization, the filters were washed in 0.2 x SSC/0.2% SDS for 15 min at 
65°C. Northern blots were hybridized to radiolabeled human ID1 (kindly provided by Dr. S. 
Stegman, NKI, Amsterdam, The Netherlands), murine Id2 (kind gift from Dr. X.H. Sun, NYU, New 
York, NY, USA), human ID3 (kindly provided by Dr. J.D. Norton, Christie CRC Research Centre, 
Manchester, UK), human ID4 (kindly provided by Dr. L. Lania, University of Naples ‘Federico II’, 
Naples, Italy) and E2A (kindly provided by Dr. S. Stegman). As a control for equal loading, filters 
were stripped and hybridized to a 777bp HindIII-EcoRI human GAPDH fragment. 
Western blotting
Non-stimulated and ATRA-stimulated NB4 cells were lysed in RIPA-buffer containing 1% 
Nonidet P-40 (NP-40), 0.5% natrium-deoxycholaat, 0.1% SDS and protease inhibitor cocktail 
(Roche Diagnostics, Basel, Switzerland). Total protein lysates (50 μg) and molecular weight 
markers were separated on 12% (ID1 and ID2) or 7% (E2A) SDS-poly-acrylamide gels and 
electrophoretically transferred onto polyvinylidenefluoride (PVDF) membranes (Bio-Rad, 
Hercules, CA, USA). Blots were probed with antibodies to ID1 (Z-8), ID2 (C-20) (Santa Cruz 
Biotechnology) and with anti-human E2A (E12/E47) antibody (BD Biosciences, San Diego, CA, 
USA). As a control for equal loading, blots were probed with antibodies to Cdc2 p34 (H-297) or 
to Actin (I-19) (Santa Cruz Biotechnology). 
Construction of retroviral vectors
The pLZRS retroviral vector in which the multiple cloning site is linked to the downstream 
internal ribosomal entry sequence (IRES) and a truncated form of the nerve growth factor 
receptor (∆NGFR) were kindly provided by Dr. G.P. Nolan and Dr. M.H.M. Heemskerk, LUMC, 
Leiden, The Netherlands, respectively. The pLZRS-ID1-IRES-∆NGFR was constructed by cloning 
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the human ID1 cDNA sequence into the BamH1/Xho1 site of pLZRS-∆NGFR and pLZRS-ID2-
IRES-∆NGFR was constructed by cloning the human ID2 cDNA sequence into the BamH1 site 
of pLZRS-∆NGFR. The pLZRS-∆NGFR and pLZRS-EGFP-IRES-∆NGFR were used as control vectors 
in the experiments. The pLZRS-EGFP-IRES-∆NGFR was constructed as follows: pEGFP-C1 was 
purchased from Clontech Laboratories (Palo Alto, CA, USA) and the EGFP fragment was isolated 
by BamH1/Not1 digestion. This EGFP fragment was cloned into the BamH1/Not1 site of pcDNA3, 
isolated by BamH1/Xho1 digestion and subsequently cloned into the BamH1/Xho1 site of pLZRS-
∆NGFR. 
Retroviral supernatants, transduction of NB4 cells and magnetic cell sorting 
Retroviral constructs were transfected into Φ-NX-A cells using the calcium phosphate 
precipitation method. At 24 hours prior to transfection, Φ-NX-A cells were seeded at 2.8 x 
106 cells/75cm2. At 16 hours after transfection, the medium was replaced with fresh medium. 
Supernatants were harvested, centrifuged and frozen in aliquots at -80°C. For transduction, 
cells were cultured on retronectin (Takara Bio Inc., Otsu, Shiga 520-2193, Japan) -coated 
35 mm Petri dishes together with 2 ml of thawed supernatant for 22 hours and then washed 
with phosphate-buffered saline (PBS) (B. Braun Melsungen AG, Melsungen, Germany). The 
transduction efficiencies, measured by the expression of the marker ∆NGFR, were analyzed 
by flow cytometry 1 day after transduction on a Beckman Coulter Cytomics FC 500 (Beckman 
Coulter, Miami, FL, USA). Transduction efficiencies were between 17 and 21% for all different 
transduced cells. Expression levels of the ∆NGFR were followed during a culture period of at 
least 22 days and revealed that levels did not change during culture. ∆NGFR expression was 
detected by using the supernatant of the 20.4 hybridoma (American Type Culture Collection) 
producing anti-human NGFR antibody. Transduced NB4 cells were isolated by magnetic cell 
sorting (MACS) on the basis of ∆NGFR positivity. Flow cytometric analysis of ∆NGFR expression 
of the MACS-sorted cells showed a purity of more than 90% in all experiments. Expression of ID1 
and ID2 in isolated transduced cells was confirmed by Western blotting. 
Colony-forming assay
Clonogenic growth of tranduced and MACS-sorted NB4 cells was measured by plating 800 cells/
ml in semisolid (1.2% methylcellulose; Methocel, Fluka Chemie, Buchs, Switzerland) culture 
medium (Iscove’s modified Dulbecco’s medium, IMDM, Life Technologies) supplemented with 
20% FCS. Where appropriate, ATRA was added to the semisolid medium at final concentrations 
as indicated in the figure legends. Colonies were counted after 6 days of culture. 
ID1 and ID2 inhibit APL cell proliferation
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Cellular differentiation and cell cycle characteristics
Differentiation of transduced and MACS-sorted NB4 cells was assessed on May-
Grünwald-Giemsa stained cytospin slides. In addition, the nitroblue-tetrazolium 
(NBT, Sigma) reduction test was performed as described.23 The expression of the 
differentiation-related surface marker CD11c was measured with a phycoerythrin 
(PE)-conjugated monoclonal antibody (Immunotech, Marseille, France), apoptosis 
was measured using Annexin-V-Alexa Fluor 647 (Molecular Probes, Eugene, OR, USA). 
Results were analyzed on a Beckman Coulter Cytomics FC 500 (Beckman Coulter). More 
than 5 days after transduction and MACS-sorting NB4 cells were stained for DNA by 
incubation with a hypotonic propidium iodide solution. Bivariate staining for BrdUrd 
incorporation and DNA content and calculation of the cell cycle time was performed 
as described previously.24 Flow cytometric analysis of the results was performed on a 
Coulter Epics Elite flowcytometer (Beckman Coulter, Miami, FL, USA).
Results
ID1 and ID2 are rapidly induced upon ATRA treatment of APL cells
bHLH transcription factors and their inhibitors, ID proteins, play an important 
role in the regulation of proliferation and differentiation of various cell types. We 
assessed the expression of all four ID gene family members (ID1-ID4) in APL cells 
before and after incubation with 10-6 M ATRA. Total RNA was isolated from the PML-
RARα positive APL cell line NB4 that can be induced to differentiate with ATRA. ID1 
and ID2 mRNA levels strongly increased after exposure to ATRA (Figure 1A and B). 
ID1 mRNA expression was upregulated within 2 hours and returned to undetectable 
levels at 48 hours after ATRA stimulation. ID2 mRNA expression was also upregulated 
within 2 hours but remained elevated and further increased after 48 to 96 hours after 
stimulation. In contrast, ID3 and ID4 mRNA could not be detected on Northern blots 
using total RNA (not shown) or polyA+ mRNA (Figure 1C and D, respectively). 
The expression pattern of ID1 and ID2 was confirmed in APL patient cells (Figure 
1E and F). Leukemic cells were freshly isolated from bone marrow of newly diagnosed 
patients with previously untreated APL and incubated in the presence or absence of 
ATRA. After culture for various times RNA was isolated. Both ID1 and ID2 mRNA were 
rapidly induced by ATRA. Figure 1E shows that ID1 was induced within 2 hours and 
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declined to undetectable levels after 24 hours. ID2 levels remained elevated at 24 
hours of incubation (Figure 1F).
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Figure 1. ID1 and ID2 mRNA and protein are upregulated upon ATRA treatment in both NB4 
and fresh APL patient cells. Northern blot analysis was performed with total RNA from NB4 
cells (A,B) after exposure to 10-6 M ATRA for 0, 2, 8, 24, 48 and 96 hours. (C,D) ID3 and ID4 
mRNA was not detectable in APL cells. PolyA+ RNA was extracted from NB4 cells after exposure 
to 10-6 M ATRA for 0, 8 and 24 hours and blots were hybridized with radiolabeled ID3 (C) and 
ID4 (D) probes. Analysis of ID1 and ID2 mRNA expression in patient cells (E,F) was performed by 
Northern blot analysis with total RNA derived from APL patient cells after ATRA treatment. The 
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blots were hybridized with radiolabeled ID1 (A,E) and ID2 (B,F) probes. A GAPDH probe was used 
as a control for equal loading of RNA in all Northern blot experiments. (G,H) Total cell lysates 
(50 μg) from non-stimulated and ATRA-stimulated NB4 cells (10-6 M ATRA was added for 0, 4, 8, 
24, 48 and 96 hours) were subjected to immunoblot analysis using antibodies to ID1 (G) and ID2 
(H). The same blots were reprobed with a CDC2 antibody to demonstrate equal loading. 
In response to ATRA, ID1 and ID2 were also clearly induced at the protein level 
(Figure 1G and H). Western blotting demonstrated that ID1 protein levels were 
increased at 4 and 8 hours after ATRA incubation to diminish to almost undetectable 
levels at 24 hours after incubation with ATRA (Figure 1G). ID2 protein was induced at 
48 to 96 hours after ATRA incubation (Figure 1H). Thus, ID1 and ID2 mRNA and protein 
are rapidly upregulated by ATRA in both NB4 as well as fresh APL cells.
E2A is downregulated during ATRA-induced APL cell differentiation
Since ID proteins act as general inhibitors of bHLH transcription factors by inhibiting 
their binding to DNA, we measured the expression of E2A, a ubiquitously expressed 
bHLH protein that serves as a promiscuous heterodimerization partner for many, 
more tissue-restricted bHLH proteins. Myeloid specific bHLH proteins are not known 
yet. E2A mRNA was expressed in non-stimulated NB4 cells but was downregulated 
within 48 hours after exposure to ATRA (Figure 2A). Also at the protein level, E2A 
expression strongly decreased upon ATRA-induced differentiation (Figure 2B): within 
48 hours, E2A protein expression dropped to undetectable levels. The simultaneous 
downregulation of E2A and upregulation of ID1 and ID2 suggest a strong repression 
of bHLH transcription factor activity upon differentiation induction of APL cells by 
ATRA. 
ID1 and ID2 inhibit the clonogenic growth of NB4 cells 
To determine the biological relevance of this induction pattern, we tested the effect 
of forced ID1 and ID2 overexpression in NB4 cells. Cells were retrovirally transduced 
using a pLZRS retroviral vector that contains the ID1 or ID2 coding sequence in front 
of an IRES-∆NGFR cassette, allowing the isolation of transduced cells with anti-NGFR 
coated immunobeads. As controls, cells were transduced with a vector containing 
the enhanced green-fluorescent protein (EGFP) coding sequence in front of the 
IRES-∆NGFR cassette and with a vector that contained the IRES-∆NGFR cassette 
alone (empty vector). Immunobead selection resulted in more than 90% purity in all 
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experiments. Stable enhanced expression of ID1 and ID2 in these cells was confirmed 
by Western blotting (Figure 3A). The levels of ID1 and ID2 expression in the transduced 
cells were comparable to the endogenous levels in NB4 cells after induction with 
ATRA as determined by Western blotting (data not shown). The effect of ID1 and ID2 
expression was analyzed in a colony-forming assay (Figure 3B). Compared to control-
transduced cells, expression of ID1 and ID2 resulted in inhibition of clonogenic growth 
by 70 and 50% respectively. 
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Figure 2. E2A mRNA and protein is downregulated upon ATRA treatment of NB4 cells. (A) 
Northern blot analysis was performed with total RNA extracted from NB4 cells after exposure 
to 10-6 M ATRA for 0, 2, 8, 24, 48 and 96 hours. The blot was hybridized with a radiolabeled E2A 
probe. A GAPDH probe was used as a control for equal loading of RNA. (B) Total cell lysates 
(50 μg) from non-stimulated and ATRA-stimulated NB4 cells (10-6 M ATRA was added for 0, 8, 24, 
48 and 96 hours) were subjected to immunoblot analysis using an anti-human E2A antibody. As a 
control for equal loading, the same blot was reprobed with an Actin antibody.
Since PML-RARα requires higher concentrations of ATRA to become active as a 
transcriptional activator than the normal, unrearranged RARα,1 we tested whether 
overexpression of ID1 and ID2 would be sufficient to restore responsiveness of the 
cells at lower concentrations. Colony-forming assays were performed in the presence 
of increasing concentrations of ATRA (Figure 3B). Apart from the reduction of colony 
numbers, overexpression of ID1 or ID2 did not alter the concentration at which 
inhibition of colony formation was observed, which remained at between 10-8 and 3 x 
10-8 M ATRA for both control and ID1 or ID2 expressing cells.
ID1 and ID2 inhibit the proliferation of APL cells
To explain the inhibitory effect of ID1 and ID2 on colony formation, we compared 
the growth characteristics and differentiation of ID1-, ID2- and vector-transduced 
ID1 and ID2 inhibit APL cell proliferation
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NB4 cells in liquid cultures. To ensure exactly comparable growth conditions, non-
transduced and transduced NB4 cells were mixed 1:1, seeded into culture flasks and 
analyzed at various time intervals afterwards. Proliferation of the transduced and 
non-transduced cells was analyzed using ∆NGFR expression to distinguish between 
the transduced and non-transduced cells (Figure 4). When empty vector- or EGFP-
transduced cells were seeded, the proportion of transduced cells remained constant 
over a 3-week period, indicating comparable growth rates of transduced and non-
transduced NB4 cells. When ID1- or ID2-transduced cells were seeded, a steady 
decrease of transduced cells was observed (from 50 to 16 and 22%, respectively) 
during a 3-week culture period. As the transduced cells represent a population of 
cells with different viral integration sites, and the number of empty vector- and 
EGFP-transduced cells did remain stable during culture, silencing of the expression 
from the viral construct can not explain this result. Therefore, we concluded that 
ID1 and ID2 inhibited the growth of NB4 cells, consistent with the inhibition of colony 
formation. To determine whether ID1 and ID2 induced the cells to differentiate 
towards granulocytes, we measured various differentiation parameters in isolated 
ID1- and ID2-transduced cells. Overexpression of ID1 and ID2 did not induce CD11c 
expression (Table 1) and did not stain positive in the NBT reduction assay (not shown). 
Furthermore, apoptosis (as measured by Annexin-V positivity) was not different in 
ID1- or ID2-transduced cells compared to vector-transduced or non-transduced cells 
(Table 1). Together, this indicates that ID1 and ID2 did not induce differentiation 
or apoptosis of the NB4 cells. In order to analyze cell proliferation parameters in 
more detail, cells were pulse-labeled with BrdUrd. BrdUrd is incorporated into the 
DNA during the S phase. Dividing cells are labeled and the transition of these cells 
through the cell cycle can be monitored. At 0 and 7 hours after labeling, BrdUrd/
DNA flow cytometry was performed (Figure 5A). In five independent experiments, 
no significant difference in the duration of one complete cell cycle between the ID1- 
(25,6 hrs ± 3,3), ID2- (22,5 hrs ± 1,2) and vector- (22,8 hrs ± 2,4) transduced cells was 
observed. However, calculation of the percentage of cells in the different phases of 
the cell cycle indicated that both ID1 and ID2 caused an increase of cells in the G0/
G1 phase, from 34,7% (± 0,9) in the vector-transduced cell populations to 41,6% (± 
1,4) and 38,9% (± 1,9) in the ID1 and ID2 overexpressing cell populations, respectively 
(Figure 5B). Therefore, what we show is that once cells divide to enter mitosis, the 
cell cycle time of ID1- and ID2-transduced and vector-transduced cells is comparable, 
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whereas the number of cells that are cycling is different. We conclude that ID1 and 
ID2 increased accumulation of cells in G0/G1 in NB4 cells, without inducing apoptosis 
or enhancing differentiation.
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Figure 3. ID1 and ID2 inhibit the clonogenic growth of NB4 cells. NB4 cells were retrovirally 
transduced with pLZRS-ID1-ΔNGFR (ID1) and pLZRS-ID2-ΔNGFR (ID2) and as a control with 
pLZRS-EGFP-ΔNGFR (EGFP) and pLZRS-ΔNGFR (empty vector). (A) Total cell lysates from ID1-, 
ID2-, EGFP-, and empty vector-transduced cells were subjected to immunoblot analysis using 
antibodies to ID1 (left panel) and ID2 (right panel) after a culture period of 39 days. (B) Colony-
forming assays were performed on transduced and MACS-sorted ΔNGFR-positive cells (n=4). 
Transduced cells were plated per 800 cells in semisolid culture medium supplemented with 
ATRA at final concentrations (conc.) as indicated in the figure and colonies were counted after 
6 days. pLZRS-EGFP-ΔNGFR and pLZRS-ΔNGFR showed a mean (± SD) of 86 (± 8) and 76 colonies, 
respectively. Overexpression of ID1 and ID2 resulted in only 24 (± 3) and 39 (± 22) colonies 
per 800 cells, respectively. The concentration of ATRA at which colony growth decreased was 
similar for  pLZRS-ID1-ΔNGFR, pLZRS-ID2-ΔNGFR and control-transduced cells.
ID1 and ID2 inhibit APL cell proliferation
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Figure 4. ID1 and ID2 inhibit proliferation of NB4 cells. pLZRS-ID1-ΔNGFR (ID1), pLZRS-ID2-
ΔNGFR (ID2) and as a control pLZRS-EGFP-ΔNGFR (EGFP) and pLZRS-ΔNGFR (empty vector) were 
retrovirally transduced to NB4 cells. A mixed population of 50% ΔNGFR-positive transduced and 
sorted cells and 50% non-transduced NB4 cells were flow cytometrically analyzed for ΔNGFR 
expression during 22 days of liquid culture in at least two independent experiments. ID1 
and ID2 overexpression demonstrated a decrease in ΔNGFR-positive cells from 50 to 16 and 
22%, respectively. Percentages ΔNGFR-positive cells of the control (empty vector- or EGFP-
transduced cells) remained constant.
% CD11c positive cells % Annexin-V positive cells
Days in 
culture
Non-
transduced Vector ID1 ID2
Non-
transduced Vector ID1 ID2
1 0.3 0.4 0.2 0.4 1.7 2.1 2.5 2.7
2 0.2 0.5 0.3 0.3 1.3 1.6 2.1 3.1
3 0.5 0.5 0.5 0.4 1.6 1.3 4.6 3.2
4 0.4 0.3 0.7 1.0 1.6 1.1 4.0 2.8
14 0.6 0.3 0.5 0.7 2.7 4.5 5.5 3.8
Table 1. ID1 and ID2 do not induce CD11c expression or Annexin-V positivity. pLZRS-ID1-
ΔNGFR (ID1), pLZRS-ID2-ΔNGFR (ID2) and as a vector control pLZRS-EGFP-ΔNGFR and pLZRS-
ΔNGFR were retrovirally transduced to NB4 cells. The populations of the different transduced 
and MACS-sorted ΔNGFR-positive cells and non-transduced cells were flow cytometrically 
analyzed for CD11c expression and Annexin-V positivity at different time points after 
transduction. No differences between non-transduced, vector-transduced and ID1- or ID2-
transduced cells were observed.
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Figure 5. ID1 and ID2 cause an increase of cells in G0/G1 without affecting the cell cycle time. 
pLZRS-ID1-ΔNGFR (ID1), pLZRS-ID2-ΔNGFR (ID2) and as a vector control pLZRS-EGFP-ΔNGFR and 
pLZRS-ΔNGFR were retrovirally transduced to NB4 cells. (A) ID1 and ID2 overexpression does 
not alter the cell cycle time of NB4 cells as compared to vector-transduced and sorted cells, as 
calculated from the results of five independent BrdUrd incorporation experiments done at 7, 8 
16 or 25 days after transduction (mean values ± SD). (B) ID1 and ID2 overexpression in NB4 cells 
cause an increase of cells in G0/G1 phase of the cell cycle as compared to vector-transduced 
and sorted cells as measured at different time points after transduction, either 7, 8 or 23 
days. DNA histograms of five independent experiments showed a mean (± SD) of 41,6% (± 1,4) 
and 38,9% (± 1,9) cells in G0/G1 phase for ID1 and ID2 overexpressing NB4 cells, respectively, 
compared to 34,7% (± 0,9) for the vector-transduced and sorted cells.
Discussion
We identified two genes, ID1 and ID2, which are rapidly induced by ATRA in APL 
cells. In both the NB4 cell line and in freshly isolated patient cells, ATRA induced 
the expression of these genes within 2 hours. ID2 expression remained high and was 
more enhanced after 48 hours of stimulation. In contrast, the expression of ID1 was 
transient, being downregulated again within 24 hours after stimulation. The rapid 
induction of ID1 and ID2 mRNA expression in NB4 cells by ATRA was not affected by 
cycloheximide indicating that ID1 and ID2 are direct ATRA-responsive genes (Van 
Wageningen et al., see Chapter 3 of this thesis). 
One of the main biological actions of ID proteins is their capacity to inhibit the 
DNA binding by bHLH transcription factor complexes. They bind and inactivate 
various lineage-specific bHLH proteins as well as their more ubiquitously expressed 
heterodimerization partners (E12/47, HEB, E2-2). The four different ID proteins 
ID1 and ID2 inhibit APL cell proliferation
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(ID1-ID4) contain a highly conserved HLH domain and are capable of binding 
to various common partner proteins.8 In line with this, they were shown to exert 
similar or redundant biological functions in various experimental models. However, 
the differential expression of different ID proteins in various tissues indicate 
different biological functions for each of the ID proteins under normal physiological 
conditions.9;25 Various knockout mice were generated carrying null mutations in the 
different Id proteins. While no gross abnormalities were observed in Id1-/- mice,26 
Id2-/- mice showed retarded growth and high neonatal morbidity. Surviving Id2-/- mice 
displayed severely disturbed natural killer cell production and defective peripheral 
lymphoid organ development.27 Redundancy of Id protein function was illustrated by 
the observation that breeding of various single Id gene knockout mice did not produce 
viable offspring carrying null mutations in two different Id proteins.25 
One of the important bHLH proteins that is inactivated by ID proteins is E2A. E2A 
is important for lymphoid development and E2A-/- mice show severe defects in early 
B cell development.28 In addition, a high incidence of T-cell tumours was observed in 
these mice.26 In line with this, inhibition of bHLH trancription factors by the ectopic 
overexpression of Id2 in developing thymocytes led to the rapid development of 
lymphomas.29 Further evidence for the antagonistic action of Id and E2A proteins 
came from studies with E2A/Id1 double knockout mice. Compared to single E2A 
knockout mice, the double knockout mice survived significantly better.26 The 
biological role of E2A may be dependent on the differentiation stage and cell type 
in which it is expressed. It has been shown to inhibit G1/S progression in various cell 
types including fibroblasts and early thymocytes.30;31 However, E2A was also reported 
to be highly expressed in proliferating centroblastic B-cells32 and to promote cell 
cycle progression in other cells as well.33 This difference might be explained by the 
presence of different bHLH heterodimerization partners for E12 and E47 in different 
tissues. 
The simultaneous upregulation of ID proteins and downregulation of E2A may 
represent a dual mechanism to ensure that E2A–dependent transcription is shut-off 
during differentiation. Alternatively, as various bHLH proteins were shown to be 
able to bind to DNA in a homodimeric configuration as well,8 the primary function of 
ID1 and ID2 induction may be to inhibit E2A-independent homodimeric DNA-binding 
by more lineage-restricted bHLH transcription factor complexes. The decreased 
expression of E2A in maturing APL cells may be consistent with the extinguished 
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E2A expression in differentiated myeloid cells.34 The induction of ID proteins during 
neutrophilic differentiation may be consistent with the reported expression of ID1 and 
ID2 in various myeloid cell lines, and in primary granulocytes and monocytes.35-37 The 
rapid downregulation of ID1 at later stages after the initial upregulation is striking 
(Figure 1). However, our data suggest that downregulation of ID1 is not a prerequisite 
for terminal neutrophilic differentiation, as ID1 overexpressing cells did not become 
resistant to ATRA. This was shown by the inhibition of colony formation (Figure 3B), 
and also by the induction of the differentiation marker CD11c and NBT positivity 
in ID1-transduced NB4 cells after treatment with ATRA, which was comparable to 
non-transduced cells (data not shown). In various cell types, ID proteins have been 
characterized as proteins that inhibit differentiation, and overexpression of these 
proteins has been reported in many different types of tumours.38 Two distinct 
pathways have been described coupling ID function directly to promotion of cell 
cycle progression. One pathway involves the interaction between the retinoblastoma 
proteins and ID2 and ID4 that leads to the expression of genes required for S phase 
progression. The second pathway, which is described for ID1, involves the inhibition 
of the E2A-mediated activation of the cyclin-dependent kinase inhibitor p21waf1/Cip1.9 
Our data suggest that during neutrophilic differentiation, ID1 and ID2 have a different 
role, being associated with the induction of differentiation and accumulation of cells 
in G0/G1. The combined effects of ATRA on E2A and ID1 and ID2 suggest that the 
inactivation of specific bHLH transcription factor complexes in immature APL cells is 
important to allow neutrophilic differentiation. Different models by which such bHLH 
proteins could act may be suggested. Upregulation of ID proteins would effectively 
insulate the cell against any bHLH transcription factor, including those that are 
involved in other (non-neutrophilic) pathways of differentiation. One candidate 
could be the bHLH protein SCL/TAL-1 that stimulates erythroid differentiation.39;40 
This would be in line with the observation that ectopic expression of C/EBPα in 
human CD34 positive cells induced granulocytic differentiation and inhibited 
erythrocytic differentiation, while strongly inducing ID1 expression in these cells.41 
Potentially, a similar mode of action might be operational at other differentiation 
pathway crossroads, for instance at the neutrophil-eosinophil branchpoint, as 
ectopic expression of ID1 inhibited the growth of CD34 positive cord blood cells 
that were stimulated with IL-5, which induces eosinophilic rather than neutrophilic 
differentiation. (PJ Coffer et al., Blood 2003, 102(11): abstract 49)
ID1 and ID2 inhibit APL cell proliferation
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Our data show that the mere overexpression of ID1 or ID2 is not sufficient to induce 
the differentiation of the cells. However, the increased accumulation of cells in G0/
G1 might render the cells more sensitive for other differentiation stimuli, similar to 
what has been suggested for the differentiation of HL-60 cells in response to retinoic 
acid.42 
We conclude that ID1 and ID2 are two retinoic acid-induced proteins in acute 
promyelocytic leukemia cells and suggest that the increased accumulation of the 
leukemic cells in G0/G1 may contribute to the beneficial effect of retinoic acid in the 
treatment of APL. Furthermore, we suggest that ID and bHLH proteins may have an 
important role in differentiation branchpoint decisions during myelopoiesis. 
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Gene transactivation without direct DNA-binding 
defines a novel gain-of-function for PML-RARα
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Abstract
PML-RARα is the causative oncogene in 5-10% of the cases of acute myeloid leukemia. 
At physiological concentrations of retinoic acid PML-RARα silences RARα target 
genes, blocking differentiation of the cells. At high concentrations of ligand, it (re)
activates the transcription of target genes, forcing terminal differentiation. The 
study of RARα target genes that mediate this differentiation has identified several 
genes that are important for proliferation and differentiation control in normal and 
malignant hematopoietic cells. In this paper we show that the PML-RARα fusion 
protein not only interferes with the transcription of regular RARα target genes. We 
show that the ID1 and ID2 promoters are activated by PML-RARα but, unexpectedly, 
not by wild type RARα/RXR. Our data support a model in which the PML-RARα fusion 
protein regulates a novel class of target genes by interaction with the Sp1 and NF-Y 
transcription factors, without directly binding to the DNA, defining a gain-of-function 
for the oncoprotein.
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Introduction
Acute promyelocytic leukemia (APL) is characterized by an excess of immature 
promyelocytes in the bone marrow that fail to differentiate towards mature 
granulocytes. In approximately 98% of the cases, the retinoic acid receptor-α (RARα) 
gene is fused to the promyelocytic leukemia (PML) gene resulting in a PML-RARα 
fusion protein. The PML-RARα chimeric protein contains most of the PML sequence 
and a large part of RARα, including its DNA- and nuclear hormone-binding domains. 
APL blasts can be forced to terminally differentiate using pharmacological doses of 
all-trans retinoic acid (ATRA). When treated with chemotherapy, APL patients can be 
cured in approximately 40% of the cases. The combination of ATRA with chemotherapy 
leads to a remarkably high cure rate of approximately 90%,1;2 and APL currently 
represents the best prognostic group amongst the different forms of leukemia. 
This treatment constitutes one of the first examples of successful induction of 
differentiation of malignant cells yielding significant clinical results.
The role of PML-RARα in transformation and terminal differentiation has been 
studied intensively in the past decade. PML-RARα was shown to act as a dominant 
oncogene, interfering with the normal function of the unrearranged PML as well 
as the unrearranged RARα protein. Expression of the fusion protein in immature 
hematopoietic cells induced a maturation block at the promyelocytic stage. 
Inoculation of PML-RARα-transduced bone marrow cells into irradiated syngenic mice 
resulted in the development of retinoic acid sensitive leukemia.3;4 Furthermore, PML-
RARα transgenic mice developed a myeloproliferative syndrome which progressed to 
overt leukemia in 30% to 90% of the animals after 6-12 months, depending on the 
promoter that was used.5-7
PML is a ubiquitously expressed protein that localizes to nuclear substructures 
termed nuclear bodies. More than 50 protein partners with various biological 
functions colocalize with PML.8 In APL cells these nuclear bodies are disrupted and 
dispersed into numerous small microspeckles.9 PML has multiple tumor-suppressor 
functions and is involved in growth control, replicative senescence and apoptosis.10 
PML -/- mice are prone to develop tumors in response to various forms of stress. 
In addition, PML-RARα transgenic mice develop leukemia much faster in a PML -/- 
background.11
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Retinoic acid receptors are transcription factors that activate genes in a 
ligand-dependent manner. RARα binds to DNA as a heterodimer with RXR proteins. 
In the absence of ligand, both RARα/RXR and PML-RARα bind corepressors like 
N-Cor and SMRT and recruit histone deacetylases leading to gene silencing. In the 
presence of ligand, the corepressors are replaced by coactivators, leading to 
transcriptional activation. However, PML-RARα releases the corepressors at much 
higher concentrations of ligand compared to the unrearranged receptors. Since 
PML-RARα competes with unrearranged receptors for the same DNA-binding sites, 
the presence of the fusion protein results in dominant silencing of retinoic acid 
receptor target genes at physiological concentrations of ligand. At higher, supra-
physiological concentrations the fusion protein can still function as a transcriptional 
activator releasing the corepressor complex and allowing the transcription of 
genes that are important for granulocytic differentiation.12-15 The release of 
the differentiation block by high concentrations of retinoic acid leads to terminal 
granulocytic differentiation of the leukemic cells and the induction of hematological 
remissions in the patients. RARα target genes are not restricted to genes that contain 
a consensus retinoic acid receptor binding-site in their promoter. Liganded RARα is 
able to repress AP-1 mediated transcription.16-18 PML-RARα abnormally regulates 
AP-1 activity as it stimulates AP-1-dependent transcription in the presence of ligand, 
whereas unliganded PML-RARα inhibits AP-1 dependent transcription.19 In addition, 
RARα may interfere with GATA-2-dependent transcription. Liganded RARα enhances 
GATA-2-dependent gene transcription via direct protein-protein interaction.20 This 
activity is retained in the PML-RARα fusion protein.21 Furthermore, interaction of 
normal retinoid receptors with the transcription factor Sp1 has been shown.22;23 
Together, the data support a model in which PML-RARα interferes with RARα target 
gene expression in a dominant fashion, and that restoration of target gene expression 
by high concentrations of ligand is important for the induction of differentiation.
Apart from interference with the function of both parental proteins in a dominant-
negative manner, a gain-of–function for PML-RARα is suggested by various observations. 
PML-RARα may bind to DNA as a heterodimer with RXR, but also independently from 
RXR as a homodimer.24 It may bind to regular retinoic acid receptor binding sites 
consisting of a repeated consensus [(A/G)G(T/G)TCA] sequence, but the required 
spacing between the two half-sites is less stringent for the fusion protein. This allows 
the fusion protein to bind to a wider range of DNA-target sequences compared to 
Sp1 and NF-Y dependent gene activation by PML-RARα
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normal receptors.25;26 The importance of PML-RARα as a transcriptional activator 
of differentiation-inducing genes was shown by in vitro experiments. Expression of 
PML-RARα in the myeloid cell line U937 (that also expresses normal retinoic acid 
receptors) enhanced their sensitivity to the induction of differentiation by ATRA.27 In 
addition, forced expression of PML-RARα, but not RARα, in an ATRA resistant APL cell 
line with constitutive degradation of the chimeric protein restored ATRA sensitivity.28 
Importantly, in APL patients that became resistant to differentiation induction with 
ATRA during therapy, additional mutations were found in the ligand-binding domain 
of the RARα part of the PML-RARα fusion protein, indicating an important role for 
the fusion protein during the retinoic acid-induced differentiation of the leukemic 
cells.29 Finally, experimental mouse models in which various natural and artificial 
RARα fusion proteins were expressed also support a model in which interference 
with the function of RARα and PML is important, but in addition, they suggest that 
the PML-RARα fusion protein exhibits gain-of function characteristics, unique to the 
fusion protein.7;30 So far, the mechanisms behind these observations remain largely 
unclear.
We have previously shown that the transcription factor inhibitors ID1 and ID2 are 
upregulated upon treatment with ATRA and play a role in cell cycle arrest during APL 
differentiation.31 In this study we investigated the mechanism by which these genes 
are regulated in APL cells. We found that ID1 and ID2 are regulated by PML-RARα 
through a novel mechanism, which is not shared with normal RARα, defining an as yet 
unrecognized class of retinoic acid-induced genes in APL.
Materials and Methods 
Cell culture 
NB4 cells, U937 and U937-PR9 cells (kindly provided by Dr. P.G. Pelicci and Dr. F. Grignani) were 
cultured in RPMI 1640 medium (Gibco, Gaithersburg, MD, USA), Hep3b cells in IMDM (Gibco) and 
HEK293 cells in DMEM + 2 mM L-glutamine. Media were supplemented with 10% FCS (Gibco). 
ATRA was used at a final concentration of 10-6 M (Sigma, St Louis, MO, USA) and ZnSO4 at 100 μM. 
Cycloheximide (ICN, Costa Mesa, CA, USA) was added 30 min prior to ATRA at 4 μg/ml.
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DNA constructs and antibodies
The human ID1 promoter was obtained from J. Campisi (University of California, 
USA). The ID2 promoter32 was cloned into the XhoI-HindIII sites of the pGL3-
basic vector (Promega, Madison WI, USA) after amplification with the following 
primers: sense 5’-GTACGGTACCTCGAGTTGGGCATGGTTTGCAATA-3’ and anti-sense 
5’-GTACAGATCTAAGCTTGAAGCCCGAGCCCGGC-3’. RARE3-tk-luc,
33 PML-RARα∆R34 and PML-
RARα∆CC, PML-RARα, RARα and RXR expression constructs25 were as described. FLAG-PML-RARα 
was from A. Tomita35 and was recloned into a CMV-expression vector. ID1 promoter deletion/
mutation fragments were constructed by PCR and cloned into the XhoI-HindIII sides of PGL3-
basic (Promega). All constructs were sequence verified. The dominant-negative NF-YA (YAm29) 
construct and anti-NF-YB polyclonal antiserum were from R. Mantovani (University of Milan, 
Italy). pGEX-Sp1 was from H. Rotheneder (University of Vienna, Austria). Anti-Sp1 (PEP-2), 
anti-NF-YA (H-209), anti-RARα (C-20) and anti-ID1 (Z-8) antibodies were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA, USA). Anti-PML rabbit antibody was as described.9 Anti-
FLAG (M2) antibody was from Sigma. As a control in the ChIP experiments, human IgG was used 
(Ivegam, Sanquin, The Netherlands)
Northern blotting 
Total cellular RNA was isolated by guanidium-isothiocyanate lysis and centrifugation on a 5.7 M 
cesium chloride cushion. 10 μg of total RNA was size-fractionated by 1% agarose-formaldehyde 
gel electrophoresis and transferred onto Hybond N+ nylon membranes (Amersham, 
Buckinghamshire, UK). Filters were hybridized at 65°C overnight in phosphate buffer (2N 
NaH2PO4, 7% sodium dodecyl sulphate (SDS), 1 mM EDTA pH 8 and 1% BSA). DNA probes were 
labeled with [32P]α-dATP by random primed labeling (Boehringer, Mannheim, Germany). After 
hybridization, filters were washed in 0.2xSSC/0.2% SDS for 15 min at 65°C. Northern blots were 
hybridized to radiolabeled human ID1 or ID2 probes (kindly provided by Dr. S. Stegman). As a 
control for equal loading, filters were stripped and hybridized to a 777bp HindIII-EcoRI human 
GAPDH fragment. 
Transactivation studies 
Cells were transfected using calcium-phosphate precipitates with 0.25 μg pGL3-ID1 or -ID2 
promoter, 0.05 μg nuclear receptor expression vector, 0.1 μg of Renilla vector (pRL-CMV, 
Promega) and 1 μg YAm29 expression vector. The total amount of DNA was normalized to 1.4 μg 
for all transfections using empty vectors. Cells were harvested 16 hours after ATRA treatment 
Sp1 and NF-Y dependent gene activation by PML-RARα
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using 100 μl Passive Lysis Buffer (Promega). Firefly luciferase and renilla luciferase activities 
were measured on a luminometer (Lumat LB 9507, Perkin-Elmer/Applied Biosystems, CA, USA) 
using Dual-Luciferase Reporter Assay System reagents (Promega). 
Electrophoretic mobility shift assay (EMSA) 
Nuclear extracts were prepared as described.36 5 μg was incubated in a total volume of 15 μl 
containing 1 μg of double stranded poly(dI)-poly(dC), 10 mM Hepes, 50 mM KCL, 1 mM DTT, 
1 mM PMSF, 2.5 mM MgCl2, 10% (w/v) glycerol, 300 μg/ml BSA and 0.5 ng of a labeled double 
stranded oligonucleotide probe: ID1 5’-CCGCCCATTGGCTGCTTTTGAACGT. To show specificity 
of binding, non-labeled 100 fold excess of double-stranded oligonucleotides were added to 
compete for binding with the labeled probe. For this, either the ID1 probe (self competition), 
a sequence not containing any CCAAT box 5’- TCAGAGTTCAAGGTTCTAGTCGCTGCGGC, 
or a NF-Y binding site containing oligonucleotide from the CD10 gene was used 
5’-ATCCCGACCAATGAGCGCACGGGGCCGGGT.37 DNA-Protein complexes were resolved on a 5% 
non-denaturing polyacrylamide gel in 0.5xTBE buffer.
GST pull-down 
GST-fusion proteins were produced in E.coli BL21 which were induced at A600 = 0.5 with 300 
μM IPTG for 4 hours. Proteins were released by sonication and loaded onto glutathion-agarose 
(Sigma) by incubation at 4ºC for 2 hours in Lysis buffer (0.15 M NaCl, 50 mM Tris [pH 8.3], 10 mM 
EDTA, 0.5% NP40 and protease inhibitors). Pull-down was performed using in vitro translated 
PML-RARα and PML-RARα∆cc (reticulocyte lysate, Promega) or rHSp1 (Promega), by 2 hours 
incubation at 4°C. Beads were washed in lysis buffer and subsequently resuspended in SDS-
loading buffer.
Chromatin immunoprecipitation 
DNA-protein cross-linking was done for 30 min at room temperature by adding formaldehyde 
at a final concentration of 1% directly to the culture medium. Cross-linking was stopped by 
the addition of glycine to a final concentration of 125 mM. Cells were washed with ice-cold 
phosphate-buffered saline, buffer B (10 mM EDTA, 0.5 mM EGTA, 0.25% Triton X-100, 20 mM 
HEPES [pH 7.6]), buffer C (1 mM EDTA, 0.5 mM EGTA, 0.15 M NaCl, 50 mM HEPES [pH 7.6]) 
and resuspended in incubation buffer (0.15% SDS, 1% Triton X-100, 0.15 M NaCl, 1 mM EDTA, 
0.5 mM EGTA, 20 mM HEPES [pH 7.6] and protease inhibitors) at 33x106 cells/ml. Chromatin 
was sonicated using the Bioruptor (Cosmo Bio, Tokyo, Japan), at high intensity for 15 min with 
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0.5 min intervals. Insoluble material was removed by centrifugation at 4°C for 15 min 120 μl 
supernatant was incubated with 30 μl precoated protein A/G plus agarose beads 50% v/v (Santa 
Cruz), 0.1% BSA, 36 μl 5x incubation buffer, protease inhibitors and 2-5 μg antibody (anti-NF-YA, 
anti-PML, anti-FLAG or non-specific IgG from human serum) and rocked at 4°C for 16 hours. 
Beads were harvested by centrifugation and washed twice with buffer 1 (0.1% SDS, 0.1% NaDOC, 
1% Triton X-100, 0.15 M NaCl, 1 mM EDTA, 0.5 mM EGTA and 20 mM HEPES [pH 7.6]), once with 
buffer 2 (0.1% SDS, 0.1% NaDOC, 1% Triton X-100, 0.5 M NaCl, 1 mM EDTA, 0.5 mM EGTA and 20 
mM HEPES [pH 7.6]), once with buffer 3 (0.25 M LiCL, 0.5% NaDOC, 0.5% NP-40, 1 mM EDTA, 
0.5 mM EGTA, 20 mM HEPES [pH 7.6]), and twice with buffer 4 (1 mM EDTA, 0.5 mM EGTA, 20 
mM HEPES [pH 7.6]). Chromatin antibody complexes were eluted by the addition of 1% SDS and 
0.1 M NaHCO3 to the pellet and incubated for 20 min at room temperature. Cross-linking was 
reversed by the addition of NaCl (0.44 M final conc.) and incubation of the eluted samples for at 
least 4 h. at 65°C. DNA was recovered by phenol-chloroform-isoamylalcohol extraction followed 
by chloroform-isoamylalcohol extraction and precipitated by the addition of 0.1 volume of 1 M 
sodium acetate (pH 5.2), and 2.5 volumes of ethanol. Precipitated DNA was dissolved in water, 
and input as well as immunoprecipitated DNA was analyzed using quantitative PCR for genomic 
sequences from the ID1, ID2, RARβ and p21 promoter regions.38
 
Quantitative PCR 
Quantitative PCR to measure ID1 and ID2 mRNA expression was performed with the ABI/PRISM 
7700 Sequence Detection system (ABI/PE, Foster City, CA, USA). As a reference gene PBGD was 
used. The primer/probe sequences for the ID1 gene were: sense 5’-GTTACTCACGCCTCAAGGAGCT, 
anti-sense 5’-GAGAATCTCCACCTTGCTCACC, probe FAM 5’-CCCACCCTGCCCCAGAACCG; for ID2: 
sense 5’-GACTGCTACTCCAAGCTC-AAGGA, anti-sense 5’-CGTGCTGCAGGATTTCCAT, probe FAM 
5’-CCCAGCATCCCCCAGAA-CAAGAAGG. PCRs were done in a 50 μl reaction mixture (1.25 U 
AmpliTaq Gold, 1xbuffer A (both Perkin-Elmer), 250 mM dNTPs (Pharmacia) and 5 mM MgCl2, for 10 
min at 95°C followed by 45 cycles of 15 sec at 95°C and 1 min at 62°C. Quantitative PCR following 
ChIP was done using Sybr Green PCR (Applied Biosystems). Primer sequences for the ID1 promoter 
were; sense 5’- CACTGCGAGCAGGCACTAGAC, anti-sense 5’-AGCCACAGCTTGTCTTT; for the ID2 
promoter; sense 5’-CTGTAC-TCTATTTACCACCCCAGCTG, anti-sense 5’-GGCGTGGGCTTGGTTCTT; 
for the RARβ promoter; sense 5’-TTGGGTCATTTGAAGGTTAGCA, anti-sense 5’-CACACAGAATG-
AAAG-ATTGAATTGC, for the p21 gene sense 5’-GGCGGGGCGGTTGTAT, anti-sense 5’-AAGGAA-
CTGACTTCGGCAGC.
Sp1 and NF-Y dependent gene activation by PML-RARα
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Results 
ID1 and ID2 are direct retinoic acid-responsive genes in APL cells 
Basic helix-loop-helix (bHLH) transcription factors and their inhibitors, ID proteins, 
play crucial roles in the regulation of differentiation in various cell types. We 
have shown that ID1 and ID2 are upregulated in APL cells upon exposure to ATRA.31 
Upregulation of ID1 and ID2 mRNA was confirmed with qPCR (Figure 1A and B), 
showing clear upregulation within 4 hours after the addition of ATRA. To investigate 
whether ID1 and ID2 were directly upregulated by ATRA, cells were treated with 
cycloheximide prior to the addition of ATRA to inhibit protein translation. Both ID1 
and ID2 mRNAs were upregulated within 0.5 hours by ATRA, regardless of the addition 
of cycloheximide (Figure 1C and D). This indicates that both genes were directly 
upregulated, without intermediate protein production. 
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Figure 1. ID1 and ID2 are direct retinoic acid target genes in NB4 cells.  Quantitative PCR and 
Northern blot analysis of NB4 cells treated with ATRA. mRNA was isolated from NB4 cells and ID1 
(A) and ID2 expression (B) were determined using specific primers and probes by quantitative 
PCR (n=4). Quantities were normalized based on β-actin expression. To investigate whether the 
induction of ID1 and ID2 was dependent on intermediate protein production, cells were treated 
with cycloheximide alone (4 μg/ml) or with the combination of cycloheximide and ATRA (10-6 
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M). Blots were hybridized using radiolabeled ID1- (C) and ID2-specific (D) probes. As a control 
for equal loading blots were stripped and rehybridized with GAPDH specific probes. 
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Figure 2. The ID1 promoter is transactivated by PML-RARα but not by RARα/RXR.(A) Hep3B 
cells were transfected with the 963bp ID1 promoter-luciferase reporter construct (ID1-luc) 
together with a control vector expressing Renilla-luciferase. In addition, vectors coding for 
the various proteins indicated in the figure were transfected. Transactivation is expressed as 
arbitrary units and is corrected for transfection efficiency measured by Renilla-luciferase. 
Background luminescence of the cells transfected with only the reporter construct without 
nuclear receptors and in the absence of ATRA was set at 1. Cells were cultured for 16 hrs without 
(light gray bars) and with ATRA (dark gray bars). Mean values and standard deviations from 
three independent experiments ± SD are shown. (B) To show transactivation by unrearranged 
retinoic acid receptors, cells were transfected with the RARE3-tk-luc vector, containing three 
bona-fide RAREs. Mean values of three independent experiments ± SD are shown. (C) ID1 
expression is increased by PML-RARα in the presence of ATRA. The zinc-inducible PML-RARα 
cell line U937-PR9 was grown in the absence (left panel) or presence (right panel) of zinc for 16 
hours. Cells were treated with ATRA and harvested at the indicated time points. Proteins were 
size-fractionated by SDS-PAGE. Immunostaining was done with anti-ID1 antibody. 
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The ID1 upstream promoter is transactivated by PML-RARα but not by 
RARα/RXR
To identify the regulatory DNA sequences through which the induction of ID1 by 
retinoic acid was mediated, we analyzed the 5’ upstream promoter sequence in 
transactivation assays. A 963 bp fragment of the promoter, including the putative TATA 
box, was cloned into a luciferase reporter construct. When expressed alone, RARα, 
RXR and PML were not able to transactivate the ID1 promoter both in the absence and 
presence of ATRA (Figure 2A). In contrast, PML-RARα transactivated the promoter 
more than 12-fold in an ATRA-dependent fashion. Surprisingly, the combination of 
RARα/RXR did not transactivate the promoter, both in the absence and presence of 
ATRA. To verify that RARα and RXR were expressed and functional, a control luciferase 
construct was used containing three bona-fide RAREs from the RARβ promoter [RARE3-
tk-luc39]. This construct was strongly transactivated in the presence of ATRA through 
endogenous retinoic acid receptors (Figure 2B, left bars). This was further enhanced 
when RARα and RXR were co-transfected (Figure 2B, right bars). Together this shows 
that PML-RARα may regulate ID1 expression through the upstream 963 bp promoter 
whereas RARα/RXR cannot. 
To test whether PML-RARα expression would result in ATRA-dependent induction 
of the endogenous ID1 gene, we used the U937-PR9 cell line that is stably transfected 
with a Zn2+-inducible PML-RARα expression cassette.34 In PML-RARα expressing U937 
cells, ATRA strongly induced ID1 expression (Figure 2C, right panel), in contrast to 
U937 cells that did not express PML-RARα (Figure 2C, left panel).
Transactivation of the ID1 promoter is dependent on GC- and CCAAT box 
motifs
To determine the DNA sequences that are relevant for the observed PML-RARα-
dependent transactivation, we analyzed the 963 bp upstream promoter construct 
of the ID1 gene further. The consensus RAR/RXR binding sequence (RARE) consists 
of a repeated (A/G)G(T/G)TCA sequence that is separated by two or five base 
pairs. However, in the 963 bp ID1 promoter, no consensus RARE was found. As PML-
RARα may bind to a much wider variety of DNA sequences,25;26 we made luciferase 
constructs with different promoter truncations. All the truncation mutants could still 
be transactivated by PML-RARα (Figure 3B), including the smallest, 121bp promoter 
construct. This construct does not contain any sequence that even remotely resembles 
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a retinoic acid receptor-binding site (Figure 3A). Analysis of the 121 bp promoter 
sequence for putative binding sites for other transcription factors showed a perfect 
consensus-binding site for the transcription factors NF-Y (CCAAT box), and Sp1 (GC 
box). To test their relevance, we mutated these sites individually and in combination 
in the context of the 963 bp promoter fragment. Mutation of the GC box or the CCAAT 
box alone partially impaired transactivation by PML-RARα, while deletion of the GC 
box and the CCAAT box in combination almost completely abolished transactivation 
(Figure 3C, raw Renilla and Firefly luciferase data are given in Supplemental figure 1). 
This indicated that transactivation of the ID1 promoter by PML-RARα was dependent 
on the GC and CCAAT motifs.
Functional NF-Y is necessary for transactivation of the ID1 promoter by 
PML-RARα 
Sp1 and NF-Y are ubiquitously expressed transcription factors. NF-Y is a trimeric 
protein complex consisting of the subunits NF-YA, NF-YB and NF-YC. All three 
subunits are necessary for the complex to bind to the DNA.40 Using real-time PCR, we 
confirmed that Sp1 and all three NF-Y subunits were expressed in primary APL cells 
(Supplemental figure 2). Binding of Sp1 to the promoter of ID1 was shown previously.41 
Therefore, we tested whether NF-Y was able to bind to the CCAAT site from the ID1 
promoter. Incubation of a radioactively labeled DNA-probe containing the CCAAT box 
with cellular protein extracts resulted in a clear shifted complex (Figure 4A, lane 1). 
This shift was competed by a 100-fold excess of non-labeled probe (lane 2) and by an 
excess of an oligo containing the NF-Y binding site of the CD10 promoter (lane 542), 
but not by an excess of probe lacking a NF-Y binding site (lane 3). When anti-NF-YB 
antiserum was added (lane 4) the protein-DNA complex was supershifted, identifying 
the DNA binding protein complex as NF-Y. To further test whether NF-Y is present on 
the endogenous ID1 promoter, we performed chromatin immunoprecipitation (ChIP) 
assays. Using anti-NF-YA antibody, recovery of the ID1 promoter sequences from 
U937 cells was over 70 times higher than recovery with non-specific IgGs (Figure 4B, 
right bars). In the same experiment, no enrichment was seen for the RARβ promoter 
(Figure 4B, left bars), indicating that NF-Y is present on the endogenous ID1 promoter 
but not on the RARβ promoter. 
Sp1 and NF-Y dependent gene activation by PML-RARα
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Figure 3. The CCAAT- and GC-box in the ID1 promoter are required for PML-RARα-mediated 
transactivation. (A) ID1 promoter region showing the presence of consensus Sp1 and NF-Y 
binding sites. (B) Transactivation of ID1 promoter-luciferase constructs. Several deletion 
constructs were generated and transfected in combination with RARα plus RXR, or with PML-
RARα. Transactivation assays were performed as described in figure 2. Mean values from three 
independent experiments ± SD are shown. (C) To investigate the importance of the putative 
Sp1 and NF-Y binding sites in the -121 bp upstream promoter sequence of the ID1 gene for 
transactivation by PML-RARα, these sites were mutated in the context of the –963 bp promoter 
fragment. Mutations were introduced either alone, or in combination. Transactivation by 
PML-RARα was performed as described in figure 1. Sequences were mutated as follows; GC 
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box: CCGCCC was replaced by CTATCC and for the NF-Y site: ATTGG was replaced by ACACG. 
Transactivation was significantly lower in the promoter fragments with one mutated binding 
site in comparison to the wt promoter fragment (p<0.01).
A dominant-negative form of NF-YA has been described (YAm2943). This mutated 
NF-YA subunit can still bind to the NF-YB and NF-YC subunits, but is not able to bind to 
DNA, preventing the formation of a functional trimeric NF-Y complex. To investigate 
whether functional NF-Y was necessary for the transactivation of ID1, the YAm29 
mutant was tested in a transactivation assay. Transactivation of ID1 by PML-RARα 
upon ATRA treatment was severely decreased in the presence of dominant-negative 
NF-YA (Figure 4C). This effect was promoter-specific as YAm29 did not influence 
transactivation of the RARβ promoter construct (RARE3-tk-luc) by PML-RARα or RARα/
RXR (data not shown).
Upregulation of ID1 is dependent on PML-RARα, but does not require the 
DNA-binding domain of the fusion protein
To test whether PML-RARα might transactivate the ID1 promoter without directly 
binding to the DNA, we used a PML-RARα construct from which the DNA binding 
domain was deleted (PML-RAR/∆R34). PML-RAR/∆R has been shown to be unable to 
transactivate a promoter containing a bona-fide RARE. In contrast, PML-RAR/∆R 
retained the ability to transactivate the ID1 promoter (Figure 4D). Similar results were 
found when the transactivation assay was repeated in the myeloid cell line HL-60 
(Supplemental figure 3). This indicated that transactivation of the ID1 promoter by 
PML-RARα does not require direct binding of PML-RARα to the DNA. 
PLZF-RARα is generated by a t(11;17) translocation that is found in approximately 
2% of the patients with APL. It contains the same part of the retinoic acid-receptor as 
PML-RARα. Similar to PML-RARα, this fusion protein may form homodimers with DNA-
binding capacity.44 Interestingly, PLZF-RARα was not able to transactivate the ID1 
promoter, suggesting that the PML part of PML-RARα is necessary for transactivation 
of the ID1 promoter (Figure 4D). When the coiled-coil domain of PML-RARα was 
deleted (PML-RAR/∆CC25;34) it was no longer able to transactivate the ID1 promoter 
(Figure 4D). As this domain is involved in protein-protein interactions, this suggested 
that PML-RARα homodimerization or interaction of PML-RARα with another protein 
was necessary for the transactivation of ID1.
Sp1 and NF-Y dependent gene activation by PML-RARα
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Figure 4. NF-Y binds to the CCAAT-box element from the ID1 promoter and is required for 
PML-RARα mediated transactivation. (A) EMSA showing binding of NF-Y to the putative NF-Y 
binding site from the ID1 promoter. Hep3B-nuclear extracts were incubated with a labeled 
DNA probe containing the NF-Y-box from the ID1 promoter region. A clearly shifted protein-
DNA complex was seen (lane 1). Competition experiments were done with 100x cold ID1 probe 
(lane 2) and with an unlabeled probe containing the confirmed NF-Y binding site from the 
CD10 gene promoter (lane 5). In addition, a sequence without any recognizable NF-Y binding 
site was used for competition (lane 3). Addition of anti-NF-YB antibody shifted the complex 
to a higher molecular weight complex (lane 4). Arrows indicate free probe (1), shifted DNA-
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protein complex (2) and the supershifted DNA-protein-antibody complex (3). (B) To detect 
DNA-binding of NF-Y in intact cells, ChIP assays were performed using anti NF-YA antibodies. 
As a control, the non-specific IgG fraction from human serum was used. The Y-axis shows the 
recovery (%) of ID1 or RARβ sequences relative to the input In U937 cells, NF-Y clearly bound 
to the ID1 promoter (right bars), but not to the RARβ gene (left bars). Mean values from three 
independent experiments ± SD are shown. (C) To further show the importance of NF-Y for the 
PML-RARα mediated transcriptional activation of ID1, transfections (as described in figure 2) 
were performed using the dominant-negative NF-YA subunit (YAm29) and the 963 ID1 promoter 
construct. In the presence of YAm29 PML-RARα mediated transcription was severely diminished 
(right bars). (D) To investigate the importance of different domains of PML-RARα, vectors 
encoding the DNA binding-defective PML-RARαΔR mutant, and a mutant lacking the coiled-coil 
protein-protein interaction domain of PML (PML-RARαΔCC) were used. In addition, a PLZF-RARα 
expression construct was used. Transfections were performed as in figure 2 using the 963 ID1 
promoter construct, mean values of three independent experiments ±SD are shown.
The ID2 promoter is also transactivated by PML-RARα but not by RARα/
RXR
To investigate whether ID2 was regulated in a similar manner as ID1, we cloned the 
upstream promoter of ID2 (812bp) into a luciferase reporter plasmid. Similar to ID1, 
no consensus retinoic acid receptor-binding site could be found in the ID2 promoter 
sequence. Also comparable to ID1, RARα, RXR, PML, PLZF-RARα and RARα/RXR did 
not transactivate the ID2 promoter whereas PML-RARα did (Figure 5A). Furthermore, 
transactivation of ID2 by PML-RARα was abolished in the presence of dominant-
negative NF-YA (Figure 5B). Inspection of the ID2 promoter sequence revealed 3 NF-Y 
and 5 Sp1 consensus binding sites (Figure 5C). Together, these data show that like ID1, 
ID2 may also be transactivated by PML-RARα without direct DNA binding of the fusion 
protein. 
PML-RARα directly interacts with Sp1 
NF-Y and Sp1 have been shown to work in concert on many promoters. Direct physical 
interaction between Sp1 and NF-YA has been shown, indicating that these proteins may 
bind to adjacent DNA binding sites and form a complex that regulates transcription.45 
We investigated whether PML-RARα could physically interact with Sp1 or NF-YA. GST-
tagged, bacterially produced NF-YA, and Sp1 proteins were made, as well as in vitro 
translated (reticulocyte lysate) PML-RARα for GST pull-down experiments. rhSp1 was 
Sp1 and NF-Y dependent gene activation by PML-RARα
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commercially available. Whereas a clear interaction was observed between GST-NF-YA 
and recombinant Sp1 (Figure 6A), in none of the conditions tested we could show a 
direct interaction between NF-YA and PML-RARα. In contrast, an interaction between 
PML-RARα and Sp1 was readily observed, whereas no interaction was seen with 
non-loaded or GST-loaded beads (Figure 6A). GST-Sp1 was also able to capture PML-
RAR/∆CC although with a much lower efficiency than PML-RARα. This suggests that 
the binding of PML-RARα is partly through the coiled-coil region and partly through 
the RARα part of the fusion protein. This is in agreement with earlier publications 
that have shown binding of both PML and RARα to Sp1.23;46
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Figure 5. The ID2 promoter is transactivated by PML-RARα but not by RARα/RXR. (A) Cells 
were transiently transfected with an 812 bp ID2-luciferase reporter construct (ID2-luc). 
Transfections and controls were as described in figure 2. Background luminescence of the cells 
transfected with only a reporter construct (no nuclear receptor and no ATRA) was set at 1. 
Transactivation was measured after treatment without (light gray bars) and with (dark gray 
bars) 10-6 M ATRA. Mean values from at least three independent experiments ± SD are shown. (B) 
Dominant negative NF-Y (YAm29) inhibits the transactivation of the ID2 promoter construct by 
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PML-RARα. Transfections were done as described in figure 2, mean values of three independent 
experiments ± SD are shown. (C) Promoter region of the ID2 gene with putative Sp1 and NF-Y 
binding sites.
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Figure 6. PML-RARα binds Sp1 and is present on the endogenous ID1 promoter. (A) To test 
binding of PML-RARα to Sp1 and NF-Y, GST pull-down experiments were performed. Empty 
beads and beads loaded with GST or GST-NF-YA (panels to the left) were incubated with in vitro 
translated Sp1 (positive control) or in vitro translated PML-RARα. GST-Sp1 (panels to the right) 
was incubated with in vitro translated PML-RARα or PML-RARαΔCC. Beads were washed and 
subsequently resuspended in loading buffer. Protein was resolved on SDS-PAGE. Immunostaining 
was performed with anti-Sp1 or anti-RARα antibody. Clear interactions between NF-YA and Sp1 
and between PML-RARα and Sp1 were observed. To show binding of PML-RARα to the endogenous 
RARβ (B) and ID1 (C) genes, ChIP assays were performed in PML-RARα positive NB4 cells and in 
PML-RARα negative U937 cells. Cells were treated with ATRA for 30 min. ChIP was done with 
anti-PML antiserum. As a control, the non-specific IgG fraction from human serum was used. 
The Y-axis shows the recovery (%) of ID1 or RARβ sequences relative to the input. Mean values ± 
SD of 4 independent experiments are shown.
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Figure 7. Binding of PML-RARα to the endogenous p21, RARβ, ID1 and ID2 genes. (A) To show 
binding of PML-RARα and NF-Y to the endogenous p21, RARβ, ID1 and ID2 gene ChIP assays were 
performed. As anti-PML antibodies do not discriminate between the unrearranged PML protein 
and the PML-RARα fusion protein, FLAG-tagged PML-RARα was used. Cells were transfected 
with or without FLAG-PML-RARα and cultured in the presence or absence of 10-6 M ATRA. ChIP 
was performed using anti-FLAG-antibodies, anti-NF-YA antibodies and control IgGs. The Y-axis 
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shows the recovery (%) of ID1/ID2/p21 or RARβ sequences relative to the input. Mean values of 
three independent experiments ± SD are shown. (B) Dominant negative and gain-of-function 
model for PML-RARα. Genes that are regulated through a retinoic acid responsive element 
(RARE) may be bound by PML-RARα (1). Competition with normal, unrearranged retinoid 
receptors results in a dominant-negative silencing of the gene by PML-RARα in the absence of 
ligand. Addition of high dose retinoic acid may reverse the silencing, allowing transcription. 
Sp1 and NF-Y regulated genes may be targeted by PML-RARα through interaction with Sp1 
(2). Tethering of PML-RARα to these promoters renders them responsive to retinoic acid, 
representing a gain-of-function for the PML-RARα fusion protein. 
PML and PML-RARα are present on the endogenous ID1 promoter
To show the physical interaction of PML-RARα with the endogenous ID1 and ID2 
promoters in intact cells, we performed ChIP assays using PML-specific antibodies. 
The RARβ promoter, that contains a well defined RARE, served as a positive control. 
In NB4 cells, we found a clear enrichment for the RARβ promoter (Figure 6B, right 
panel). In contrast, in U937 cells which are PML-RARα negative, no enrichment for 
the RARβ promoter was seen (Figure 6B, left panel), indicating that PML-RARα binds 
to the RARβ promoter in NB4 cells. The ID1 gene was also precipitated with anti-PML 
antibody in NB4 cells (Figure 6C, right panel). However, this was not only observed 
in the PML-RARα positive NB4 cells, but also in the PML-RARα negative U937 cells 
(Figure 6C, left panel). This indicates that in U937 cells, unrearranged PML protein 
was present on the ID1 promoter. As the anti-PML does not discriminate between PML 
and PML-RARα, we could not determine which of these two proteins was bound to the 
ID1 promoter in NB4 cells. To investigate this further we used a FLAG-tagged PML-
RARα expression construct, allowing us to unequivocally identify binding by the PML-
RARα fusion protein. HEK-293 cells were transfected with FLAG-PML-RARα (Figure 
7A). As a negative control, ChIP was performed using non-specific IgGs. We compared 
the presence of (FLAG-tagged) PML-RARα and NF-Y on the two classical ATRA target 
genes RARβ and p21, and on ID1 and ID2. Enrichment of all 4 promoters was found 
using anti-FLAG antibody, indicating that PML-RARα was bound to these four genes in 
intact cells (Figure 7A, compare upper and middle rows). Using anti-NF-Y antibody, 
enrichment of the ID1 and ID2 promoters was found but no enrichment of RARβ and 
p21, indicating that NF-Y was present on ID1 and ID2, but not on the two classical 
ATRA target genes RARβ and p21. To see whether the presence of PML-RARα and NF-Y 
Sp1 and NF-Y dependent gene activation by PML-RARα
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on the different promoters would be altered by the presence of retinoic acid, ChIP 
assays were performed in the presence and the absence of ATRA (Figure 7A, middle 
and bottom rows). ATRA did not influence the binding of NF-Y or PML-RARα to these 
promoters showing that their binding is ligand-independent.
Together, these data show that there are two different mechanisms by which 
PML-RARα may regulate the transcription of target genes (Figure 7B). The first class 
of target genes consists of genes that contain a retinoic acid response element in 
their promoter. These genes are normally regulated by unrearranged retinoic acid 
receptors and may be deregulated by PML-RARα in a dominant-negative manner in the 
absence of ligand. In the presence of high concentrations of ligand, their expression 
is restored. The second class of target genes consists of genes that are not normally 
regulated by retinoic acid receptors. Fusion of the RARα moiety to PML renders these 
genes responsive to retinoic acid, which defines a novel gain-of-function for the PML-
RARα fusion protein.
Discussion
The successful treatment of APL with high dose retinoic acid has shown that the 
differentiation block of the malignant cells can be overcome, leading to terminal 
differentiation of the leukemic cells and disappearance of the disease. As this is one 
of the first examples of successful differentiation-induction therapy in cancer, many 
studies focused on the molecular mechanisms that contribute to the transformation 
to leukemia, and on the mechanisms that mediate the retinoic acid-induced 
differentiation of the cells. PML-RARα was shown to interfere with the expression 
of normal RARα target genes. RARα is an important modulator of granulopoiesis 
and acts either by direct binding to the DNA, or through interaction with other 
transcription factors. In this report we show that PML-RARα interacts with Sp1 
and may interfere with the expression of genes that are not normally regulated by 
retinoic acid receptors. Previously, it was shown that both unrearranged PML46 and 
unrearranged RAR/RXR complexes22;23 are able to interact with Sp1. Therefore, the 
interaction of PML-RARα with Sp1 could be mediated by the RARα part as well as 
the PML part of the fusion protein. Here we show that PML-RARα binds Sp1 and that 
this binding is significantly less efficient when the coiled-coil domain is deleted. The 
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lack of response of the ID1 and the ID2 promoters to RARα/RXR, PLZF-RARα and PML-
RARα∆CC (Figures 2, 4 and 5) suggests that the PML part of the fusion protein is 
essential for regulating transcription.
We show that PML-RARα physically interacts with Sp1 in the absence of DNA 
(Figure 6). Roder et al. have shown that NF-Y and Sp1 interact physically in the 
absence of DNA and we obtained the same result (Figure 6). This suggests that the 
PML-RARα/Sp1/NF-Y complex may form before binding to DNA. Figure 3C suggests 
that the PML-RARα/Sp1/NF-Y complex still binds, although less efficiently, to the 
ID1 promoter when one transcription factor binding site is mutated. Figure 4C shows 
that the presence of a dominant-negative form of NF-Y abolishes transactivation of 
the ID1 promoter by PML-RARα. We hypothesize that this dominant-negative form of 
NF-Y disrupts the PML-RARα/Sp1/NF-Y complex and thereby impairs binding to and 
transativation of the ID1 promoter. We propose a model in which PML-RARα binds to 
a DNA-bound Sp1-NF-Y complex, rendering the expression of these genes sensitive 
to ATRA, and defining a novel gain-of-function for the fusion protein (Figure 7B). In 
the ChIP experiments, we show that unrearranged PML is recruited to the ID1 gene 
(Figure 6C). The physiological meaning of this remains unclear as no effect of PML 
was observed in the transactivation assays. 
As Sp1 is involved in the transcriptional control of various myeloid-specific 
genes47;48 deregulation of its target genes may be relevant in APL. For ID1 and ID2, 
a role in myelopoiesis and in APL was described previously. Overexpression of ID1 or 
ID2 in NB4 cells inhibits their proliferation and induces a G0/G1 arrest.31 In addition, 
ectopic expression of ID1 in CD34+ cells inhibited eosinophil development, whereas 
neutrophilic differentiation was enhanced. Expression of ID2 accelerated the 
definitive maturation of myeloid cells.49 Other genes may be targeted by a similar 
mechanism as well. The promoter of the important retinoic acid responsive gene C/
EBPβ was transactivated by PML-RARα, but also lacks a consensus RARE within the 
tested region.50;51 Possibly, also this gene is (de)regulated by tethering of PML-RARα 
to the promoter through protein-protein interactions rather than by direct DNA-
binding.
Apart from the DNA-binding domain from RARα, the coiled-coil domain of PML 
was shown to be important for optimal induction of terminal differentiation by the 
fusion protein.52 This suggested that homodimerization of PML-RARα is an important 
feature of the fusion protein, but might also indicate that other protein-protein 
interactions mediated through the PML part are involved. Several alternative RARα 
Sp1 and NF-Y dependent gene activation by PML-RARα
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fusion proteins occur at low frequency (2% of the cases) in APL patients, in which the 
same part of RARα is fused to other proteins than PML (reviewed in44). Common to the 
various RARα partner proteins is the presence of a dimerization domain, suggesting 
that homodimerization is an important property of these fusion proteins. However, 
depending on the fusion partner, the sensitivity to retinoic acid differs suggesting a 
broader role for the RARα partner protein than just the provision of a dimerization 
domain. Specifically, PLZF-RARα positive leukemia appears to be more resistant to 
ATRA, which has been explained by the recruitment of corepressors by the PLZF-
part of the fusion protein that are not released upon treatment with ATRA.15;53 This 
insensitivity could be reversed, as treatment with a combination of ATRA and G-CSF 
induced granulocytic differentiation in a synergistic manner.54 Also in transgenic 
mice, different types of disease with different sensitivities to ATRA developed for 
the various fusion proteins.7;30 Furthermore, when RARα fusion proteins were made 
by the coupling of RARα to artificial dimerization domains, several characteristics of 
PML-RARα were recapitulated in vitro, but in vivo these proteins induced leukemia 
with very low efficiency.55 Interestingly, when these fusion proteins were expressed in 
a PML -/- background, the animals did still not develop leukemia efficiently, leading 
to the conclusion that the mere combination of disruption of PML and dimerization 
of RARα does not recapitulate the full oncogenic potential of PML-RARα, and that 
the fusion protein has gain-of-function characteristics. Together, this showed that 
dimerization of RARα is important but not sufficient to reproduce the complete 
phenotype of PML-RARα. 
It remains to be investigated whether PML-RARα recruits co-repressors to the 
promoters of Sp1 and NF-Y target genes. This would lead to repression of gene 
expression in the absence of ATRA, possibly contributing to transformation of the 
cells, similar to the effect of PML-RARα on regular retinoic acid receptor target genes. 
So far, we did not observe important downregulation of ID1 and ID2 mRNA in freshly 
isolated leukemia cells from APL patient cells compared to non-APL acute myeloid 
leukemia cells, suggesting that this is not the case (data not shown). However, as ID1 
and ID2 expression in most leukemic samples was low, further studies are required.
Potentially, RXR may also be present in the PML-RARα/Sp1/NF-Y complex. RXR is an 
essential part of the PML-RARα complex during transformation and synergy has been 
shown between ATRA and RXR specific agonist on transcriptional activation.24-26;56 
Therefore, RXR specific agonist may also affect transcription of Sp1 and NF-Y target 
genes. In summary, we define a novel, Sp1 and NF-Y-dependent mechanism by which 
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the PML-RARα fusion protein interferes with gene transcription. This implicates that 
PML-RARα (de)regulates an additional class of genes that are normally not regulated 
by retinoid receptors and defines a gain-of-function for the PML-RARα fusion protein.
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Supplemental figure 1. Transactivation data before correction. Raw luciferase activaties 
are shown for one transactivation experiment from figure 3C. The ID1 promoter, wt or with a 
mutated GC box and/or CCAAT box, was cloned in front of the firefly gene. A renilla expression 
construct was co-transfected for correction. Note that the correction does not qualitatively 
change the results.
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Supplemental figure 2. NF-Y and 
Sp1 are expressed in APL cells. 
mRNA expression levels of NF-Y 
(A) and Sp1 (B) were determined 
in mononuclear cells from 3 APL 
patients. Bone marrow samples 
were obtained from t(15;17) 
APL patients following informed 
consent. Mononuclear cells were 
isolated by density gradient 
centrifugation using ficoll (1.077 
g/ml, Sigma). Cells were taken up 
in RNA-bee (ISO-TEX Diagnostics, 
Friendswood, USA). RNA was used 
as template in a RT-DNA reaction 
as described before (de Vries; br 
j cancer 1999). Quantitative PCR 
was performed with the ABI/PRISM 
7700 Sequence Detection system 
(ABI/PE, Foster City, Ca, USA). As 
a reference gene we used PBGD 
(de Vries; BJC 1999). The primer/
probe sets for detecting NF-Y and 
Sp1 were from Applied biosystems 
(Foster City, Ca, USA). PCRs were 
performed in universal master 
mix (Roche). Conditions were as 
follows: 10 min 95°C followed by 
45 cycles of 15 sec 95°C and 1 min 
62°C.
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Supplemental figure 3. Transactivation of the ID1 promoter in myeloid cells. HL60 cells were 
electroporated with the 963bp ID1 promoter-luciferase reporter construct (ID1-luc) together 
with a control vector expressing Renilla-luciferase. In addition an empty vector or a vector 
coding for PML-RARαΔR was transfected. Transactivation is expressed as arbitrary units and is 
corrected for transfection efficiency measured by Renilla-luciferase. Back-ground luminescence 
of the cells trans-fected with only the reporter construct without nuclear receptors and in the 
absence of ATRA was set at 1. Cells were cultured for 8 hrs without (light gray bars) and with 
(dark gray bars) ATRA.
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HES1 gene expression is directly regulated by 
PML-RARα in a NF-Y-dependent manner
Chapter 4
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Abstract
The oncogenic fusion protein PML-RARα is expressed in 98% of the cases of acute 
promyelocytic leukemia (APL). PML-RARα interferes with the expression of normal 
retinoic acid receptor target genes, blocking the differentiation of the malignant cells 
at physiological concentrations of retinoids. Restoration of the expression of these 
PML-RARα target genes using high concentrations of all-trans retinoic acid (ATRA), 
forces the leukemic cells into terminal granulocytic differentiation. Here we report 
the identification of a novel direct ATRA-responsive gene in APL: Hairy-Enhancer of 
Split 1 (HES1). ATRA induced a rapid, transient increase in HES1 expression, followed 
by a clear decrease, both in PML-RARα positive cell lines as well as in primary APL 
patient cells. We show that PML-RARα is directly involved in the transcriptional 
regulation of HES1, while wild type RARα/RXR is not. We demonstrate that 
transactivation of HES1 by PML-RARα does not require the DNA-binding domain of the 
fusion protein but depends on NF-Y transcription factors. These results indicate that 
PML-RARα not only interferes with the transcription of regular retinoic acid receptor 
target genes, but may also interfere with the expression of NF-Y-regulated genes. 
PML-RARα regulates HES1 expression via NF-Y
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Introduction
Acute promyelocytic leukemia (APL) accounts for 5-10% of all acute myeloid leukemias 
(AMLs) and is classified as AML-M3, according to the French-American-British (FAB) 
classification system based on morphological criteria. APL is chacarterized by a block 
in differentiation at the promyelocytic stage of hematopoietic development and by 
mutations that affect the retinoic acid receptor α (RARα). In 98% of the cases of APL, 
the promyelocytic leukemia (PML) gene on chromosome 15 is fused to the retinoic 
acid receptor α (RARA) gene on chromosome 17 resulting in a PML-RARα fusion 
protein. This chimeric protein acts as a dominant oncogene, interfering with the 
normal function of the unrearranged PML as well as the unrearranged RARα protein. 
PML-RARα may silence normal RARα target genes at physiological concentrations of 
the RARα ligand, all-trans retinoic acid (ATRA). It has been postulated that these 
target genes mediate PML-RARα-induced transformation. At high concentrations 
of ligand, PML-RARα (re)activates the transcription of genes, forcing the leukemic 
cells into terminal granulocytic differentiation.1 The importance of PML-RARα as 
a transcriptional activator of differentiation-inducing genes has been illustrated 
by in vitro experiments. Forced expression of PML-RARα, but not RARα, in an ATRA 
resistant APL cell line with constitutive degradation of the chimeric protein restored 
ATRA sensitivity.2 In addition, in APL patients that became resistant to differentiation 
induction with ATRA during therapy, additional mutations were found in the ligand-
binding domain of the PML-RARα fusion protein, indicating an important role for the 
fusion protein in retinoic acid-induced differentiation of APL cells.3 To date, several 
important RARα target genes have been identified that are deregulated by PML-RARα 
in APL cells including p21waf1/Cip1 4-6 and CCAAT/enhancer-binding-protein-β and ε 
(C/EBPβ and C/EBPε).7;8 Previously, we described the involvement of Inhibitor of DNA 
binding 1 and 2 (ID1 and ID2) proteins in the response of APL cells to ATRA treatment 
and we showed that ectopic expression of these genes induced an accumulation of 
APL cells in the G0/G1 phase of the cell cycle.9 Recently, we found that ID1 and 
ID2 are direct retinoic acid responsive genes that are transcriptionally regulated by 
PML-RARα. Interestingly, we found that PML-RARα transcriptionally regulates ID1 and 
ID2 expression via a novel mechanism, which is not shared with normal RARα. ID1 
and ID2 are transcriptionally activated by PML-RARα independently of its DNA-binding 
domain and transcriptional activation by PML-RARα requires the presence of the NF-Y 
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transcription factor complex and Sp1 binding sequences. These results indicate that 
PML-RARα not only interferes with the transcriptional regulation of regular retinoic 
acid receptor target genes, but also with the expression of an additional class of 
genes that are normally not regulated by retinoic acid receptors (Van Wageningen et 
al., manuscript accepted for publication in Blood). Whether this is restricted to ID1 
and ID2 gene expression or represents a more common mechanism remains unknown. 
ID1 and ID2 belong to the family of helix-loop-helix (HLH) proteins that act as 
negative regulators of basic-HLH (bHLH) transcription factors. Many developmental 
processes are positively or negatively controlled by bHLH genes and their inhibitors 
and members of this family have been implicated in cell fate decisions in many 
different tissues.10 In hematopoiesis, bHLH transcription factors and their inhibitors 
have been implicated in lymphopoiesis and three bHLH family members (SCL/TAL-1, 
LYL-1 and E2A) are located at the sites of recurrent chromosomal translocation 
breakpoints in leukemia.11-14 Besides the ID proteins, Hairy-Enhancer of Split (HES) 
proteins (HES1-7) also act as transcriptional repressors of bHLH-regulated genes. Like 
ID proteins, HES1 proteins act by sequestration of bHLH transcription factors into 
non-functional heterodimeric complexes.15;16 In addition to this passive repression 
mechanism, HES1 proteins may function as active repressors by binding to DNA. HES1 
proteins contain a DNA binding domain that preferentially recognizes the consensus 
sequences CACNAG (or N-box), unlike most other bHLH factors, which bind to the 
consensus sequences CANNTG (or E-box).15 HES1 homodimers bind to N-box sequences 
and the corepressor TLE/Groucho is subsequently recruited to mediate repression 
by interaction with histone deacetylases. Furthermore, the orange domain/helix3-
helix4 of HES1 contributes to transcriptional repression, but the exact underlying 
mechanism is not known.17 Transcriptional repression by HES1 of its own promoter is 
mediated through this latter mechanism.18 Apart from repression of its own promoter, 
human achaete-scute homolog-1 (hASH1)19, CD4,20 acid α-glucosidase (GAA)21 and 
p21waf1/Cip1 22 have been proposed as candidate HES1 target genes. A dual function has 
been described for HES1 both as a transcriptional activator and as a transcriptional 
repressor of GAA depending on the cell type.23 
In the present study we investigated whether transcriptional regulation of 
inhibitors of bHLH transcription factors by PML-RARα during ATRA-induced APL cell 
differentiation is a more general mechanism. We investigated whether besides 
the ID proteins, HES1 is also regulated in APL cells. We show that HES1 is a direct 
PML-RARα regulates HES1 expression via NF-Y
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ATRA-responsive gene, which is transcriptionally regulated by PML-RARα via a NF-Y-
dependent mechanism.
Materials and methods
Cell culture
Leukemic cells were isolated from bone marrow of patients at diagnosis after informed consent. 
Mononuclear cells were isolated by means of a Ficoll-1077 (Amersham, Buckinghamshire, 
UK) gradient and cultured in RPMI 1640 medium (Life Technologies, Gaithersburg, MD, USA) 
supplemented with 20% fetal calf serum (FCS). NB4 and U937-PR9 cells (kindly provided by 
Dr. P.G. Pelicci) were cultured in RPMI 1640 medium (Life Technologies) supplemented with 
10% FCS. HEK 293 cells were cultured in DMEM (Life Technologies) and Hep3B cells were 
cultured in IMDM (Life Technologies) both supplemented with 10% FCS and 2 mM glutamine (Life 
Technologies). Cultures were incubated at 37°C in a 5% CO2 completely humidified atmosphere. 
ATRA (Sigma, St Louis, MO, USA) was used at a concentration of 10-6 M, and where indicated 
100 μM ZnSO4 was added 16 hours prior to ATRA. Cycloheximide (ICN, Costa Mesa, CA, USA) was 
used at 4 μg/ml, and was added 30 min prior to ATRA.
Quantitative PCR
RNA from cell lines was isolated using RNA-Bee (Iso-Tex Diagnostics, Friendswood, TX, USA) 
and RNA from primary cells was isolated using the mini RNA isolation II kit (Zymo Research, 
Orange, CA, USA). Bone marrow mononuclear cells of AML patients were isolated by lysis of 
erythrocytes in 0.14 M NH4Cl buffer for 30 min on ice, after which RNA was isolated using RNA-
Bee (Iso-Tex Diagnostics). cDNA was generated in a reverse transcription reaction as previously 
described.24 HES1 mRNA levels were measured with real-time quantitative PCR using the 
primers: sense 5’-GAAGG-CGGACATTCTGGAAA-3’, anti-sense 5’-GCGGGTCACCTCGTTCAT-3’. 
Quantitative PCR was done using SYBR green PCR (Applied Biosystems, Foster City, CA, 
USA). β-actin or PBGD was used as a reference gene. Primer sequences for the HES1 
promoter were as follows: sense 5’-AGTCAAAGCAGCTCTGTTACATATGAG-3’, anti-sense 
5’-TTTGGTCTTGATCTTGTCTATTTCTTTT-3’. Primers for the RARβ promoter were: sense 
5’-TTGGGTCATTTGAAGGTTAGCA-3’, anti-sense 5’-CACACAGAATGAAAGATTGAATTGC-3’. 
Quantitative PCR for the ALBUMIN promoter was performed using probe ALB-VIC 
5’-TGCTGAAACATTCACCTTCCATGCAGA-3’ with the primers, sense 5’-TGAAACAT-
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ACGTTCCCAAAGAGTTT-3’, anti-sense 5’-CTCTCCTTCTCAGAAAGTGTGC-ATAT-3’. Primers and 
probe were all located to one exon of the ALBUMIN gene. Quantitative PCR reactions were 
performed on the ABI/PRISM 7700 Sequence Detection system (ABI/PE, Foster City, CA, USA).
Western blotting
Cells were lysed in RIPA-buffer containing 1% Nonidet P-40 (NP-40), 0.5% natrium-deoxycholaat, 
0.1% SDS and protease inhibitor cocktail (Roche Diagnostics, Basel, Switzerland). Total protein 
lysates (75 μg) and molecular weight markers were separated on a 10% SDS-polyacrylamide gel 
and electrophoretically transferred onto polyvinylidenefluoride (PVDF) membranes (Bio-Rad, 
Hercules, CA, USA). Blots were probed with anti-murine HES1 rabbit polyclonal antibody (a kind 
gift from Dr. Tetsuo Sudo, Toray Industries, Inc., Japan). As a control for equal loading, blots 
were probed with an antibody to Actin (I-19) (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Chromatin immunoprecipitation (ChIP)
HEK 293 cells were transiently transfected with FLAG-PML-RARα (kindly provided by A. Tomita25 
which was re-cloned into a pCMV expression vector) using the calcium phosphate precipitation 
method. ChIP assays were performed as described previously.26 At 24 hours after transfection 
DNA-protein cross-linking was done for 30 min at room temperature by adding formaldehyde at 
a final concentration of 1% directly to the culture medium. Where indicated, ATRA was added 
30 min before cross-linking. Cross-linking was stopped by the addition of glycine to a final 
concentration of 125 mM for 5 min at room temperature. Cells were scraped and washed with 
ice-cold phosphate-buffered saline, buffer B (10 mM EDTA, 0.5 mM EGTA, 0.25% Triton X-100, 20 
mM HEPES [pH 7.6]), buffer C (1 mM EDTA, 0.5 mM EGTA, 0.15 M NaCl, 50 mM HEPES [pH 7.6]) 
and resuspended in incubation buffer (0.15% SDS, 1% Triton X-100, 0.15 M NaCl, 1 mM EDTA, 
0.5 mM EGTA, 20 mM HEPES [pH 7.6] and protease inhibitors) at 33x106 cells/ml. Chromatin 
was sonicated using the Bioruptor (Cosmo Bio, Tokyo, Japan), at high intensity for 15 min with 
0.5 min intervals. Insoluble material was removed by centrifugation at 4°C for 15 min. A total 
of 120 μl supernatant was incubated with 30 μl pre-coated protein A/G plus agarose beads 50% 
v/v (Santa Cruz), 0.1% BSA, 36 μl 5x incubation buffer, protease inhibitors and 2-5 μg antibody 
(anti-NF-YA (H-209, Santa Cruz), anti-FLAG (M2, Sigma) or non-specific IgG from human serum) 
and rocked at 4°C for 16 hours. Beads were harvested by centrifugation and washed twice with 
buffer 1 (0.1% SDS, 0.1% NaDOC, 1% Triton X-100, 0.15 M NaCl, 1 mM EDTA, 0.5 mM EGTA and 20 
mM HEPES [pH 7.6]), once with buffer 2 (0.1% SDS, 0.1% NaDOC, 1% Triton X-100, 0.5 M NaCl, 
1 mM EDTA, 0.5 mM EGTA and 20 mM HEPES [pH 7.6]), once with buffer 3 (0.25 M LiCL, 0.5% 
PML-RARα regulates HES1 expression via NF-Y
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NaDOC, 0.5% NP-40, 1 mM EDTA, 0.5 mM EGTA, 20 mM HEPES [pH 7.6]), and twice with buffer 4 
(1 mM EDTA, 0.5 mM EGTA, 20 mM HEPES [pH 7.6]). Chromatin antibody complexes were eluted 
by the addition of 1% SDS and 0.1 M NaHCO3 to the pellet and incubated for 20 min at room 
temperature. Cross-linking was reversed by the addition of NaCl (0.44 M final concentration) 
and incubation of the eluted samples for at least 4 hours at 65°C. DNA was recovered by phenol-
chloroform-isoamylalcohol extraction followed by chloroform-isoamylalcohol extraction and 
precipitated by the addition of 0.1 volume of 1 M sodium acetate (pH 5.2), and 2.5 volumes of 
ethanol. Precipitated DNA was dissolved in water, and input as well as immunoprecipitated DNA 
was analyzed using quantitative PCR for genomic sequences of the HES1 and RARβ promoter 
regions. For calculation of the fold enrichment, quantitative PCR was performed for ALBUMIN 
genomic sequences before and after the immunoprecipitation. Quantitative PCR following ChIP 
was done using SYBR green PCR (Applied Biosystems).
 
Transactivation studies
Hep3B cells were transfected using the calcium phosphate precipitation method with an 
equal amount of reporter plasmid (0.25 μg pGL3-HES1) and different amounts of effector 
plasmids (0.25 μg nuclear receptor expression vector, 1.0 μg YAm29 expression vector, 
0.1 μg Renilla vector (pRL-CMV, Promega, Madison, WI, USA). The total amount of plasmid 
was normalised by the addition of empty vector as the carrier in each transfection. The 
HES1 promoter (containing the –252 to +31 promoter fragment of HES1) was cloned into 
the XhoI-HindIII site of the pGL3-basic vector (Promega) after amplification with the 
following primers: sense 5’-GTACCTCGAGGAGAGTAGCAAAGGGTTAAAATCCT-3’, anti-sense 
5’-GTACAAGCTTCTGTTATCAGCACCAGCTCCG-3’. RARE3-tk-luc,
27 PML-RARαΔR,28 PML-RARαΔCC, 
PML-RARα, PLZF-RARα, RARα and RXR29 expression vectors were as described and dominant-
negative NF-YA (YAm29) was kindly provided by R. Mantovani (University of Milan, Italy). Where 
indicated ATRA (Sigma) was added 24 hours after transfection. Cells were lysed 40 hours after 
transfection using Passive Lysis Buffer (Promega). Firefly and Renilla activity was measured on a 
luminometer (Lumat LB 9507, ABI/PE) using Luciferase Assay reagents (Promega).
Results
HES1 is rapidly and directly induced in APL cells upon ATRA treatment
To investigate whether, besides the ID proteins, other inhibitors of bHLH transcription 
factors are regulated in APL cells, we assessed the expression level of HES1 during 
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ATRA-induced granulocytic differentiation of APL cells. Total RNA and protein was 
isolated from the PML-RARα positive APL cell line NB4, cultured in the absence or 
presence of ATRA for several time intervals, and HES1 expression levels were measured 
by RT-PCR (Figure 1A) and Western blotting (Figure 1B). HES1 mRNA and protein 
expression levels were induced within half an hour of ATRA stimulation and reached 
maximum levels (> 5-fold induced) at 1 hour of ATRA stimulation. Subsequently, from 1 
to 24 hours following ATRA stimulation, HES1 mRNA expression levels decreased about 
100-fold and remained at this level during further differentiation. HES1 protein levels 
diminished to undetectable levels at 4 hours of ATRA stimulation. The expression 
pattern of HES1 was confirmed in primary APL patient cells (Figure 1C). Cells were 
cultured in the presence or absence of ATRA for several time intervals, after which 
RNA was isolated. In all cases we observed a clear upregulation of HES1 mRNA levels 
within 4 hours of ATRA stimulation after which expression levels declined again. 
Thus, HES1 expression levels are rapidly upregulated by ATRA both in the NB4 cell 
line as well as in primary APL patient cells. To investigate whether HES1 was directly 
regulated by retinoic acid receptors, NB4 cells were treated with cycloheximide to 
inhibit protein translation. Upregulation of HES1 mRNA expression by ATRA was not 
affected by the presence of cycloheximide, indicating that HES1 is directly induced, 
without intermediate protein production (Figure 1D).
PML-RARα regulates HES1 expression
APL is characterized by a block in granulocytic differentiation and PML-RARα is 
involved in this process by deregulating expression of retinoic acid response genes. 
To investigate whether HES1 expression levels are regulated by PML-RARα, we used 
the U937-PR9 cell line, which is stably transfected with a Zn2+ -inducible PML-RARα 
expression cassette. This cell line was cultured in the presence or absence of zinc, 
and the expression level of HES1 was measured by RT-PCR. Expression of PML-RARα in 
U937 cells resulted in slightly enhanced HES1 expression levels in the absence of ATRA 
(Figure 2).
To study the effect of PML-RARα on HES1 expression during ATRA-induced 
differentiation, U937-PR9 cells were cultured with or without zinc followed by ATRA 
stimulation for several time intervals. Figure 2 shows that the presence of PML-RARα 
caused an upregulation of HES1 mRNA expression at 4 hours of ATRA stimulation. 
Comparable to NB4 cells, this induction was transient. Unlike in NB4 and primary APL 
patient cells, no suppression of HES1 was observed at later time points. Perhaps this 
PML-RARα regulates HES1 expression via NF-Y
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suppression in NB4 and APL patient cells is due to degradation of PML-RARα following 
ATRA treatment of these cells. 
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Figure 1. HES1 is a direct ATRA-responsive gene in APL cells.(A) Total RNA samples derived 
from non-stimulated and ATRA-stimulated NB4 cells (10-6 M ATRA was added for indicated time 
intervals) were subjected to RT-PCR using specific primers for the detection of HES1 mRNA. 
Mean values and standard deviations of at least two independent experiments are shown. (B) 
Total cell lysates (75 mg) from non-stimulated and ATRA-stimulated NB4 cells (10-6 M ATRA 
was added for indicated time intervals) were subjected to immunoblot analysis using HES1 
antibody. The same blot was reprobed with a β-actin antibody to demonstrate equal loading. 
The molecular weight (kDa) marker is indicated at the left. (C) RT-PCR was performed with 
total RNA from bone marrow derived mononuclear cells from five APL patients after in vitro 
exposure to 10-6 M ATRA for indicated time points (dark gray bars). As a control cells were 
cultured in the absence of ATRA (light gray bars). (D) NB4 cells were treated with cycloheximide 
(light gray bars), ATRA (dark gray bars) or cycloheximide and ATRA (black bars). Total RNA was 
derived from these samples and subjected to RT-PCR using specific primers for the detection of 
HES1 mRNA. Values were normalised for β-actin expression in all experiments. 
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Figure 2. PML-RARα is involved in the transcriptional regulation of HES1. RT-PCR was 
performed with total RNA extracted from U937-PR9 after culturing the cells in the presence 
(dark gray bars) or absence (light gray bars) of Zn2+ and ATRA for indicated time points. β-actin 
was used for normalisation. 
To investigate whether PML-RARα is associated with deregulated HES1 expression 
in primary patient cells, we analysed the expression level of HES1 in cells from 
patients diagnosed with AML subtypes M0 to M7, and compared these with the level 
of expression in cells from patients with AML-M3 (Figure 3). As in U937 cells, also 
in primary leukemic cells expression of PML-RARα resulted in a somewhat higher 
expression level of HES1. These data indicate that PML-RARα-mediated leukemic 
transformation does not involve active downregulation of HES1. 
PML-RARα transactivates the HES1 promoter without direct DNA binding
Since we demonstrated that expression of HES1 is directly upregulated in APL cells 
upon stimulation with ATRA and that expression of PML-RARα contributes to this 
ATRA-induced upregulation of HES1 expression in U937 cells, we investigated the 
mechanism that results in the transcriptional activation of HES1 by PML-RARα. We 
cloned a 283 bp fragment of the HES1 promoter, including the putative TATA-box, into 
a luciferase reporter construct. When expressed alone, RARα, RXR and PML were not 
able to transactivate this HES1 promoter construct both in the absence and presence 
of ATRA. The combination RARα/RXR also did not transactivate the promoter. In 
contrast, PML-RARα transactivated the promoter more than 6-fold in an ATRA-
dependent fashion and almost 2-fold in the absence of ligand (Figure 4A). To verify 
PML-RARα regulates HES1 expression via NF-Y
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that RARα and RXR were expressed and functional, a control luciferase construct was 
used containing three bona-fide retinoic acid response elements (RAREs) from the 
RARβ promoter (RARE3-tk-luc30). This construct was strongly transactivated in the 
presence of ATRA through endogenous retinoic acid receptors and transactivation was 
further enhanced when RARα and RXR were co-transfected (Figure 4B). 
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Figure 3. HES1 expression levels in APL cells compared to non-APL AML cells. RNA was 
isolated from bone marrow mononuclear cells of newly diagnosed AML patients (M0 n=2, M1 
n=7, M2 n=6, M3 n=14, M4 n=5, M5 n=5, M6 n=1 and M7 n=2). RT-PCR for HES1 was performed 
and PBGD was used as a reference gene. Compared are the expression levels of HES1 in AML-M3 
(M3, n=14) versus AML-M0 to M7 (M0-7, n=28). The black horizontal bar indicates the median. 
The significance level (p-value) between the two groups was calculated using Student’s t-test 
and was set at 0.05. 
To investigate the importance of the different domains of PML-RARα, we tested 
whether vectors encoding the DNA-binding-defective PML-RARα mutant (PML-
RARα∆R) and a mutant lacking the coiled-coil domain (PML-RARα∆CC) were able 
to transactivate the HES1 promoter. In figure 4C we show that PML-RARα∆R is able 
to transactivate the HES1 promoter, indicating that transactivation of the HES1 
promoter by PML-RARα does not require direct binding of PML-RARα to the DNA. 
However, PML-RARα∆CC did not transactivate the HES1 promoter, suggesting that 
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PML-RARα homodimerisation or interaction with another protein is necessary for 
transactivation. When PLZF-RARα, which contains the same part of the retinoic acid 
receptor as PML-RARα, was used no transactivation could be observed (Figure 4C).
NF-YA is necessary for PML-RARα-dependent transactivation of the HES1 
promoter
Recently, we have found that PML-RARα-dependent transactivation of the ID1 and ID2 
promoter is dependent on NF-Y (CCAAT box) and on Sp1 (GC box) binding sequences 
in the 5’ upstream promoter region (Van Wageningen et al., manuscript accepted for 
publication in Blood). We investigated whether PML-RARα-dependent transactivation 
of the HES1 promoter might also be regulated via NF-Y. When analysing the sequence 
of a 283 bp fragment of the HES1 5’ promoter to determine the DNA sequences that 
are relevant for the observed PML-RARα-dependent transactivation, no consensus 
RARE was found. However, we observed perfect consensus binding sites for the NF-Y 
transcription factor and Sp1 (Figure 5A). NF-Y is a trimeric protein complex consisting 
of the subunits NF-YA, NF-YB and NF-YC. All three subunits are necessary for the 
complex to bind to DNA. A dominant-negative form of NF-YA has been described 
(YAm2931). This mutated NF-YA subunit can still bind to the NF-YB and NF-YC subunits, 
but is not able to bind to DNA, preventing the formation of a functional trimeric NF-Y 
complex. To investigate whether functional NF-Y was necessary for transactivation 
of the HES1 promoter the YAm29 mutant was used in a transactivation assay. Figure 
5B shows that transactivation of HES1 by PML-RARα was strongly decreased in the 
presence of dominant-negative NF-YA. This indicates that PML-RARα-dependent 
transactivation of the HES1 promoter is dependent on a functional NF-Y complex. 
PML-RARα and NF-YA bind to the HES1 promoter 
To study whether PML-RARα is present on the HES1 promoter we performed ChIP 
assays. HEK293 cells were transfected with FLAG-PML-RARα and immunoprecipitation 
was performed using chromatin from these cells and an antibody directed against 
FLAG or non-specific IgG as a control. Quantitative PCR was used to measure the 
amount of immunoprecipitated HES1 promoter, which was compared to the control 
genomic sequences of ALBUMIN. ChIP assays using chromatin from PML-RARα 
transfected cells revealed a clear increase in HES1 promoter recovery when compared 
to untransfected cells, indicating that PML-RARα is present on the HES1 promoter 
PML-RARα regulates HES1 expression via NF-Y
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(Figure 6, compare upper and middle rows). ChIP assays were performed both in the 
presence and absence of ATRA and we found that ATRA did not influence the binding 
of PML-RARα to the HES1 promoter, suggesting that binding of PML-RARα is ligand-
independent (Figure 6, middle and bottom rows). The RARβ promoter, which contains 
a well-defined RARE served as a positive control.
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Figure 4. Transactivation of the HES1 promoter by PML-RARα. (A and C) Hep3B cells were 
transfected with a HES1 promoter-luciferase reporter construct (pGL3-HES1), a control vector 
expressing Renilla-luciferase and vectors coding for the various proteins indicated in the 
figure. Background luminescence of the cells transfected with only the reporter construct in 
the absence of ATRA was set to 1. Transactivation was corrected for transfection efficiency 
measured by Renilla activity. Cells were cultured with (dark gray bars) or without (light gray 
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bars) ATRA. Mean values and standard deviations from three independent experiments are 
shown. (B) To show transactivation by unrearranged retinoic acid receptors, Hep3B cells were 
transfected with the luciferase construct RARE3-tk-luc, containing three bona-fide RAREs. Mean 
values and standard deviations from three independent experiments are shown. 
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Figure 5. Functional NF-YA is necessary for PML-RARα-dependent transactivation of the 
HES1 promoter.  (A) The 283 bp promoter fragment of the HES1 gene showing the consensus 
NF-Y and Sp1 binding sites. (B) Hep3B cells were transfected with a HES1 promoter-luciferase 
reporter construct (pGL3-HES1), a control vector expressing Renilla-luciferase and vectors 
coding for the various proteins indicated in the figure. Background luminescence of the cells 
transfected with only the reporter construct in the absence of ATRA was set to 1. Transactivation 
was corrected for transfection efficiency measured by Renilla activity. Cells were cultured with 
(dark gray bars) or without (light gray bars) ATRA. Mean values and standard deviations from 
three independent experiments are shown.
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Figure 6. PML-RARα and NF-YA bind to the HES1 promoter. ChIP assays were performed 
both for the HES1 promoter and for the RARβ promoter. Sonicated chromatin of HEK 293 cells 
transfected with FLAG-PML-RARα or of non-transfected HEK 293 cells were used for ChIP 
analysis using antibodies against NF-YA or FLAG or non-specific IgG as a control (n=4). Where 
indicated, cells were cultured in the presence of ATRA. Quantitative PCR was used to measure 
the amount of immunoprecipitated DNA of the HES1 and RARβ promoter, which was compared 
to the control genomic sequences of ALBUMIN. The recovery of HES1 and RARβ was plotted as 
the fold enrichment over the recovery of ALBUMIN. 
Since NF-YA is necessary for PML-RARα-dependent transactivation of the 283 bp HES1 
promoter fragment, we tested whether NF-YA is present on the endogenous HES1 
promoter. ChIP assays were performed as described using an anti-NF-YA antibody. We 
found a more than 7-fold enrichment of NF-YA on the HES1 promoter compared to 
the control (Figure 6, upper row). No enrichment was found for the RARβ promoter, 
indicating that NF-YA was present on the HES1 promoter but not on the RARβ 
promoter. The addition of ATRA did not influence the binding of NF-YA to the HES1 
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promoter (Figure 6, compare upper and middle row with bottom row). In summary, 
these data show that besides ID1 and ID2 another repressor of bHLH transcription 
factors, HES1, is a direct ATRA-responsive gene in APL cells. HES1 is transcriptionally 
regulated by PML-RARα in a NF-Y-dependent manner. 
Discussion
PML-RARα has been shown to silence normal retinoic acid receptor target genes 
at physiological concentrations of retinoic acid and it has been postulated that 
repression of these genes contributes to malignant transformation. By restoring the 
expression of these RARα target genes using high concentrations of retinoic acid, the 
leukemic cells will be forced into terminal differentiation. In the present study we 
demonstrate that both protein and RNA expression of HES1 is transiently upregulated 
and subsequently downregulated during ATRA-induced granulocytic differentiation of 
APL cells. Transactivation studies revealed a lack of response of the HES1 promoter to 
wild type retinoic acid receptors whereas PML-RARα transactivated the promoter in 
a ligand-dependent manner. These results indicate that PML-RARα not only interferes 
with the transcriptional regulation of regular retinoic acid receptor target genes via a 
consensus RARE, but also with the expression of an additional class of genes that are 
normally not regulated by retinoic acid receptors. We show that transactivation of 
the HES1 promoter by PML-RARα was independent of its DNA-binding domain, but that 
the coiled-coil domain of PML-RARα was important for transactivation. Furthermore, 
transactivation of HES1 by PML-RARα also required the presence of a functional NF-Y 
transcription factor complex. ChIP experiments revealed that both NF-YA and PML-
RARα are associated with the HES1 promoter. Previously, we proposed a model in 
which PML-RARα binds to a DNA-bound Sp1-NF-Y complex, rendering the expression 
of the genes ID1 and ID2 sensitive to ATRA, thereby defining a novel gain-of-function 
for the fusion protein. Here we suggest that apart from ID1 and ID2, HES1 may be 
transcriptionally regulated by PML-RARα via a similar mechanism.
As indicated above, gene silencing mediated by PML-RARα has been implicated 
in leukemogenesis. Remarkably, unliganded PML-RARα upregulated the expression of 
HES1. Expression of PML-RARα both in U937 cells and in Heb3B cells resulted in slightly 
enhanced HES1 expression in the absence of ligand. Also in primary leukemic cells a 
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somewhat higher expression of HES1 was observed in APL patient cells compared to 
leukemic cells from patients with other FAB-subtypes lacking PML-RARα. These data 
are in line with a study by Alcalay et al. in which the mRNA expression level of HES1 
in normal CD34+ cells was compared with the level of expression in blasts bearing 
the t(15;17).32 They found higher HES1 expression levels in the APL cells. These data 
indicate that PML-RARα does not target HES1 gene expression in a dominant-negative 
manner. 
HES1 is an important gene functioning in stem cell biology by keeping 
hematopoietic cells in a proliferative and undifferentiated state. Overexpression 
of HES1 in murine early hematopoietic precursor cells caused suppression of the 
development of B-lineage cells in vivo. The myeloid compartment in these mice 
showed no abnormalities in vivo, but myeloid clonogenic assays revealed that HES1 
expressing cells remained immature and retained proliferative capability ex vivo.33 
Furthermore, it has been demonstrated that murine Hes1 plays a role in the expansion 
of immature thymocytes.34;35 In line with the effects of HES1 overexpression in 
murine bone marrow cells,33 overexpression of HES1 in human CD34+ cord blood cells 
inhibited B-cell development. In addition, when HES1 was overexpressed in CD34+ 
cells they remained more immature than vector transduced controls.36 Furthermore, 
preservation of long-term reconstituting activity of HES1-transduced hematopoietic 
stem cells (HSCs) in vitro was demonstrated in several reports.37-39 As HES1 expression 
has been implicated in a block in differentiation it is tempting to speculate that 
the slight induction mediated by PML-RARα in the absence of ligand contributes to 
leukemogenesis. Because HES1 expression also correlates with proliferation, the 
further transient HES1 induction, observed after stimulation with ATRA, might be 
involved in the transient leukocytosis, which occurs in APL patients treated with 
ATRA.40;41 Further studies are required to test this hypothesis. After 24 hours of ATRA 
stimulation a significant downmodulation of HES1 was observed. The shutdown of 
HES1 may be necessary to allow terminal granulocytic differentiation of the cells. 
HES1 is known as a target gene of Notch signaling and by targeting Notch1, many 
of the HES1 phenotypes, induced by overexpression or knockdown, can be mimicked. 
Notch signaling is involved in many cellular processes, including the maintenance of 
stem cells, cell fate determination, differentiation, proliferation and apoptosis. Its 
role in these processes is very much cell type dependent. For example, Notch signaling 
induces HSCs to maintain their undifferentiated state, while Notch signaling directs 
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a common lymphoid progenitor towards T-lineage cells at the expense of B-lineage 
cells. Activating mutations in the Notch1 gene have been involved in tumorigenesis, 
which has been illustrated by the development of T-cell leukemias.42-44 Alcalay et 
al. reported that expression of PML-RARα resulted in activation of Notch signaling 
through Jagged1, which functions as a ligand for the Notch receptor, thereby 
activating expression of Notch target genes, including HES1.32 Here we demonstrate 
that PML-RARα directly activates expression of HES1 by binding to its promoter 
region. The effects of Notch activation on ATRA-induced differentiation of NB4 
cells has been investigated and revealed a reduction of ATRA-induced apoptosis and 
a partial alteration of ATRA-induced neutrophilic differentiation into monocytic.45 
Further studies using overexpression and knockdown of HES1 should help to clarify 
the exact role of HES1 in APL. 
PML-RARα regulates HES1 expression via NF-Y
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The helix-loop-helix protein ID2 interacts with the 
transcriptional repressor MBD1
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Abstract
Inhibitor of DNA binding 2 (ID2) belongs to the family of helix-loop-helix (HLH) proteins 
and is involved in cell lineage commitment and proliferation- differentiation control 
in many mammalian tissues. ID proteins inhibit DNA binding of basic-HLH transcription 
factors by forming heterodimeric complexes. Previously, we demonstrated that ID2 
is upregulated during retinoic acid induced granulocytic differentiation of acute 
promyelocytic leukemia (APL) cells and that forced expression of ID2 is involved in cell 
cycle arrest of APL cells. Since myeloid-specific binding partners of ID proteins have 
not been identified yet, we performed a yeast two-hybrid assay with ID2 and a bone 
marrow derived hematopoietic cDNA library to search for unknown ID2-interacting 
proteins. Here, we present all the known and novel ID2-interacting proteins we 
identified in this assay. One of the novel identified ID2-interacting proteins is methyl-
CpG binding protein 1 (MBD1). We confirmed the interaction between ID2 and MBD1 
using co-immunoprecipitation studies. 
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Introduction
ID2 is a member of the helix-loop-helix (HLH) family of proteins which is involved 
in many developmental processes, including hematopoiesis.1 ID2 is essential for the 
generation of peripheral lymph nodes and Peyer’s patches, for the differentiation 
of natural killer cells, and for the formation of Langerhans cells and splenic CD8α+ 
dendritic cells. Furthermore, the development of nasopharyngeal-associated 
lymphoid tissue is defective in ID2 deficient mice.2-4 Overexpression studies in 
chicken embryos implicated ID2 in the promotion of ectodermal cells towards neural 
rather than epidermal lineages.5 The involvement of ID2 in cellular proliferation 
and differentiation depends on the specific cell lineages and developmental 
stages. ID2 expression levels increase during terminal differentiation of myeloid 
lineages,6-8 during development of Langerhans cells3 and following differentiation 
of mammary epithelial cells.9 In B- and T-cell development and oligodendrocyte 
development the expression of ID2 is correlated with proliferation and decreases 
during differentiation.10-12 ID2 may play a role in tumorigenesis as mRNA and protein 
levels of ID2 are elevated in many different tumour cell types.13 ID2 is a direct 
target of Myc family members. Activation of N-Myc and c-Myc (in neuroblastoma 
and Ewing sarcoma) results in increased ID2 expression levels.14-18 Furthermore, ID2 
is a downstream target of the retinoblastoma (Rb) protein. By keeping control of 
ID2, Rb might prevent ID2-mediated inhibition of transcription factors that control 
normal development.19;20 Overexpression of ID2 in thymocytes leads to development 
of lymphomas, suggesting a role for ID2 in transformation.10 Interestingly, a tumour-
inhibitory effect of ID2 in the intestinal epithelium was reported, since mice that 
lack ID2 develop intestinal tumours.21
Previously, we identified ID2 as a direct retinoic acid responsive gene in acute 
promyelocytic leukemia (APL) cells and we demonstrated that ectopic expression 
of ID2 in APL cells inhibits proliferation and induces cell cycle arrest. We suggested 
that the inhibition of specific bHLH transcription factor complexes by ID2 may play 
a role in the therapeutic effect of retinoic acid in APL. In addition, Buitenhuis et 
al. demonstrated that expression of ID2 in CD34+ cells accelerated the definitive 
maturation of myeloid cells, indicating a more general role for ID2 in the regulation 
of myelopoiesis.22 Since myeloid-specific binding partners of ID2 have not been 
identified yet, we performed a yeast two-hybrid assay to search for ID2-interacting 
proteins.
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Materials and methods
Cell Culture
COS-1 cells were cultured in IMDM (Life Technologies, Gaithersburg, MD, USA) supplemented 
with 10% fetal calf serum and cultures were incubated at 37˚C in a 5% CO2 completely 
humidified atmosphere.
Plasmids
The bait vector pGBDK-ID2 used in the yeast two-hybrid analysis was constructed by 
cloning the human ID2 cDNA sequence into the BamH1 site of the pGBDK-c1 vector. For the 
co-immunoprecipitation assay, the HA-tagged MBD1 cDNA insert was isolated from the pACT2 
vector by BglII and cloned into the BamH1 site of a pCMV expression vector generating pCMV-HA-
MBD1. pCMV-ID1 and pCMV-ID2, used in the co-immunoprecipitation assays, were constructed 
by cloning their human cDNA sequences into a pCMV expression vector.
Yeast two-hybrid analysis
For yeast two-hybrid analysis the yeast strain AH109 (Clontech, Palo Alto, CA, USA) transformed 
with the pGBDK-ID2 vector and a MATCHMAKER bone marrow derived hematopoietic cDNA library 
cloned in the pACT2 vector and pre-transformed in the yeast strain Y187 (Clontech) were used. 
Library screening and identification of genes coding for interacting proteins were performed as 
described in the ‘Pre-transformed MATCHMAKER Libraries User Manual’ from Clontech.
Co-immunoprecipitation and Immunoblotting assays
For co-immunoprecipitations, COS-1 cells were cultured in T75 flasks and transiently transfected 
with pCMV-HA-MBD1 and pCMV-ID2 or pCMV-ID1 using the calcium phosphate precipitation 
method. Cells were lysed 48 hours after transfection in TNI-buffer containing 0.1% Nonidet P-40 
(NP-40), 50 mM Tris-HCl pH 8.0, 150 mM NaCl and protease inhibitor cocktail (Roche, Basel, 
Switzerland) and lysates were incubated with HA-antibody (12CA5, Roche) and Prot-G Sepharose 
beads (Amersham, Buckinghamshire, UK) for 4 hours at 4˚C with gentle rotation. Beads were 
washed 3 times with TNI-buffer. Bound proteins were eluted in loading buffer by heating for 
3 min at 100˚C, separated on sodium dodecyl sulfate-polyacrylamide gels (SDS-PAGE) and 
electrophoretically transferred onto polyvinylidenefluoride (PVDF) membranes (Bio-Rad, 
Hercules, CA, USA). Blots were probed with antibodies to ID1 (Z-8, Santa Cruz Biotechnology, 
Santa Cruz, CA, USA), ID2 (C-20, Santa Cruz Biotechnology) and HA (12CA5, Roche).
ID2 interacts with MBD1
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Results and Discussion
Identification of ID2-interacting proteins
To understand the function of ID2 during myelopoiesis, we searched for ID2-interacting 
proteins using a yeast two-hybrid assay. For this experiment an ID2 construct, 
containing the entire human ID2 coding sequence, was screened against a bone 
marrow derived cDNA library. Plasmid DNA was isolated from more than 90 positive 
clones and all inserts were sequenced. We found several known ID2-interacting 
proteins, but in addition we identified putative novel ID2-interacting proteins (Table 
1). 
The generally accepted role of all four members of the ID family (ID1-4) is to 
inhibit basic-HLH (bHLH) transcription factors from forming functional homo- or 
heterodimers, thereby inhibiting transcriptional activation of bHLH target genes. ID 
proteins lack a basic DNA-binding domain and their dominant-negative function on 
bHLH transcription factors involves protein-protein interactions mediated via their 
HLH-domain. In many different cell types bHLH transcription factors activate genes 
that are necessary for diffentiation. Of the known ID2-interacting proteins, TCF3 
(E2A), a widely expressed bHLH transcription factor, was found at high frequency 
(> 50%) in this yeast two-hybrid screening. In addition, the muscle-specific bHLH 
transcription factors MYOD and MYF6 were found. 
The specificity and functional activity of the individual ID proteins is determined by 
their expression level and their cytoplasmic or nuclear localization.23-25 In addition, 
posttranslational modifications may alter the activity of the proteins.26;27 It has 
been described that ID2 is able to form homodimers and heterodimers with ID1.28;29 
We show that ID2 is able to bind to all other ID family members suggesting that the 
inhibitory function of the individual ID proteins may also be determined by mutual 
interactions, apart from posttranslational modifications or cellular localization.
The effects of ID2 are not only mediated via binding to members of the HLH family 
of proteins, as ID2 is also found to interact with non-HLH proteins. ID2 has been 
demonstrated to interact with non-HLH proteins like retinoblastoma,30;31 Ets-family 
proteins,32 Pax,33 and PC2,34 upon which the activity of these proteins is inhibited. We 
show that ID2 is able to interact with COPS5. An interaction between COPS5 and ID1 
and ID3 has been decribed by Berse et al..35 COPS5 is a subunit of a multifunctional 
protein complex called the COP9 signalosome (CSN). CSN is highly homologous to the 
19S regulatory subunit of the 26S proteasome, and is postulated to play a role in 
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protein degradation.36 It has been demonstrated that ID1 and ID3 are degraded in 
a CSN regulated manner. The interaction of ID2 with COP5S may suggest a similar 
mechanism for ID2. 
ID2 
preys
Accession 
number
Gene description #
Known
TCF3                
ID1                    
ID2                    
ID3                   
ID4                  
MYF6
MYOD1
Novel
COPS5
DEFA1
EEF1A1
EEF1G
EFEMP1
ELA2
ERAF
FSCN1
GADD45B
KIF22
LGALS1
LRRC14
MBD1
MYL1
MYLPF
NCF1
PKM2
PPP3CC
PSMA4
PX19
RHAG
RPL4
RPL24
TMSB4X
VAMP5
VPS28
NM_003200
NM_002165
NM_002166
NM_002167
NM_001546
NM_002469
NM_002478
NM_004236
NM_004084
NM_001402
NM_001404
NM_018894
NM_001972
NM_016633
NM_003088
NM_015675
NM_007317
NM_002305
NM_014665
NM_015846
NM_079420
NM_013292
NM_000265
NM_002654
NM_005605
NM_002789
NM_013237
NM_000324
NM_000968
NM_000986
NM_021109
NM_006634
NM_016208
Transcription factor 3 (E2A immunoglobulin enhancer binding factors 
E12/E47)
Inhibitor of DNA binding 1, dominant negative helix-loop-helix protein
Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein
Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein
Inhibitor of DNA binding 4, dominant negative helix-loop-helix protein
Myogenic factor 6 (herculin) 
Myogenic differentiation 1
COP9 constitutive photomorphogenic homolog subunit 5 (Arabidopsis)
Defensin, alpha 1
Eukaryotic translation elongation factor 1 alpha 1 
Eukaryotic translation elongation factor 1 gamma
EGF-containing fi bulin-like extracellular matrix protein 1
Elastase 2, neutrophil
Erythroid associated factor
Fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus)
Growth arrest and DNA-damage-inducible, beta
Kinesin family member 22
Lectin, galactoside-binding, soluble, 1 (galectin 1)
Leucine rich repeat containing 14
Methyl-CpG binding domain protein 1
Myosin, light polypeptide 1, alkali; skeletal, fast
Fast skeletal myosin light chain 2
Neutrophil cytosolic factor 1 (chronic granulomatous disease, 
autosomal 1)
Pyruvate kinase, muscle
Protein phosphatase 3, catalytic subunit, gamma isoform 
(calcineurin A gamma)
Proteasome (prosome, macropain) subunit, alpha type, 4 
Px19-like protein
Rh-associated glycoprotein 
Ribosomal protein L4 
Ribosomal protein L24
Thymosin, beta 4, X-linked 
Vesicle-associated membrane protein 5 (myobrevin)
Vacuolar protein sorting 28 homolog (S. cerevisiae) 
48
5
1
1
2
4
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
1
1
1
1
3
1
1
Table 1. Known and novel ID2-interacting proteins as identified by yeast two-hybrid 
screening. Summary of cDNAs isolated in a yeast two-hybrid screen using ID2 as bait and a 
human bone marrow derived hematopoietic cDNA library as prey. # indicates the number of 
found clones.
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To our knowledge, the other proteins that are listed in Table 1 have not been 
associated with ID proteins before. As we are interested in ID2-interacting proteins 
that are involved in proliferation and differentiation of hematopoietic cells we 
analysed the function of the putative novel ID2-interacting proteins. One potentially 
interesting protein partner that may be involved in the regulation of hematopoiesis, is 
methyl-CpG-binding protein 1 (MBD1). MBD1 is involved in transcriptional repression 
in association with DNA methylation.37;38 Methylation of DNA, which occurs at 
cytosine residues in CpG dinucleotides, is an important epigenetic modification to 
modulate the expression of many genes. Most of the CpG dinucleotides throughout the 
genome are methylated in normal cells, however, CpG-rich areas (CpG islands) that 
are located in promoter regions of many genes, may be protected from methylation 
resulting in transcriptional activation. Altered methylation patterns of CpG islands 
have been associated with cancer cells. 
ID2 interacts with MBD1 in mammalian cells
In this yeast two-hybrid screening we identified MBD1 as a putative ID2-interacting 
protein. A ~3000bp insert containing human full-length MBD1 (variant 1; capable 
of repressing transcription from both methylated and unmethylated promoters) 
was isolated from one of the positive clones. Because yeast two-hybrid assays can 
produce false positive results, we tested the interaction by co-immunoprecipitation 
analysis. HA-tagged MBD1, isolated from the yeast expression vector, was cloned 
into a mammalian expression vector and transfected into COS-1 cells together with 
a mammalian expression vector that contains the human full-length ID2 coding 
sequence. When we immunoprecipitated MBD1 with an HA-antibody (Figure 1A), we 
were able to co-immunoprecipitate ID2 (Figure 1B), indicating that also in mammalian 
cells these two proteins interact with each other. As ID2 is coexpressed with ID1 
in myeloid cells,8 and since both proteins show high sequence homology and share 
several common binding partners, we tested whether ID1 could interact with MBD1 as 
well. Co-immunoprecipitation analysis with HA-tagged MBD1 and ID1 did not show an 
interaction between these two proteins (Figure 1C and 1D). 
In conclusion, in the present study we show that ID2 interacts with MBD1. The 
upregulation of ID2 during retinoic acid induced terminal granulocytic differentiation 
of APL cells suggests a role for ID2 in this process. We hypothesize that the binding of 
ID2 to MBD1 may alter the function of MBD1, which contributes to the (re)expression 
of genes that were silenced by MBD1.
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Figure 1. ID2 interacts with MBD1 in mammalian cells. (A) COS-1 cells were transfected with 
ID2 alone or in combination with HA-tagged MBD1 (HA-MBD1) and immunoprecipitated (IP) with 
anti-HA antibody and Prot-G Sepharose beads (anti-HA), or, as a control, with Prot-G Sepharose 
beads alone (control). Equal amounts of total cell lysates from transfected COS-1 cells were 
subjected to immunoblot analysis using anti-HA antibody (upper panel; lane 1 and 2) or using 
anti-ID2 antibody (lower panel; lane 1 and 2). ID2 was detected when co-transfecting HA-MBD1 
and ID2 followed by immunoprecipitation using anti-HA antibody and immunoblot analysis 
using anti-ID2 antibody (lane 4). No ID2 was co-immunoprecipitated in the control experiments 
(lane 3 and 5) or when cells were transfected with ID2 alone (lane 6). (B) COS-1 cells were 
transfected with ID1 alone or in combination with HA-MBD1 and immunoprecipitated with 
anti-HA antibody and Prot-G Sepharose beads (anti-HA), or, as a control, with Prot-G Sepharose 
beads alone (control). Equal amounts of total cell lysates from transfected COS-1 cells were 
subjected to immunoblot analysis using anti-HA antibody (upper panel; lane 1 and 2) or using 
anti-ID1 antibody (lower panel; lane 1 and 2). ID1 was neither detected when co-transfecting 
HA-MBD1 and ID1 followed by immunoprecipitation using anti-HA antibody and immunoblot 
analysis using anti-ID1 antibody (lane 4) nor in the control experiments (lane 3, 5 and 6). The 
molecular weight (kDa) marker is indicated at the right.
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Direct regulation of miR-132 and miR-212 by the 
PML-RARα oncogene
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Abstract
The oncogenic fusion protein PML-RARα plays a crucial role in the development of 
acute promyelocytic leukemia (APL). By interfering with the expression of retinoic 
acid receptor target genes, PML-RARα blocks the differentiation of the malignant 
cells. Treatment of APL with high doses of retinoic acid activates a transcriptional 
program resulting in terminal differentiation of the malignant blasts. Several genes 
that are important for the regulation of myeloid differentiation control were shown 
to be directly regulated by PML-RARα. We have analyzed the expression of mature 
microRNAs (miRNAs) before and after induction of differentiation in APL cells. We 
show that several miRNAs are significantly differentially expressed. To investigate 
whether the PML-RARα fusion protein might be directly involved in miRNA (de)
regulation, we performed chromatin immunoprecipitation assays (CHIP). We found 
that two miRNAs (miR-132 and miR-212) are directly targeted by the PML-RARα fusion 
protein. As single miRNAs may regulate the expression of multiple target genes, 
direct deregulation of miRNAs by the PML-RARα fusion protein potentially deregulates 
multiple biological pathways, which may contribute to the transforming properties of 
the fusion protein.
PML-RARα regulates miRNA expression
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Introduction
MicroRNAs (miRNAs) are small, non-coding, single stranded RNAs that have recently 
been uncovered as an important new class of gene regulatory molecules. Mature 
miRNAs are approximately 22 nucleotides in length and are processed from longer 
primary miRNA transcripts (pri-miRNAs) that are transcribed by RNA Polymerase 
II. Two RNase III enzymes, Drosha and Dicer process the mature miRNA from these 
pri-miRNA transcripts. As a final step towards functional activity, miRNAs are 
incorporated into a RNA induced silencing complex (RISC). The miRNA within a RISC 
complex binds its target mRNAs, which are then either degraded or translationally 
repressed.1;2 It has been predicted that miRNAs regulate the expression of many 
human genes.3 Since the sequence complementarity with their target mRNAs allows 
mismatches, one miRNA may regulate multiple genes and, vice versa, one gene may 
be targeted by several miRNAs.4 This property makes it difficult to determine which 
mRNAs are targeted by a particular miRNA. Progress towards the unraveling of miRNA 
involvement in specific biological processes has been made by the identification 
of tissue- and cell type-specific miRNA expression patterns.5;6 Strong evidence 
exists for a role of miRNAs during hematopoiesis and the functional involvement 
of several miRNAs during hematopoietic differentiation has been experimentally 
confirmed. The murine miRNAs miR-142s, miR-181a and miR-223 were the first to 
be identified as preferentially expressed in hematopoietic tissues, with miR-142s 
being expressed in B- and myeloid lineages, preferential expression of miR-181a 
in the B-lineage, and miR-223 preferentially expressed in myeloid lineages. When 
ectopically overexpressed in hematopoietic precursor cells, miR-181a induced an 
increase of B-lineage cells. Ectopic expression of miR-142s or miR-223 showed an 
increase in T-lineage cells.7 Another miRNA that has been implicated in hematopoiesis 
is miR-155. MiR-155 negatively regulates normal myelopoiesis and erythropoiesis.8 
In addition, enhanced expression of miR-155 is associated with activation of B- and 
T-cells (reviewed in Kluiver et al.9). MiR-221 and miR-222 have been demonstrated 
to play a role in erythrocyte differentiation.10 Downregulation of both miRNAs is 
correlated with increased expression of the KIT receptor, which is a key factor to 
regulate hematopoietic progenitor cell and erythropoietic cell proliferation.
Alterations in miRNA expression patterns may be involved in hematological 
malignancies. For example, downregulation of the miR-15a/miR-16-1 cluster 
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due to deletion of 13q14 has been shown in the majority of chronic lymphocytic 
leukemia (CLL) cases, indicating that these miRNAs might serve as possible tumour 
suppressors.11 The miR-17-92 cluster and miR-155 show overexpression in different 
types of lymphoma.12;13 Furthermore, two case reports indicated that miRNAs might 
be involved in chromosomal translocations. First, in an acute lymphoblastic B-cell 
leukemia case, the pre-miRNA sequence of miR-125b-1 on 11q24 was inserted in the 
IgH gene locus. Second, a t(8;17) was observed in a patient with aggressive B-cell 
leukemia. The resulting fusion transcript contained part of the MYC gene, and the 
promoter, 5’ portion and stem-loop sequences of miR-142 (originally termed BCL-3). 
Under the influence of the regulatory elements of miR-142, the translocated MYC 
gene was highly expressed.14;15 Further work needs to be done to determine the 
contribution of both miRNAs in B-cell leukemia. 
Leukemia is characterized by a differentiation block in hematopoietic progenitor 
cells that may be caused by a variety of mutations in factors that are required for 
normal hematopoiesis. Mutations that affect the retinoic acid receptor α (RARα) 
are characteristic for acute promyelocytic leukemia (APL). In 98% of the APL cases, 
a chromosomal translocation occurs involving chromosome 15 and 17, fusing the 
promyelocytic leukemia (PML) and the RARA genes. The resulting chimeric fusion 
protein, PML-RARα, has oncogenic potential and may interfere with the normal 
function of PML and RARα.16 Pharmacological doses of the RARα ligand, all-trans 
retinoic acid (ATRA), overcomes the differentiation arrest of the leukemic blasts 
and activates granulocytic differentiation. To date, PML-RARα is known to be 
involved in the deregulation of several important RARα target genes in APL cells.17-21 
Recently, human miR-223 has been demonstrated to be specifically expressed 
during granulopoiesis, by studying retinoic acid induced myeloid differentiation 
in APL cells.22 MiR-223 expression is positively regulated by binding of CCAAT/
enhancer binding protein α (C/EBPα), and negatively regulated by binding of NFI-A 
to its promoter region. Binding competition between these two transcription factors 
determines the transcriptional activation of miR-223. C/EBPα directs myeloid 
precursor cells towards granulocytic maturation.23;24 Fazi et al. demonstrated that 
miR-223 may control granulocytic differentiation by targeting the transcription factor 
NFI-A, thereby inducing sustained expression of miR-223. 
In the present study, we investigated which miRNAs are expressed during APL cell 
differentiation and whether PML-RARα is directly involved in their transcriptional 
PML-RARα regulates miRNA expression
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regulation. We screened for the expression profile of 157 mature miRNAs during 
retinoic acid induced granulocytic maturation of APL cells, using a sensitive, 
quantitative PCR based method. We describe the direct involvement of PML-RARα in 
the transcription of several miRNAs.
Materials and Methods
Cell Culture
Leukemic cells were isolated from bone marrow of patients at diagnosis after informed consent. 
Mononuclear cells were isolated by means of a Ficoll-1077 (Amersham, Buckinghamshire, 
UK) gradient and cultured in RPMI 1640 medium (Life Technologies, Gaithersburg, MD, USA) 
supplemented with 20% fetal calf serum (FCS). NB4, U937 and U937-PR9 (kindly provided by 
Prof. P.G. Pelicci) cells were cultured in RPMI 1640 medium (Life Technologies) supplemented 
with 10% FCS. HEK 293 cells were cultured in DMEM (Life Technologies) supplemented with 
10% FCS and 2 mM glutamine (Life Technologies). Cultures were incubated at 37°C in a 5% CO2 
completely humidified atmosphere. ATRA (Sigma, St Louis, MO, USA) was used at a concentration 
of 10-6 M, and where indicated 100 μM ZnSO4 was added 16 hours prior to ATRA. 
MiRNA reverse transcriptase reaction
RNA from cell lines and cultured primary APL patient cells were isolated using RNA-Bee (Tel-
Test, Inc., Friendswood, TX, USA). Bone marrow mononuclear cells of AML patients were 
isolated by lysis of erythrocytes in 0.14 M NH4Cl buffer for 30 min on ice, after which RNA was 
isolated using RNA-Bee (Tel-Test). Reverse transcriptase (RT) reactions contained 10 ng total 
RNA, 50 nM stem-loop RT primer (PN 4365381, Applied Biosystems, Foster City, CA, USA), 1x RT 
buffer, 1.0 mM dNTPs, 3.33 U/μl MultiScribe reverse transcriptase and 0.25 U/μl Rnase inhibitor 
(PN 4366597, Applied Biosystems). The 15 μl reactions were incubated in a Biozym PTC-100 
Thermal Controller for 30 min at 16°C, 30 min at 42°C, 5 min at 85°C and then kept at 4°C. 
MiRNA PCR reaction
Quantitative PCR reactions contained 1.33 μl RT product, 1x TaqMan Universal PCR Master 
Mix (PN 4324018, Applied Biosystems), 0.2 μM TaqMan probe, 1.5 μM forward primer and 0.7 
μM reverse primer (PN 4365381, Applied Biosystems). The 20 μl reactions were incubated 
in a 96-well plate for 10 min at 95°C, followed by 40 cycles of 15 sec at 95°C and 1 min at 
120
C
ha
pt
er
6
60°C. Quantitative PCR reactions were performed on the 7500 Real-Time PCR system (Applied 
Biosystems). Quantification of PCR product was based on the threshold cycle (Ct), which is 
defined as the fractional cycle number at which the amount of amplified target reached a fixed 
threshold. Let7a, a miRNA that is considered to be expressed in all kind of tissues, was used to 
correct for differences in the amount of total RNA added to a reaction and to compensate for 
different levels of inhibition during reverse transcription of RNA into cDNA and during PCR (2Ct 
Let7a-Ct miR).
Chromatin immunoprecipitation (ChIP)
HEK 293 cells were transiently transfected with Flag-PML-RARα (kindly provided by A. Tomita25 
which was re-cloned into a pCMV expression vector) using the calcium phosphate precipitation 
method. ChIP assays were performed as described previously.26 At 24 hours after transfection 
DNA-protein cross-linking was done for 30 min at room temperature by adding formaldehyde 
at a final concentration of 1% directly to the culture medium. Cross-linking was stopped by 
the addition of glycine to a final concentration of 125 mM for 5 min at room temperature. 
Cells were scraped and washed with ice-cold phosphate-buffered saline, buffer B (10 mM 
EDTA, 0.5 mM EGTA, 0.25% Triton X-100, 20 mM HEPES [pH 7.6]), buffer C (1 mM EDTA, 0.5 mM 
EGTA, 0.15 M NaCl, 50 mM HEPES [pH 7.6]) and resuspended in incubation buffer (0.15% SDS, 
1% Triton X-100, 0.15 M NaCl, 1 mM EDTA, 0.5 mM EGTA, 20 mM HEPES [pH 7.6] and protease 
inhibitors) at 33x106 cells/ml. Chromatin was sonicated using the Bioruptor (Cosmo Bio, Tokyo, 
Japan), at high intensity for 15 min with 0.5 min intervals. Insoluble material was removed by 
centrifugation at 4°C for 15 min. A total of 120 μl supernatant was incubated with 30 μl pre-
coated protein A/G plus agarose beads 50% v/v (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA), 0.1% BSA, 36 μl 5x incubation buffer, protease inhibitors and 2-5 μg antibody (anti-FLAG 
(M2, Sigma) or non-specific IgG from human serum) and rocked at 4°C for 16 hours. Beads 
were harvested by centrifugation and washed twice with buffer 1 (0.1% SDS, 0.1% NaDOC, 
1% Triton X-100, 0.15 M NaCl, 1 mM EDTA, 0.5 mM EGTA and 20 mM HEPES [pH 7.6]), once 
with buffer 2 (0.1% SDS, 0.1% NaDOC, 1% Triton X-100, 0.5 M NaCl, 1 mM EDTA, 0.5 mM EGTA 
and 20 mM HEPES [pH 7.6]), once with buffer 3 (0.25 M LiCL, 0.5% NaDOC, 0.5% NP-40, 1 mM 
EDTA, 0.5 mM EGTA, 20 mM HEPES [pH 7.6]), and twice with buffer 4 (1 mM EDTA, 0.5 mM 
EGTA, 20 mM HEPES [pH 7.6]). Chromatin antibody complexes were eluted by the addition of 
1% SDS and 0.1 M NaHCO3 to the pellet and incubated for 20 min at room temperature. Cross-
linking was reversed by the addition of NaCl (0.44 M final concentration) and incubation of 
the eluted samples for at least 4 hours at 65°C. DNA was recovered by phenol-chloroform-
isoamylalcohol extraction followed by chloroform-isoamylalcohol extraction and precipitated 
PML-RARα regulates miRNA expression
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by the addition of 0.1 volume of 1 M sodium acetate (pH 5.2), and 2.5 volumes of ethanol. 
Precipitated DNA was dissolved in water, and input as well as immunoprecipitated DNA was 
analysed using quantitative PCR for genomic sequences of the indicated miRNA promoter 
regions. For calculation of the fold enrichment, quantitative PCR was performed for ALBUMIN 
genomic sequences before and after the immunoprecipitation. Quantitative PCR following ChIP 
was done using SYBR green PCR (Applied Biosystems). For genomic primer sequences used in the 
ChIP assay see Table 1. Quantitative PCR for the ALBUMIN genomic sequences was performed 
using probe ALB-VIC 5’-TGCTGAAACATTCACCTTCCATGCAGA-3’ with the primers, sense 
5’-TGAAACATACGTTCCCAAAGAGTTT-3’, anti-sense 5’-CTCTCC-TTCTCAGAAAGTGTGCATAT-3’. 
Quantitative PCR reactions were performed on the ABI/PRISM 7700 Sequence Detection system 
(Applied Biosystems). 
Table 1. Table showing genomic primer sequences used in the ChIP assay. The sequences of 
the forward and the reverse primers used for detection of specific genomic regions near the 
indicated miRNAs in the ChIP assay are presented in this table. For miR-135a, primers were 
designed for chromosome 3 (3) and 12 (12).
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Results
MiRNA expression profile in NB4 cells
We measured the expression profile of 157 different mature miRNAs in the APL cell 
line NB4, before and after exposure to retinoic acid. For this, we used real-time 
quantification by stem-loop RT-PCR as described by Chen et al..27 We found that more 
than 60% (101 out of 157) of the measured miRNAs were expressed in untreated NB4 
cells, showing a broad range of expression levels (Supplemental S1). After stimulation 
of NB4 cells with ATRA, many different miRNA expression profiles were observed. We 
focussed on those miRNAs that showed a more than 10-fold up- or downregulation 
at 96 hours after ATRA stimulation. As shown in Figure 1, thirteen miRNAs were 
more than 10-fold upregulated at 96 hours after ATRA stimulation. No miRNAs were 
more then 10-fold downregulated. We confirmed upregulation of miR-223 (10-fold), 
which has already been reported, using Northern blot analysis, by Fazi et al..22 
Mir-132 and miR-135a were found to be most strongly induced by ATRA, 393-fold and 
79-fold, respectively. These results show that ATRA is involved in the regulation of 
the expression of many miRNAs in NB4 cells, which suggests their involvement in 
granulocytic differentiation of leukemic blasts.
MiR-132 and miR-135a are upregulated by ATRA in APL patient cells
To confirm the expression patterns of miRNAs that showed a more than 10-fold 
induction in NB4 cells, we measured the miRNA expression level in primary APL 
patient cells. Bone marrow cells were isolated at diagnosis and cultured in the 
presence or absence of ATRA for several time intervals after which RNA was isolated. 
We confirmed the expression patterns of four miRNAs in primary APL patient cells. 
MiR-223 was slightly induced by ATRA in cells from patient 2, but no induction could 
be observed in cells from patient 1 (Figure 2A). MiR-326 showed elevated expression 
after culturing cells from patient 1 for 72 hours in the presence of ATRA (Figure 2B). 
Two miRNAs, miR-132 (Figure 2C) and miR-135a (Figure 2D), showed a clear and 
sustained ATRA-induced upregulation in both patient samples (see also Figure 2E). 
Upregulation of miR-212 in NB4 cells
Interestingly, miR-132 is located 360 bp upstream of another miRNA, miR-212, 
suggesting that both miRNAs may be processed from the same pri-miRNA transcript. 
PML-RARα regulates miRNA expression
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As miR-212 was not included in the original panel of 157 Taqman miRNA assays, we 
tested whether miR-212 was also upregulated in NB4 cells following stimulation with 
ATRA. We found that miR-212 is induced to a similar extent and with similar kinetics 
as miR-132 (Figure 3A,B), suggesting that miR-212 and miR-132 are processed from a 
common pri-miRNA transcript. 
When early time points were considered of miR-132, miR-135a, miR-212 and miR-
223, we observed that the upregulation of miR-132, miR-212 and miR-223 was induced 
after more than 8 hours following ATRA stimulation (Figure 3A,B,C). This suggests 
that these miRNAs are not directly targeted by ATRA. For miR-223, this is supported 
by the report of Fazi et al., showing regulation of miR-223 by C/EBPα, a PML-RARα 
target gene. However, the upregulation of miR-135a was very fast with a more than 
10-fold induction after 4 hours of ATRA stimulation, suggesting that miR-135a could 
be directly targeted by ATRA (Figure 3D). 
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Figure 1. Top 13 ATRA-responsive miRNAs in NB4 cells. NB4 cells were cultured in the presence 
of 10-6 M ATRA for indicated time points after which RNA was isolated. These RNA samples were 
subjected to quantitative PCR for 157 different miRNAs. Presented are the more than 10-fold 
upregulated miRNAs, as measured by fold difference in expression level (2ΔCt) between 0 and 
96 hours of ATRA stimulation.
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-ATRA (hrs) + ATRA (hrs)
Patient 1 0 72 72
miR-132 31,43 30,03 26,75
miR-135a 36,80 36,36 31,96
miR-223 21,36 21,42 20,24
miR-326 35,99 34,81 32,29
-ATRA (hrs) + ATRA (hrs)
Patient 2 0 72 72
miR-132 31,04 29,56 28,10
miR-135a 36,32 34,80 29,32
miR-223 22,43 21,79 20,17
miR-326 34,44 34,14 32,72
E
Figure 2. ATRA-induced miRNA expression in primary APL patient cells. Quantitative PCR for 
miR-223 (A), miR-326 (B), miR-132 (C) and miR-135a (D) was performed with total RNA from 
bone marrow derived mononuclear cells from two APL patients after in vitro exposure to 10-6 M 
ATRA for indicated time points (dark gray bars). As a control cells were cultured in the absence 
of ATRA (light gray bars). Plotted are the fold inductions compared to T=0 measured by 2ΔCt. (E) 
The Ct values, indicative for absolute expression, at T=0 and T=72 are presented in this table.
MiR-132, miR-135a, miR-212 and miR-223 are targets of PML-RARα
PML-RARα has been shown to act as a dominant oncogene, interfering with the 
normal function of the unrearranged RARα and PML proteins. We investigated 
whether miRNA expression may be (de)regulated by PML-RARα. To investigate this we 
used the parental U937 cell line and a U937 cell line stably transfected with a zinc-
inducible PML-RARα expression cassette (U937-PR9). Both cell lines were stimulated 
with zinc, and the expression levels of miR-132, miR-135a, mir-212 and miR-223 
were measured. Comparison of the expression levels in the parental U937 versus the 
U937-PR9 cell line after zinc-stimulation showed that expression of PML-RARα did not 
affect expression of miR-132 and miR-212 (Figure 4A,B). Expression of miR-223 was 
clearly downregulated upon expression of PML-RARα (Figure 4C). Compared to Let7a, 
miR-135a is hardly expressed in U937 cells, but in U937-PR9 cells we were able to 
detect low levels of miR-135a expression (Figure 4D). 
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Figure 3. Kinetics of upregulation of miR-132, mir-135a, miR-212 and miR-223 in NB4 cells. 
Total RNA from non-stimulated and ATRA-stimulated NB4 cells (10-6 M ATRA was added for 0, 
4, 8, 24, 48, 72, 96 hours) was used to perform quantitative PCR for miR-212 (A), miR-132 (B), 
miR-223 (C) and miR-135a (D) (n=2). The figure shows the mean fold inductions relative to non-
stimulated NB4 cells.
To investigate more extensively whether expression of PML-RARα is directly 
associated with deregulation of miR-132, miR-135a, miR-212 and miR-223 expression, 
we measured the expression level of these miRNAs in different acute myeloid leukemia 
(AML) subtypes. APL accounts for 5-10% of all AMLs and is classified according to the 
French-American-British (FAB) classification system based on morphological criteria 
as AML-M3. Expression of the PML-RARα fusion protein is characteristic for APL. We 
analysed the expression level of miR-132, miR-135a, miR-212 and miR-223 in cells 
from patients diagnosed with AML subtypes M0 to M7, and we compared those with 
the level of expression in cells from patients diagnosed with AML-M3. No significant 
difference in expression was detected for miR-132, miR-135a and miR-212 (p-values 
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0.35, 0.23 and 0.18, respectively), indicating that unliganded PML-RARα does not 
affect the expression of these miRNAs (Figure 5A,B,C). These data suggest that 
leukemic transformation does not involve active downmodulation of these miRNAs 
by PML-RARα. However, a significant decrease in expression of miR-223 was observed 
in AML-M3 compared to AML M0 to M7 (p-value 0.001) (Figure 5D). These results are 
in line with the data from the U937 cells, indicating that PML-RARα may actively 
downmodulate the expression of miR-223. 
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Figure 4. PML-RARα regulates expression of miR-132, miR-135a, miR-212 and miR-223 upon 
ATRA stimulation. Quantitative PCR for miR-132 (A), miR-212 (B), miR-223 (C) and miR-135a 
(D) was performed with total RNA extracted from U937 (light gray bars) and U937-PR9 (dark 
gray bars) cells. Cells were cultured in the presence of Zn2+ for 16 hours after which ATRA was 
added for indicated time points. Indicated is the relative expression compared to Let7a.
To study the effect of PML-RARα on miRNA expression during ATRA-induced 
differentiation, both the U937 and the U937-PR9 cell line were exposed to zinc 
followed by ATRA stimulation for several time intervals. Figure 4 shows that expression 
128
C
ha
pt
er
6
of all four miRNAs was enhanced upon ATRA stimulation when PML-RARα was present, 
suggesting that PML-RARα is involved in the transcriptional regulation of miR-132, 
miR-135a, miR-212 and miR-223 during ATRA-induced differentiation. 
PML-RARα binds to sequences near the miR-132 and miR-212 genes
To investigate whether PML-RARα binds in the vicinity of miRNA genes, we performed 
chromatin immunoprecipitation (ChIP) analysis. HEK 293 cells were transfected with 
FLAG-PML-RARα and immunoprecipitation was performed using chromatin from these 
cells and an antibody directed against FLAG or non-specific IgG as a control. The 
recovery of chromatin was measured by quantitative PCR using specific primer sets 
located at different positions near the miRNA genes (Figure 6A). In comparison, the 
recovery of a control region in an exon of the ALBUMIN gene was measured. 
Two genes, located at chromosomes 3 and 12, code for an identical mature miR-
135a. Since the quantitative PCR assay for detecting miRNA expression is based on 
the mature sequence it is impossible to discriminate between these two localisations. 
To study the presence of PML-RARα near the miR-135a genes we designed primer 
sets located in the vicinity of miR-135a sequences on both chromosomes. We were 
not able to detect binding of PML-RARα near mature miR-135a sequences located on 
chromosome 12 (Figure 6B). We do show some binding of PML-RARα in the vicinity of 
mature miR-135a sequences located on chromosome 3 (Figure 6C). However, we were 
not able to localize binding of PML-RARα to a specific region, as we detected binding 
of PML-RARα using primer sets spanning a region of ~5 kb. Whether or not PML-RARα 
directly binds to this gene remains unclear.
The upregulation of miR-223 has been described by Fazi et al..22 They showed a 
direct involvement of the transcription factors C/EBPα and NFI-A in the transcriptional 
regulation of miR-223 and an indirect role for PML-RARα was proposed. The relatively 
late upregulation of miR-223 upon ATRA exposure suggests that this gene is not 
directly regulated by PML-RARα. In line with these observations, we could not show 
binding of PML-RARα to sequences near the miR-223 gene (Figure 6D). This suggests 
that the downregulation of miR-223 upon expression of PML-RARα both in the U937 
cells (Figure 4C) and in primary AML patient cells (Figure 5D) is indirect.
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Figure 5. MiR-132, miR-135a, miR-212 and miR-223 expression in APL cells versus non-
APL AML cells. RNA was isolated from bone marrow or peripheral blood mononuclear cells of 
newly diagnosed AML patients (M0 n=5 or 4, M1 n=6, M2 n=5 or 4, M3 n=9 or 7, M4 n=4 or 3, M5 
n=4, M6 n=2 and M7 n=2). Quantitative PCR for miR-132 (A), miR-135a (B), miR-212 (C) and 
miR-223 (D) was performed and values were normalised for Let7a expression. Compared are 
the expression levels of miR-132, miR-135a, miR-212 and miR-223 in cells from AML-M3 patients 
(M3) versus cells from AML-M0 to M7 patients (M0-7). The black horizontal bar indicates the 
median. Statistically significant differences between the groups M0-7 and M3 (using Student’s 
t-test, P<0.05) are indicated with an asterix.
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Figure 6. PML-RARαα binds to DNA sequences near the miR-132 and miR-212 genes. (A) 
Schematic representation of the location of the quantitative PCR primer sets (for sequences 
see Table 1) as used in the ChIP assay. Indicated at the left are the chromosomes on which the 
miRNAs are located. (B to E) Sonicated chromatin of HEK 293 cells overexpressing FLAG-PML-
PML-RARα regulates miRNA expression
131
C
ha
pt
er
6
RARα was used for ChIP analysis using anti-FLAG antibody or non-specific IgG as a control (n=3). 
Quantitative PCR was used to measure the amount of immunoprecipitated genomic region 
near the miRNA indicated, which was compared to the control genomic sequence of ALBUMIN. 
The legend in each figure indicates the primer sets used (see also Table 1 and Figure 6A). The 
percentage of recovery of the indicated genomic region near the miRNA was plotted as the fold 
enrichment over the percentage of recovery of ALBUMIN.
In contrast, ChIP analysis revealed binding of PML-RARα to sequences near the 
miR-132 and miR-212 genes (Figure 6E). We observed binding of PML-RARα when 
using primer sets located 0.9 kb upstream and 0.3 kb downstream of mature miR-
132 sequences. The ChIP was not positive when using primer sets located 1.1 kb, 1.6 
kb and 5.0 kb downstream of mature miR-132 sequences. These data suggest that 
binding of PML-RARα localizes to a region upstream of the mature miR-132 sequence 
or at a distance less than ~1 kb downstream of the mature miR-132 sequence. The 
data strongly suggest that ATRA-induced upregulation of miR-132 and miR-212 is 
mediated by association of PML-RARα to the promoter region of these miRNAs. 
Discussion
In this study we investigated the miRNA expression profile during ATRA-induced 
myeloid differentiation of APL cells. We found that many miRNAs are expressed in 
APL cells and that several miRNAs are strongly upregulated upon ATRA induction. This 
suggests that they contribute to the post-transcriptional regulation of gene expression 
in these cells. As each miRNA is believed to regulate multiple genes, multiple target 
genes may be affected by the upregulation of these miRNAs. Recently, Garzon et 
al. reported the expression profile of miRNAs during ATRA treatment of APL cells by 
using a miRNA microarray platform.28 When comparing their and our data set, some 
differences can be observed which might be due to the different (hybridization) 
methods used. 
MiRNAs can be located both in intergenic- as well as in intronic regions. When 
located in introns, miRNAs share their regulatory elements with their host genes. 
When located in intergenic regions, it is postulated that miRNAs have their own 
promoter regions. MiR-132, miR-135a, miR-212 and miR-223 are located in intergenic 
regions and have their own promoter region. Therefore, we studied whether these 
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miRNAs are directly regulated by PML-RARα. Using ChIP analysis we showed that PML-
RARα binds to sequences near the miR-132 and miR-212 genes, suggesting that PML-
RARα is directly involved in the transcriptional regulation of these miRNAs. The rapid 
upregulation of miR-135a in NB4 cells suggests that miR-135a is directly regulated 
by PML-RARα. However, we were not able to localize binding of PML-RARα to regions 
near the miR-135a genes. It remains to be clarified whether or not PML-RARα directly 
binds to this gene. Fazi et al. demonstrated that miR-223 is a direct target of the 
transcription factors C/EBPα and NFI-A, which in turn are regulated by PML-RARα. In 
line with these results, we could not show binding of PML-RARα to sequences near the 
miR-223 gene. 
PML-RARα may silence normal retinoic acid receptor target genes at physiological 
concentrations of retinoic acid. It has been postulated that these target genes 
mediate PML-RARα-induced transformation. At high concentrations of ligand, PML-
RARα (re)activates the transcription of genes, forcing the leukemic cells into terminal 
differentiation. We studied whether unliganded PML-RARα is able to deregulate 
expression of miR-132, miR-135a, miR-212 and miR-223 by investigating the miRNA 
expression levels in U937 cells with or without expression of PML-RARα and in 
various AML subtypes. Expression of PML-RARα in U937 cells downregulates miR-223 
expression. In addition, a significantly lower expression level of miR-223 was observed 
when comparing cells from APL patients with cells from non-APL AML patients. In 
the absence of ligand, expression of PML-RARα does not modulate the expression of 
miR-132, miR-135a and miR-212, both in U937 cells as well as in primary AML patient 
cells. However, a clear PML-RARα dependent regulation was demonstrated following 
ATRA-induced differentiation. This suggests a role for miR-132, miR-135a and miR-212 
in differentiation rather than in PML-RARα-mediated transformation. The reduced 
expression of miR-223 in the presence of PML-RARα may suggest that miR-223 is 
involved during transformation.
In summary, we identified miRNAs that are differentially regulated upon ATRA 
stimulation of APL cells. These observations suggest a potential role for these miRNAs 
in APL cell differentiation. Functional studies should reveal the biological relevance 
of the induction of miR-132, miR-135a and miR-212 expression during ATRA-induced 
granulocytic differentiation. Our study demonstrates for the first time a direct 
interference of an oncoprotein with miRNA expression.
PML-RARα regulates miRNA expression
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Supplemental S1. MiRNA expression profile in NB4 cells. NB4 cells were cultured in 
the presence of 10-6 M ATRA for indicated time points after which RNA was isolated. These 
RNA samples were subjected to quantitative PCR for 157 different miRNAs. The level of 
miRNA expression is shown as Ct value, which is indicative for absolute expression. ND = not 
detectable.
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Summary
Leukemia is a hematological malignancy that is characterized by the clonal expansion 
of immature hematopoietic cells, which have escaped from the tightly coordinated 
cell cycle regulation, differentiation and apoptosis controls. In general, leukemia is 
characterized by a variety of mutations in pathways that are required for normal 
hematopoiesis. This thesis describes target genes of the mutated transcription factor 
PML-RARα, which is expressed in acute promyelocytic leukemia (APL) cells. APL, 
which accounts for 5-10% of all acute myeloid leukemias (AMLs), represents the best 
prognostic group amongst the different forms of leukemia having the highest curability. 
APL requires a unique form of treatment, which constitutes the first successful form of 
leukemia therapy that is based on induction of differentiation of the malignant cells, 
using all-trans retinoic acid (ATRA). The addition of pharmacological doses of ATRA 
to standard chemotherapy has led to an improvement of cure rates from 40% with 
chemotherapy alone to up to 90% when combined with ATRA.1-3 The identification of 
the chromosomal translocation t(15;17), which causes the expression of the chimeric 
oncoprotein PML-RARα and which is the genetic hallmark of APL, is important to 
establish the diagnosis. ATRA has been proven to directly target the product of this 
molecular defect and the APL model provides an example of targeted therapy based 
on differentiation induction.4 In this thesis we describe the identification of three 
ATRA-responsive genes in APL cells that are transcriptionally regulated by PML-RARα 
via a novel mechanism. Their biological function and their mechanism of action were 
studied in more detail in APL cells. 
In chapter 2 we describe the identification of inhibitor of DNA binding 1 (ID1) and ID2 
as two direct ATRA-responsive genes in APL cells. Both genes are rapidly induced by 
ATRA in the APL cell line NB4 as well as in primary patient cells. To test the biological 
relevance of the induction of ID1 and ID2 in APL cells, both proteins were overexpressed 
in NB4 cells using retroviral transduction. We show that overexpression of ID1 and 
ID2 induced inhibition of APL cell proliferation due to an increased accumulation of 
leukemic cells in the G0/G1 phase of the cell cycle. We conclude that ID1 and ID2 play 
a role in cell cycle arrest during APL cell differentiation. In chapter 3 we studied the 
molecular mechanisms by which ID1 and ID2 are regulated in APL cells. We found that 
the oncogenic fusion protein PML-RARα is able to associate with the promoters of ID1 
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and ID2 and that PML-RARα is able to transactivate both promoters in the presence of 
ATRA, in contrast to the wild type RARα/RXR complex. We show that direct binding of 
PML-RARα to the DNA is not required for transcriptional activation of ID1 and ID2 and 
that the transcription factors Sp1 and NF-Y are involved in PML-RARα-induced gene 
transactivation. We define a novel, Sp1 and NF-Y-dependent mechanism by which 
PML-RARα interferes with gene transcription, which implicates that PML-RARα (de)
regulates an as yet unrecognized class of genes that are normally not regulated by 
retinoic acid receptors. In chapter 4, we identified HES1 as another direct ATRA-
responsive gene that is transcriptionally regulated by PML-RARα in APL cells through a 
similar mechanism as has been described for ID1 and ID2 in chapter 3. Further studies 
are necessary to elucidate the biological function of HES1 in APL cells. 
To understand the function of ID2 during myelopoiesis, we searched for ID2-
interacting proteins using a mammalian yeast two-hybrid assay and in chapter 
5 the results of this study are shown. We found that the transcriptional repressor 
methyl-CpG binding protein 1 (MBD1) is able to interact with ID2 in yeast cells and we 
confirmed this interaction in mammalian cells. We hypothesize that the binding of 
ID2 to MBD1 may alter the function of MBD1, which contributes to the (re)expression 
of genes that were silenced by MBD1. Further studies should help to clarify the 
relevance of the interaction. 
The discovery of microRNAs (miRNAs) has led to new insights into the regulation 
of gene expression. In chapter 6 we investigated whether miRNA expression is 
regulated during ATRA-induced differentiation of APL cells. We demonstrate that 
several miRNAs are differentially regulated upon ATRA stimulation and we identified 
miRNA-132, miRNA-212 and miRNA-135a as being most profoundly induced by ATRA in 
APL cells. Our data show that PML-RARα transcriptionally regulates their expression in 
the presence of ATRA. We found that PML-RARα is able to bind to sequences near the 
miRNA-132 and miRNA-212 genes indicating a direct involvement of the oncoprotein 
in the transcriptional regulation of these miRNAs.
Summary & General discussion
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General discussion 
Identification of PML-RARα target genes 
In APL cells, the mutated transcription factor PML-RARα has been demonstrated to be 
involved both in leukemic transformation as well as in ATRA-induced differentiation. 
The identification of PML-RARα target genes will broaden our understanding of 
the molecular mechanisms involved in the development of APL and ATRA-induced 
differentiation of APL cells. In this thesis we describe the identification of three PML-
RARα target genes, ID1, ID2 and HES1, which are transcriptionally regulated by the 
oncogenic fusion protein in a ligand-dependent manner. We demonstrate that ID1, 
ID2 and HES1 are not regulated by unrearranged RARα following stimulation with 
ATRA. This indicates that PML-RARα not only interferes with regular RARα target 
genes but that an additional class of genes that are normally not regulated by RARα 
is (de)regulated by PML-RARα. We demonstrate that transcriptional regulation of 
these three genes does not require the DNA-binding domain of the fusion protein and 
we propose a model in which PML-RARα binds to a DNA-bound Sp1-NF-Y complex. 
Therefore, the range of genes that are dysregulated by PML-RARα in APL may be much 
wider than initially assumed. The ChIP-on-chip assay, which is a powerful tool to study 
chromatin-protein interactions across the entire genome, can be used to identify PML-
RARα target genes. In addition, using this technique, it may be interesting to study 
the requirement of the DNA-binding domain of PML-RARα to associate with promoters 
by using a mutant form of PML-RARα that is no longer able to directly bind to DNA. 
The results of these studies may reveal additional genes, coding for regular proteins 
and miRNAs, that are (de)regulated by the oncoprotein and may provide insight into 
the molecular mechanisms of transcriptional regulation by PML-RARα.
To confirm the involvement of newly identified PML-RARα target genes in APL 
pathogenesis and during ATRA-induced differentiation of APL cells, these target 
genes should be examined for their expression and their biological function should 
be studied by ectopic expression or by inhibition of their expression. In addition, it 
would be interesting to study whether the DNA-binding mutant of PML-RARα is able to 
induce leukemic transformation and/or ATRA-stimulated differentiation in transgenic 
mice, as this may help to identify important PML-RARα target genes that are involved 
in these processes.
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ID1 and ID2 and their role in granulocytic differentiation
The differential regulation of ID1 and ID2 following ATRA stimulation of APL cells 
suggests a different role for these proteins during neutrophilic differentiation of 
APL cells. However, when overexpressing ID1 or ID2 in APL cells both proteins are 
associated with an inhibition of proliferation due to an accumulation of cells in the 
G0/G1 phase of the cell cycle. In line with these data, inhibition of ID2 expression 
in normal CD34+ cells induced proliferation during both eosinophil and neutrophil 
development.5 Overexpression of ID1 or ID2 in normal CD34+ cells also demonstrated 
similar roles for ID1 and ID2 during neutrophil development, both leading to enhanced 
neutrophil development.5 Furthermore, in normal hematopoiesis it has been 
demonstrated that ID2 is required for maturation of neutrophils, since inhibition of 
ID2 expression in CD34+ cells blocked terminal maturation of neutrophils.5 
It has been demonstrated that the various ID proteins may have similar as well 
as different binding partners and that ID1 and ID2 are able to interact with each 
other. If ID1 and ID2 interact with the same proteins in APL cells, ID2 may take over 
the function of ID1 during APL cell differentiation. Redundancy of murine Id proteins 
was illustrated by the observation that breeding of various single Id gene knockout 
mice did not produce viable offspring carrying null mutations in two different Id 
proteins.6 ID1 and ID2 may exert similar biological functions through different 
molecular mechanisms. Different binding partners may reflect a differential 
molecular mechanism for ID1 and ID2 during APL cell differentiation. Therefore, the 
identification of ID specific interacting proteins may help to elucidate the function of 
both proteins in APL cell differentiation. Not only bHLH proteins but also non-bHLH 
proteins have been found to interact with ID proteins. The relevance of these various 
interactions in mediating biological functions of ID proteins in a truly physiological 
context in vivo has now to be established.
The relevance of the interaction between ID2 and MBD1
Upregulation of ID2 during terminal granulocytic differentiation might implicate 
that ID2 abrogates the function of proteins that are involved in the transcriptional 
repression of granulocyte-specific genes. In this context, MBD1 has become 
an interesting newly identified partner of ID2. A large and growing number of 
genes show hypermethylation in cancer, including APL. DNA methylation, which is 
mediated by specific DNA methyltransferases and MBD-proteins, is associated with 
Summary & General discussion
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transcriptional repression.7 In APL cells, silencing of RARβ expression is mediated 
by binding of PML-RARα and the recruitment of a corepressor complex containing 
histone deacetylase activity. In addition, it has been found that DNA methylation 
contributes to the repressive effect of PML-RARα on RARβ transcription. ATRA has 
been demonstrated to induce demethylation and re-expression of RARβ in APL cells,8 
while the expression of ID2 is induced. It is tempting to speculate that ID2 might be 
involved in the abrogation of the function of MBD1, and in the re-expression of genes 
silenced by hypermethylation. Overexpression of ID2 in the APL cell line NB4 may 
reveal whether ID2 expression results in re-expression of genes that were silenced 
by hypermethylation by comparing the methylation profile between normal NB4 cells 
and ID2-overexpressing NB4 cells.
 
In conclusion, with the identification of ID1, ID2 and HES1 as ATRA-responsive genes 
in APL cells, this thesis is a step towards the unravelling of the involvement of these 
helix-loop-helix proteins in myeloid hematopoiesis. The elucidation of the molecular 
pathways implicated in the process of APL cell differentiation may have a much 
broader implication than APL per se.
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De bloedcelvorming of hematopoïese is een gecontroleerd en continu proces dat 
voornamelijk plaats vindt in het beenmerg. Vanuit pluripotente hematopoïetische 
stamcellen die het vermogen hebben zich te vermenigvuldigen (prolifereren), 
ontstaan alle soorten rijpe functionele bloedcellen via een proces van uitrijping 
(differentiatie). Deze bloedcellen verlaten het beenmerg en komen in de 
bloedcirculatie terecht. De meeste soorten rijpe bloedcellen hebben maar een 
korte levensduur en verlaten de bloedcirculatie vrij snel via natuurlijke celdood 
(apoptose). Tijdens normale hematopoïese bestaat een balans tussen proliferatie, 
differentiatie en apoptose van bloedcellen. Verstoring van deze balans leidt tot het 
ontstaan van bloedziekten. Leukemie is een verzamelnaam voor verschillende vormen 
van bloedkanker en de aandoening wordt gekarakteriseerd door ongecontroleerde 
proliferatie van onrijpe, meestal witte bloedcellen. De niet-functionele leukemische 
bloedcellen hopen zich op in het beenmerg en verdringen het normale beenmerg. Dit 
leidt tot een tekort aan normale bloedcellen, wat samengaat met symptomen zoals 
bloedarmoede, malaise, spontane bloedingen, terugkerende infecties en koorts. 
Per jaar krijgen wereldwijd ongeveer 300.000 mensen leukemie en 222.000 
mensen overlijden jaarlijks aan leukemie. Over het algemeen is leukemie 
gekarakteriseerd door een verscheidenheid aan mutaties in genen die van belang 
zijn tijdens de normale hematopoïese. Deze verscheidene typen mutaties hebben 
verschillende invloeden op de overleving van een patiënt. Het diagnosticeren van de 
onderliggende genetische verandering kan betekenisvolle informatie verschaffen over 
de prognose. De behandeling van leukemie richt zich voornamelijk op het vernietigen 
van de sneldelende cellen. De manier van behandelen, bijvoorbeeld de intensiteit 
van de chemotherapie of de keuze om een beenmergtransplantatie uit te voeren, 
is niet alleen afhankelijk van de leeftijd van een patiënt of de beschikbaarheid 
van een donor, maar wordt tevens afgestemd op de prognose die gerelateerd is 
aan de onderliggende genetische verandering. Een nieuwe trend is de ontwikkeling 
van doelgerichte therapie waarbij gebruik wordt gemaakt van de genetische 
eigenschappen van de leukemische cellen. De behandelingsstrategie van leukemie 
patiënten wordt steeds individueler door middel van medicijnen die zich specifiek 
richten op de onderliggende genetische verandering.
152
C
ha
pt
er
8
Acute myeloïde leukemie (AML) is de meest frequente vorm van acute leukemie 
in volwassenen en komt voor in 90% van alle gevallen van acute leukemie. Acute 
promyelocyten leukemie (APL) is een subtype van AML en komt voor in 5-10% 
van alle gevallen van AML. Bij dit type leukemie zijn onrijpe granulocytaire 
voorlopercellen (promyelocyten) geblokkeerd in hun vermogen om te differentiëren 
tot rijpe granulocyten. Van alle verschillende vormen van leukemie heeft APL de 
beste prognose met het hoogste genezingspercentage door middel van een unieke 
behandelingsmethode. Onderzoek heeft uitgewezen dat het toedienen van een hoge 
dosis vitamine A (all-trans retinoic acid (ATRA)) het differentiatie vermogen van de 
leukemische cellen herstelt en in combinatie met standaard chemotherapie leidt dit 
tot een genezingspercentage van bijna 90%. 
APL wordt gekenmerkt door een chromosomale translocatie t(15;17) die resulteert 
in de expressie van het PML-RARα fusie-eiwit. De identificatie van deze chromosomale 
afwijking is belangrijk voor het vaststellen van de diagnose. PML-RARα heeft oncogene 
eigenschappen en het is gebleken dat PML-RARα kan interfereren met de normale 
functies van het PML-eiwit en het RARα-eiwit. RARα is een ligand-afhankelijke 
transcriptiefactor die in een complex met het RXR-eiwit de expressie van genen 
kan reguleren. In afwezigheid van ATRA, het ligand van deze transcriptiefactoren, 
werkt het complex als een transcriptionele repressor door de rekrutering van een 
co-repressor complex. In aanwezigheid van ATRA wordt het co-repressor complex 
vervangen door een co-activator complex waardoor de transcriptie van target genen 
wordt geactiveerd. Het PML-RARα fusie-eiwit heeft een sterkere binding met het 
co-repressor complex dan RARα. Bij een fysiologische concentratie ATRA wordt het 
co-repressor complex niet vervangen door het co-activator complex en de target 
genen van PML-RARα worden niet tot expressie gebracht. Echter, bij een zeer hoge 
dosis ATRA wordt het co-repressor complex alsnog vervangen door het co-activator 
complex waardoor de transcriptie van PML-RARα target genen wordt geactiveerd. 
Het APL model verschaft een uitstekend voorbeeld van doelgerichte therapie waarbij 
gebruik wordt gemaakt van de genetische verandering van de leukemische cellen. 
De unieke vorm van behandeling van APL vormt de eerste succesvolle therapie voor 
leukemie welke gebaseerd is op de inductie van differentiatie van leukemische 
cellen. 
We hebben de genen ID1 en ID2 geïdentificeerd als twee directe ATRA respons 
genen in APL. ATRA stimuleert hogere expressie van beide genen zowel in NB4 cellen 
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(een APL cellijn) als in primaire APL patiënten-cellen. Om de biologische relevantie 
van de expressie van ID1 en ID2 in APL te bestuderen hebben we beide eiwitten 
door middel van retrovirale transductie tot overexpressie gebracht in NB4 cellen. 
In hoofdstuk 2 laten we zien dat overexpressie van ID1 en ID2 de groei van APL 
cellen remt door een ophoping van leukemische cellen in het G0/G1-stadium van de 
celcyclus. We concluderen dat ID1 en ID2 een rol spelen in de celcyclus-stop tijdens 
ATRA geïnduceerde differentiatie van APL cellen. In hoofdstuk 3 hebben we de 
moleculaire mechanismen bestudeerd waardoor ID1 en ID2 worden gereguleerd in APL 
cellen. We hebben ontdekt dat het PML-RARα fusie-eiwit kan binden aan de promoter 
regio’s van de twee ID genen en dat PML-RARα beide genen kan transactiveren in de 
aanwezigheid van ATRA. Dit fenomeen treedt niet op bij het wild type RARα/RXR 
eiwit complex. We tonen aan dat de transcriptiefactoren Sp1 en NF-Y betrokken 
zijn bij deze PML-RARα afhankelijke regulatie van ID1 en ID2. We definiëren een 
nieuwe functie voor PML-RARα en laten zien dat het fusie-eiwit betrokken is bij de 
transcriptionele activatie van een tot nu toe onbekende klasse van genen die normaal 
niet door ATRA wordt gereguleerd. In hoofdstuk 4 identificeren we HES1 als een 
nieuw ATRA respons gen welke transcriptioneel gereguleerd wordt door PML-RARα in 
APL cellen. We tonen aan dat deze transcriptionele regulatie van HES1 net als die van 
ID1 en ID2 afhankelijk is van de transcriptiefactor NF-Y. Verdere studie zal moeten 
ophelderen wat de biologische functie van het HES1 eiwit in APL is.
Om de biologische functie van ID2 tijdens granulocytaire differentiatie beter 
te begrijpen hebben we het gist twee-hybride systeem gebruikt om eiwitten te 
identificeren die een interactie aangaan met ID2. In hoofdstuk 5 laten we de 
resultaten van deze studie zien. We hebben ontdekt dat het methyl-CpG-bindende 
eiwit 1 (MBD1) een interactie aangaat met ID2 en we hebben deze interactie bevestigd 
door middel van co-immunoprecipitatie studies. Verdere studies zullen duidelijk 
moeten maken wat de relevantie is van de interactie tussen MBD1 en ID2.
De ontdekking van het bestaan van microRNAs (miRNAs) in de begin jaren negentig 
heeft geleid tot nieuwe inzichten op het gebied van de regulatie van gen expressie. In 
hoofdstuk 6 hebben we bestudeerd of miRNAs transcriptioneel gereguleerd worden 
tijdens ATRA geïnduceerde differentiatie van APL cellen. We tonen aan dat miRNAs 
differentieel tot expressie komen na ATRA stimulatie en we laten zien dat miRNA-132, 
miRNA-212 en miRNA-135a het sterkste worden opgereguleerd door ATRA in APL 
cellen. We hebben ontdekt dat PML-RARα betrokken is bij de ATRA geïnduceerde 
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transcriptionele regulatie van deze miRNAs en tonen aan dat het PML-RARα fusie-
eiwit aan sequenties kan binden die in de buurt van de miRNA-132 en miRNA-212 
genen liggen. Deze bevinding suggereert dat PML-RARα direct betrokken is bij de 
transcriptionele regulatie van deze miRNAs. 
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